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1 Abstract 
Subjective Cognitive Decline (SCD) is defined as an individual’s perception of 
worsening cognitive function compared to his/her earlier performance level (Jessen et 
al. 2014a). SCD may often accompany regular cognitive ageing processes (Schaefer & 
Bäckman, 2007) given the high prevalence (25-50%) of this phenomenon in people 65 
years and older (Stewart, 2012). However, during the last decade, SCD has also become 
an important research topic within the field of Alzheimer’s disease (AD; Stewart, 2012). 
SCD is today considered among the earliest clinical symptoms of AD and may occur 
even before overt cognitive impairment objectified by neuropsychological testing. At 
this earliest symptomatic stage of AD, SCD may thus reflect an individual’s perception 
of subtle intra-individual cognitive decline while cognitive performance is still within 
the normal range. SCD has therefore been proposed as a first clinical symptom that may 
emerge in the transient stage between a completely asymptomatic stage of AD and the 
pre-dementia clinical stage of AD which is commonly referred to as Mild Cognitive 
Impairment (MCI). Several studies have shown that individuals with SCD but normal 
objective cognitive test performance are at increased risk of future AD dementia and of 
having abnormal values in biomarkers indicative of AD pathology. These individuals 
may thus represent a particularly relevant target population for early prevention 
approaches as they are enriched for risk of AD dementia but are still in the earliest 
clinically detectable stage in which interventions might be most effective. However, the 
usefulness of SCD in prediction of AD has also been questioned, mainly because there 
is little cross-sectional correlation of SCD with objective cognitive performance and, 
more importantly, because SCD has consistently been related to potentially confounding 
factors such as depressive symptomatology and, to a lesser degree of evidence, to 
anxiety and personality factors.  
SCD as a symptom is not limited to the pre-MCI stage of AD but rather extends 
into the MCI stage. In fact, SCD is part of the current MCI criteria. However, the utility 
of SCD as part of these criteria has also been questioned. This is because anosognosia 
(i.e. a patient’s unawareness of his/her own disease-related deficits) as a core symptom 
of AD dementia might already emerge, and thereby confound the endorsement of SCD, 
at least in more progressed stages of MCI. This may limit the utility of SCD as a 
predictor of clinical progression or underlying AD pathology in the MCI stage. 
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Open questions remain with regard to the significance of SCD at different stages of 
AD. While the overall evidence shows that SCD is associated with incident AD 
dementia, it is unclear whether specific quantitative and/or qualitative features of SCD 
might be of higher predictive value than others. This question addresses the optimal 
operationalization and measurement of SCD. Furthermore, as mentioned above, while 
SCD has gained significant attention in the field of pre-clinical AD, the significance of 
SCD in MCI has been questioned. However, the relationship between SCD and possible 
confounders in MCI, such as objective memory impairment and reduced symptom 
insight, is not well understood. The question whether SCD has differential predictive 
value at different stages of objective impairment, is unclear and remains to be 
empirically tested. 
In this thesis, the questions above have been addressed in three consecutive, 
previously published, empirical studies which examined the significance of SCD as a 
predictor of incident AD dementia and of AD biomarkers in the pre-MCI and the MCI 
stage. These studies are based on a multicenter primary care cohort (German study on 
Ageing, Cognition and Dementia (AgeCoDe study), study 1) as well as a multicenter 
memory clinic MCI cohort of the German Competence Network Dementia (DCN 
cohort, study 2 and study 3). Study 1 (Jessen et al. 2014b) examined the risk of incident 
AD dementia in individuals with and without SCD in the pre-MCI and MCI stage 
within a long follow-up time frame of up to six years. The main finding of that study 
was that cognitively normal individuals who reported SCD in the memory domain and 
who had concerns related to their experienced memory decline were at a significantly 
elevated risk to develop AD dementia over time compared to controls. Furthermore, risk 
of AD dementia in these individuals was similar to those who had the same memory 
concerns but whose memory performance was in the range of mildly impaired MCI 
patients (called “early MCI”). This study, thus, provides evidence that stages of very 
early mild cognitive impairment are not well captured by standard neuropsychological 
testing. It further highlights the relevance of subjective indicators of memory decline 
over time to predict AD dementia at this early stage of AD. Furthermore, these results 
suggest that concerns regarding self-experienced memory decline may be a particularly 
important qualitative feature of AD-related SCD. 
Study 2 (Wolfsgruber et al. 2014b) and study 3 (Wolfsgruber et al. 2015) 
investigated the significance of SCD with regard to prediction of incident AD dementia 
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and biomarkers of AD in a memory clinic sample of patients with MCI. As mentioned 
above, the significance of SCD in the MCI population is a controversial topic. Studies 2 
and 3 found quantitative and qualitative aspects (again in the form of concerns about 
memory decline) of SCD to be significant predictors of incident AD dementia and of 
abnormal AD biomarkers. Results of study 2 further suggest that the significance of 
SCD as a predictor of incident AD dementia may decrease with decreasing memory 
performance, thereby providing evidence of a dynamic interplay of SCD and objective 
cognitive impairment in AD dementia prediction. Both studies suggest that a refined 
and improved SCD assessment in the MCI stage may be warranted in order to 
complement the broad clinical SCD criterion in current MCI definitions. This might 
eventually contribute to improved prediction of AD dementia and could also be useful 
for enrichment of MCI samples for underlying AD pathology. 
After a general introduction and the presentation of these studies, this thesis will be 
continued with a general discussion of the study results and their contributions to the 
field of AD research. Lastly, an outlook on possible directions of further research in the 
field of AD-related SCD will be given. 
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2 Introduction 
The aim of this section is to give a cohesive overview on the development of 
Alzheimer’s disease (AD) and the concept of Subjective Cognitive Decline (SCD). The 
section will start by providing a definition and short overview of dementia and AD 
dementia as its most common form (section 2.1). A description of the temporal 
development and the stages of AD from the preclinical phase to the dementia phase will 
then be given. The so called “biomarker model of AD” will be presented, which 
describes “the temporal evolution of AD biomarkers in relation to each other and to the 
onset and progression of clinical symptoms” (Jack et al. 2010; Jack et al. 2013;  section 
2.2). After presenting the model as a general framework, the proposed stages of AD will 
be outlined briefly (section 2.3). Current biomarker based criteria of preclinical AD, 
MCI due to AD and AD dementia will be summarized for a convenient reference. 
However, the informed reader may skip these passages. Next, an overview of the SCD 
concept will be given (section 2.4). Here, terminology, methods of assessment and the 
heterogeneity of the concept in the literature will be described. SCD will then be 
discussed in relation to the biomarker model and the different stages of AD. Similarly to 
the biomarker model of AD, a working model for the temporal evolution of SCD across 
the spectrum of AD, which served as a conceptual model for the empirical studies of 
this work, will be presented. The last section of the introduction (section 2.5) sums up 
the previous sections and leads to a short description of the goals and hypotheses of the 
three empirical studies presented in this thesis. 
2.1 Dementia and Alzheimer’s disease (AD): Definition and Overview 
The term “dementia” is defined as a non-specific syndrome (i.e. a set of clinical 
symptoms) rather than a specific disease. Although there is great variation regarding its 
phenotypical presentation, dementia is in its core characterized by (usually progressive) 
loss of global cognitive functioning severe enough to cause significant impairment in 
daily living. Affected cognitive domains are verbal and visual memory, language, 
executive functions, orientation and attention, intellectual abilities and visual 
perception. 
Impairment in memory and in at least one other domain is the minimal 
requirement implemented in the diagnostic algorithm for dementia according to the 
criteria of DSM-IV (American Psychiatric Association, 2000). In the recently published 
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new version of the DSM (DSM-5), the term dementia has been replaced by the terms 
“mild and major cognitive disorders”, respectively (American Psychiatric Association, 
2013). While the mild cognitive disorder basically corresponds to the diagnosis of a 
Mild Cognitive Impairment (MCI; described later), the term major cognitive disorder 
has replaced the syndrome of dementia. An important change in DSM-5 is that memory 
impairment no longer poses a necessary requirement for the diagnosis of a major 
cognitive disorder. This amendment acknowledges that memory impairment is not the 
primarily affected domain in some forms of dementia (e.g. frontotemporal dementia). 
Furthermore, specific guidelines concerning the severity of cognitive impairment (in 
terms of standard deviations below test norms) are detailed in DSM-5, which, as a 
consequence, means that neuropsychological testing is required for the diagnosis.
1
 
A detailed outline of up to date general criteria for dementia and specific criteria 
for “dementia due to Alzheimer’s disease”, which also incorporates biomarker 
information in the diagnostic procedure, is given in section 2.3.3. These are the National 
Institute on Aging-Alzheimer’s Association (NIA-AA) criteria (McKhann et al. 2011) 
which represent a revised version of the older criteria set proposed in 1984 by the 
National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) 
and the Alzheimer’s Disease and Related Disorders Association (ADRDA) (McKhann 
et al. 1984). The clinical Alzheimer’s disease dementia criteria of the NINCDS-
ADRDA have been the research standard for the last 30 years and are also the basis for 
the Alzheimer’s disease dementia diagnosis in the empirical studies of this work. 
While the term dementia is used to describe the clinical syndrome, “Alzheimer’s 
disease” (AD) is a progressive neurodegenerative disease that leads to a dementia 
syndrome. Besides AD, other neurodegenerative diseases such as Parkinson’s disease or 
Pick’s disease can lead to dementia. However, AD is by far the most common cause for 
the dementia syndrome, accounting for roughly 50-70% of all cases (Burns & Iliffe, 
2009). Vascular dementia or “multi-infarct dementia” is the second most common cause 
of dementia in the elderly (ca. 25% of cases) followed by dementia with Lewy bodies 
(ca. 15% of cases; Burns & Iliffe, 2009). Mixed dementia describes a condition in 
                                                 
1
 In this manuscript the term dementia is used instead of the DSM-5 terminology as the research 
results presented herein are based on DSM-IV criteria for dementia and NINCDS-ADRDA criteria for 
AD dementia. In addition, the term dementia is still preferred in the scientific field. 
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which pathophysiological characteristics of more than one form of dementia are 
simultaneously present. The most common form of this type of dementia etiology is a 
combination of AD and vascular pathology (Viswanathan et al. 2009) which occurs in 
about one third of the AD and vascular dementia cases, respectively (Burns & Iliffe, 
2009).
2
 
 While the definite etiological diagnosis for a patient with dementia requires a 
post-mortem brain autopsy, research of the last decades has made it possible to diagnose 
dementia due to AD and its prodromal stages with high sensitivity and specificity 
(Dubois et al. 2014). This has led to the formulation of new diagnostic criteria sets 
which incorporate specific in-vivo biomarkers that (if abnormal) increase the likelihood 
of AD pathology in patients with either dementia, MCI or in the preclinical stages of 
AD. These criteria are detailed in section 2.3 after the temporal development of AD has 
been outlined. 
Despite major advances in the understanding of the development of AD, 
pharmacological and non-pharmacological treatments have only lead to a symptom 
relief but not to a significant prevention of disease progression (Aisen et al. 2011). 
Results of clinical trials of anti-dementia drugs in MCI patients with prominent 
amnestic deficits (i.e. at increased risk of subsequent AD dementia) have also shown 
little success (Aisen et al. 2011). It has therefore been acknowledged that effective 
pharmaceutical treatment should best be located in the earlier MCI stages or even in the 
pre-MCI stage, when only little brain damage has occurred (Aisen et al. 2010; Sperling 
et al. 2011). However, in order to achieve this, an improvement of the early detection of 
incipient AD and more knowledge of  the cognitive decline in the early (pre-MCI) phase 
of AD are needed (Sperling et al. 2011). As will be discussed further below, the concept 
of SCD is important in this regard because it might be useful to define populations who 
are at increased risk of future AD dementia but are still in the earliest clinically 
detectable stage where interventions might be most effective (Sperling et al. 2011). 
Effective prevention will be crucial in order to face the socioeconomic burden of 
dementia today, and even more in future generations. As a consequence of the ageing 
                                                 
2
 A definite diagnosis of mixed dementia would require a brain autopsy. In empirical studies 
with clinical dementia diagnoses, cases of AD/vascular mixed dementia are usually included in the AD 
dementia group as it is the case in empirical studies 1 and 2 in this manuscript. 
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population, dementia prevalence is growing and will posit increasing societal costs. A 
study by Wimo and colleagues (Wimo et al. 2011) reported on 7.22 million demented 
people in the European Union and estimated the total costs of dementia to be €160 
billion corresponding to annual costs of €22 000 per dementia case with costs of 
informal care (56%) exceeding direct costs (44%). In a more recent study, the 
worldwide costs of dementia in 2010 were estimated to US$604 billion with 70% of 
these costs occurring in high-income regions of Western Europe and the USA (Wimo et 
al. 2013). For the latter, Hurd and colleagues (Hurd et al. 2013) have estimated that the 
total costs will approximately double in 2040 assuming that prevalence rates and costs 
per demented person remain stable. The implication of these numbers is straight 
forward: Improved early diagnosis and evidence based cost-effective intervention 
strategies need to be developed in order to relieve health care systems and improve the 
life of patients and their caregivers (Wimo et al. 2013). 
2.2 Temporal development: The biomarker model of AD 
This section describes the development of AD according to the “biomarker model 
of AD”, proposed by Jack and colleagues (Jack et al. 2010). The model suggests an 
ordered fashion in the dynamics of different markers of AD across progression from 
cognitively normal to dementia (see Figure 1). 
Figure 1. The biomarker model of AD as proposed in Jack et al. (2010, 2013). 
 
 
 
 
 
 
Note. Further information on Figure 1 is given in the following text. Figure reused in this dissertation 
with permission by Elsevier (RightsLink Licence number: 3390241478378). 
Figure 1 describes the temporal cascade of onset of AD pathology and clinical 
symptoms across the stages of Cognitively normal (preclinical AD), MCI due to AD 
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and AD dementia. According to the model, the level of abnormality of a disease marker 
for an individual at a given point in time is a function of (1) the time elapsed from onset 
of deviation of the marker away from normality to the point of assessment and (2) the 
marker’s average rate of change over this period of time. The first factor can be viewed 
as shifting from left to right on the x-axis of the graph The second factor can be 
described as the steepness of the trajectory which is not linear but varies across different 
intervals of the trajectory. AD is therefore viewed as an evolving process with dementia 
forming the clinical endpoint. Pathological changes in the brain, however, occur years 
to decades before the onset of overt clinical symptoms. 
For the description of the temporal development of AD, the model uses the five 
most well established indicators of AD pathological changes, which are called 
biomarkers. According to Jack and colleagues, these biomarkers can be divided into 
two major categories. The first category comprises markers of brain amyloid β (Aβ) 
plaque formation which can be measured by cerebrospinal fluid (CSF) levels of Aβ423 
and by brain PET Aβ imaging. The second category comprises three measures of 
neurodegeneration, defined as progressive loss of neurons or their functioning. 
Increased CSF tau reflects tau pathological changes and neuronal damage which also 
occurs in other conditions than AD (i.e. it is non-specific for AD). 
18
F-fluoro-deoxy-
glucose positron emission tomography (FDG-PET) is used to measure reduced brain 
metabolism (which indicates reduced synaptic activity). In early AD, hypometabolism 
can be detected in medial temporal lobes and parietotemporal posterior cortices, while 
other cortical areas are involved later as the disease progresses (Cason et al. 2011). 
Finally, structural magnetic resonance imaging (MRI) is used to measure brain atrophy.   
The temporal ordering of the biomarker changes depicted in Figure 1 follows 
the Amyloid Cascade Hypothesis of AD. This widely accepted hypothesis states that AD 
begins with abnormal processing of the amyloid precursor protein, which then leads to 
excessive production or reduced clearance, and consequently plaque formation of Aβ in 
the brain. Strong evidence for this assumption comes from genetic research on 
autosomal-dominant forms of (familial) early-onset AD (i.e. diagnosed before age of 
                                                 
3
 Aβ42 is an Aβ-peptide consisting of 42 amino acids. Aβ peptides with this length form the 
major part of the senile AD plaques in the brain. As Aβ42 cumulates into plaques in the brain, lower 
concentration of Aβ42 in the CSF indicates more AD pathology. 
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65) that is caused by genes involved in the production or cleavage of the amyloid 
precursor protein. Amyloid plaque formation is then supposed to lead to a downstream 
pathological cascade characterized by abnormal Tau protein aggregation, Tau-mediated 
neuronal injury and dysfunction, cell death, and atrophy of the brain. The mechanisms 
of this hypothetical cascade are yet not fully understood and subject to extensive 
research. 
Since the introduction of the biomarker model in 2010, it has received great 
interest in the field and numerous studies have been conducted to test the model’s 
hypotheses. In 2013, Jack and colleagues published an updated model in which this 
research is summarized (Jack et al. 2013). The accumulated evidence so far has 
supported the model’s main assumptions. However, challenging empirical data has also 
led to some important modifications. Figure 2 shows the updated biomarker model. 
Figure 2. The updated biomarker model of AD (adapted from Jack et al. 2013). 
 
Note. Further information on Figure 2 is given in the following text. Figure reused in this dissertation 
with permission by Elsevier (RightsLink Licence number: 3390241478378). 
A comparison of Figure 1 with Figure 2 shows that the main biomarkers of Aβ, 
Tau-mediated neuronal injury, and brain structure are now depicted more 
differentiatedly with slight reordering. In addition, a detection threshold has been 
introduced, which demarks the point where AD pathology can be detected by currently 
available in-vivo biomarkers. Autopsy studies (Braak & Del Tredici, 2011) have 
suggested that subcortical AD-like tauopathy precedes the Aβ pathology which 
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apparently contradicts the Amyloid Cascade Hypothesis of AD. In Figure 2 these 
findings have been integrated by proposing that subcortical AD-like tauopathy starts 
before and independently from Aβ accumulation. This process lies below the detection 
threshold of in-vivo markers and can only be found by methods of autopsy. 
Pathophysiological changes in Aβ, by yet unknown mechanisms, then accelerate the 
preceding subcortical tauopathy which will now also spread to neocortical areas. This 
accelerated tauopathy will however reach the detection threshold after the Aβ changes. 
Besides these amendments, it is important to note that both currently available 
diagnostic markers of Aβ (CSF-Aβ42 assays and Aβ-PET) provide evidence of fibrillar 
aggregates of Aβ but not of soluble Aβ oligomers. However, there is strong evidence 
from laboratory studies suggesting that oligomeric Aβ plays an important role in the AD 
cascade (Jack et al. 2013). Therefore this model might need refinement if methods to 
detect oligomeric forms of Aβ were to be developed in the future (Jack et al. 2013). 
From a clinical perspective, the most important revision has been made to the x-
axis of the model that is now labeled as “Time” rather than “Clinical disease stages”. 
The latter are now placed within a zone of cognitive impairment (green field in Figure 
2) that is delimited to the left and right by a high risk and low risk cognitive impairment 
trajectory, respectively (green lines). This new depiction of the disease progress 
accounts for inter-individual variability in the response to AD pathology. This is 
illustrated by the two points A and B within Figure 2 (inserted by the author of this 
thesis), which stand for individuals with a low risk (A) vs. high risk (B) profile, 
respectively. Likely modifiers of risk are genetic factors, lifestyle factors, comorbid 
(e.g. vascular) pathological processes, and cognitive reserve (Stern, 2012). As person A 
and B lie on the same point on the time-axis, they are confronted with the same level of 
AD pathological burden. However, while Person B will display cognitive impairment in 
the range of MCI, Person A will still perform within range of “normal test performance” 
on neuropsychological tests. Importantly, deterioration from the baseline performance 
has also taken place for Person A but this deterioration lies just at the border of the 
(cross-sectional) detection threshold of neuropsychological testing, i.e. impairment 
might not be detected with high diagnostic certainty. 
 This modification of the relationship between cognitive impairment and AD 
pathology has important implications for neuropsychological research and the concept 
of SCD. Person A is located exactly at the detection threshold of cognitive impairment. 
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As neuropsychological test results are usually a cross-sectional “snap-shot” of an 
individual’s performance, it will be difficult to classify this person either as normal or 
cognitively impaired (e.g. MCI) with sufficient diagnostic certainty. One possible 
solution to improve this dissatisfactory situation could be to apply neuropsychological 
tests that are optimized for detecting subtle, cognitive impairment due to AD, i.e. below 
the current detection threshold set by clinical standard tests. Research in this regard is 
undertaken (Rentz et al. 2013). 
The concept of SCD offers a second possibility that could complement more 
sensitive neuropsychological testing. As stated above, Person A has already deteriorated 
from a higher level of cognitive performance. Hence, although clinical standard tests 
would show no cognitive impairment, this individual might actually have perceived the 
decline from his/her former baseline performance and, as a consequence, reports SCD, 
is concerned about his/her cognitive performance and may seek medical evaluation. If 
the report of SCD already reflects the longitudinal decline of an individual below the 
threshold level of clinical standard tests, it bears the chance to detect people at higher 
risk to develop AD dementia at an earlier level of the disease process. Furthermore, as 
biomarkers of AD pathology will, according to the biomarker model, already be above 
their respective detection thresholds when SCD is reported (see Figure 2), the 
diagnostic certainty of incipient AD in these individuals can be further increased by 
more intensive, biomarker-based diagnostic procedures. Therefore SCD has the 
potential to be used as an indicator of increased likelihood of AD pathology and might 
be used in clinical practice and research, e.g. for sample enrichment in longitudinal 
studies or as a pre-selection process when defining “preclinical AD” samples on the 
basis of biomarkers (less people need to be screened which saves time and money). 
Samples defined like this might then also serve to validate new neuropsychological 
measures in the pre-MCI stage. 
2.3 Stages of AD: From preclinical AD to AD dementia 
The last section has outlined the temporal development of AD biomarkers in 
order to provide the basic context for SCD research within the field of AD. The next 
subsections will briefly describe the different stages of AD. These stages have been 
proposed in the recent years as research results have made it possible to diagnose 
probable AD in vivo with high accuracy due to the incorporation of biomarkers. 
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Two biomarker-based research criteria sets for the definition of AD are currently 
in use, namely the recommendations proposed by the workgroups of the NIA-AA in 
2011 (Sperling et al. 2011; Albert et al. 2011; McKhann et al. 2011) and those proposed 
by an International Working Group (IWG) in 2007 which were revised in 2010 and 
2014 (Dubois et al. 2007; Dubois et al. 2010; Dubois et al. 2014). Both criteria sets 
share many similarities but differ in some points regarding cognitive criteria, the 
application of biomarkers and the approach to subdivide AD stages. A detailed 
comparison of both criteria sets would be beyond the scope of this manuscript (see 
Visser et al. 2012 for a comprehensive overview). Instead, a short outline of the 
rationale to use the terminology of the NIA-AA criteria for the present document will be 
given in the following. 
Independently of specific criteria sets, AD can be divided into three stages 
(Visser et al. 2012): a pre-pathology stage (biomarkers normal, absence of cognitive 
impairment), an asymptomatic stage (biomarkers abnormal, absence of cognitive 
impairment), and a symptomatic stage (biomarkers abnormal, presence of cognitive 
impairment). Visser and colleagues further subdivide the symptomatic stage into pre-
MCI SCD, MCI and dementia. Both the IWG and NIA-AA criteria deal with the 
asymptomatic and symptomatic stages of AD. The IWG criteria propose only two 
criteria sets, namely one for the asymptomatic stage (termed “preclinical AD” in 2007, 
and “asymptomatic at risk” in the 2010/2014 revised criteria) and one for the 
symptomatic stage, which is simply named “AD”. The latter comprises subjects with 
MCI (now termed “prodromal AD”) and with AD dementia. That means that the term 
MCI is omitted in these criteria.
4
 Concerning cognitive criteria, the IWG criteria require 
a specific form of memory impairment measured by a test that controls for encoding and 
probes response to cueing (Dubois et al. 2010). Importantly, despite abnormal 
biomarkers, subjects with SCD who have normal test performance (pre-MCI SCD) 
cannot be clearly classified by these criteria (Visser et al. 2012) because they are neither 
“asymptomatic” nor do they meet the objective memory impairment criterion to be 
classified as “prodromal AD”. In contrast to this, the NIA-AA criteria propose three 
criteria sets: Preclinical AD, MCI due to AD, and AD dementia. With regard to 
                                                 
4
 In the IWG criteria, MCI is reserved for unclear diagnostic entities without clear cognitive 
criteria (i.e. the specific amnestic memory syndrome) and biomarker evidence of AD (Dubois et al. 
2010). 
 13 
cognitive criteria, (single or multiple) cognitive impairment rather than explicit memory 
impairment is required for diagnosis of MCI due to AD and AD dementia, respectively. 
Impairment in memory is considered a core feature which is seen in most (but not all) 
patients. However no specific memory test is required. Finally, in the NIA-AA criteria, 
subjects with pre-MCI SCD due to AD are part of the preclinical AD group (see section 
2.3.1). 
In summary, the NIA-AA criteria seem better suited as a framework for the 
present work as the term MCI is still used and patients presenting with pre-MCI SCD 
are explicitly addressed in these guidelines. Furthermore, the clinical-
neuropsychological criteria for MCI due to AD resemble the MCI criteria in the present 
studies. 
2.3.1 Preclinical AD 
The stage of preclinical AD as defined in the NIA-AA criteria set comprises the 
asymptomatic (abnormal biomarkers, no cognitive decline) as well as the earliest 
symptomatic phase of AD (abnormal biomarkers, subtle cognitive decline). As such 
they are centered on the early biomarkers of AD as outlined in the biomarker model (see 
section 2.2) which means that, following the Amyloid Cascade Hypothesis, abnormality 
in Aβ biomarkers (CSF-Aβ42 or Aβ brain PET imaging) are necessary features in these 
criteria. Additional markers of neurodegeneration and even subtle forms of cognitive 
impairment (not severe enough to warrant a diagnosis of MCI) are also part of the 
criteria. However, these features are complementary to the core feature of Aβ 
abnormality and are present in later sub-stages of preclinical AD (see below).  
The preclinical AD stage has been deliberately proposed using the term 
“research recommendations” instead of “diagnostic criteria” (Sperling et al. 2011). This 
is to emphasize that the proposed research criteria for preclinical AD should not yet be 
used for clinical purposes as there is currently limited knowledge on the relation 
between preclinical biomarker evidence of AD and subsequent emergence of clinical 
symptoms (Sperling et al. 2011). Instead, the aim of these criteria is to provide a 
common basis for the definition of study cohorts with increased risk of future AD in 
order to further investigate this relationship. This comprises longitudinal observational 
studies to test the predictive validity of preclinical AD criteria as well as clinical trials to 
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test the effect of disease-modifying interventions on biomarker progression or onset of 
clinical symptoms (Sperling et al. 2011). 
Sperling and colleagues have proposed a 3-stage schema to conceptualize 
preclinical AD as shown in Table 1. This staging schema describes preclinical AD as a 
continuum which comprises individuals with earliest detectable changes in biomarkers 
of Aβ (stage 1), individuals with additional abnormalities in markers of synaptic 
dysfunction and neuronal injury (stage 2) and finally those individuals who exhibit 
subtle cognitive decline in addition to evidence of abnormal biomarkers of both types 
(stage 3). 
Table 1. Stages of preclinical AD according to the NIA-AA criteria (Sperling et al. 
2011). 
Preclinical AD stage 
Evidence of 
markers of   
Aβ burden  
(CSF or PET) 
Evidence of   
markers of neuronal 
injury (CSF-Tau, 
FDG-PET, MRI) 
Evidence of 
subtle  
cognitive 
decline 
Stage 1: Asymptomatic cerebral 
amyloidosis Positive Negative Negative 
Stage 2: Asymptomatic amyloidosis + 
“downstream” neuronal injury  Positive Positive Negative 
Stage 3: Amyloidosis + neuronal 
injury + subtle cognitive decline Positive Positive Positive 
Note: Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid beta; CSF, cerebrospinal fluid; FDG, 18F-
fluoro-deoxy-glycose; MRI, (structural) magnetic resonance imaging; PET, positron emission 
tomography. 
Stage 1 represents the earliest definable stage of AD with current diagnostic 
markers. Individuals in stage 1 have evidence of Aβ deposition (CSF-Aβ42 and/or Aβ-
PET), but neither detectable abnormality in markers of early neuronal dysfunction nor 
detectable cognitive decline. 
Individuals in Stage 2 are considered “farther down the trajectory” of the AD 
pathological cascade as they show additional evidence of early neuronal injury and/or 
neurodegeneration (Sperling et al. 2011). Such evidence is defined as: (1) elevated 
CSF-Tau or phospho-tau, and/or (2) hypometabolism in an AD-like pattern on FDG-
PET (i.e., posterior cingulate, precuneus, and/or temporoparietal cortices) and/or (3) 
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cortical thinning/gray matter loss in a specific anatomic distribution (i.e., lateral and 
medial parietal, posterior cingulate, and lateral temporal cortices) and/or hippocampal 
atrophy on volumetric MRI (Sperling et al. 2011). 
Stage 3 is considered to be the last stage of preclinical AD. Individuals in this 
stage will show evidence of subtle cognitive decline in addition to biomarker evidence 
of both Aβ deposition and neurodegeneration. Subtle cognitive decline may be evident 
as a decline from a previously higher level, although a level of impairment that would 
warrant a diagnosis of MCI is not yet reached. These individuals thus can be considered 
as being in a transitional state between “cognitively normal” and “clinically impaired” 
(i.e. MCI). One major research goal is to develop sensitive and specific 
neuropsychological instruments to predict conversion from this state to incident MCI or 
dementia. Emerging evidence suggests that more challenging episodic memory tests e.g. 
the Face-Name-Test or tests that measure visual short-term feature binding (Rentz et al. 
2013) might be useful in this regard. Importantly, SCD is explicitly mentioned as an 
alternative, potentially useful indicator of subtle cognitive decline. In addition, the 
emergence of behavioral symptoms might be a feature of preclinical AD stage 3. 
However, there is only very limited evidence to date (Duara et al. 2011). Importantly, 
classification of an individual as preclinical AD will largely depend on the cutoffs for 
biomarker positivity that are applied. One goal of future research is to develop the 
optimal combination of and cutoffs for biomarkers with regard to prediction of incident 
MCI and AD dementia. The same is true for the criterion of subtle cognitive decline as 
measured either by a challenging memory test or evidence of SCD. 
2.3.2 Mild Cognitive Impairment due to AD 
The syndrome of MCI is characterized by the presence of impairment in one or 
more cognitive domains while at the same time the patient’s functional abilities are 
largely preserved, not warranting a diagnosis of dementia. Neuropsychological 
impairment is here defined as a performance deficit which is greater than would be 
expected based on the patient’s age, gender and educational background. It is typically 
expressed in units of standard deviations (SD) below the age-, gender-, and education 
adjusted norm. The necessary number of domains to be impaired (single- or multi-
domain MCI), the number of test scores per domain and the best threshold of 
impairment have constantly been debated since the introduction of the term MCI into 
the field and are still subject to extensive research (Bondi & Smith, 2014).  
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The clinical syndrome of MCI can be caused by different factors besides AD, 
such as head trauma, depression, substance abuse or other forms of neurodegenerative 
diseases. The NIA-AA criteria therefore introduce the term “MCI due to AD” (MCI-
AD), in order to characterize those individuals within the MCI spectrum, whose primary 
underlying pathology is AD. MCI-AD is thus the first clinical stage of AD and 
considered a transitional stage between clinically normal (i.e. preclinical AD) and AD 
dementia. 
 As in the preclinical AD criteria, biomarkers are part of the MCI-AD criteria. 
However, again similarly to the preclinical AD criteria, it is emphasized that the 
biomarker based criteria should at present only be applied in research contexts and 
might be subject to revision (Albert et al. 2011). As such the MCI diagnosis is still first 
and foremost based on clinical/cognitive criteria which are named the “core-clinical 
criteria” within the NIA-AA framework. The clinical research criteria for MCI-AD are 
an extension of the core-clinical criteria and incorporate biomarkers to provide 
increasing levels of certainty that AD is the cause for a patient’s MCI syndrome (Albert 
et al. 2011). 
Core-clinical criteria of MCI (NIA-AA framework) 
The core-clinical criteria for MCI are defined as follows (Albert et al. 2011): 
1. Evidence of a concern regarding a change (decline) in cognition, obtained either 
by the patient and/or a close informant or clinician. This criterion of self- or 
informant-reported cognitive change is used to infer a decline in cognitive performance 
in the (usual) scenario of a single objective cognitive evaluation. It is important to note 
here that informant reports are equally treated as a source of information on subjective 
cognitive decline. 
2. Objective impairment in one or more cognitive domains. Impairment is defined as 
performance that is lower than would be expected based on the patient’s age and 
educational background. If repeated measurement is available, then there should be 
evidence of a decline in performance over time. No specific cutoffs for impairment are 
proposed, but the NIA-AA criteria state scores of 1.0-1.5SD below the age-, (gender-) 
and education adjusted means in the impaired domains to be “typical” for MCI patients. 
By stating this, the NIA-AA take a rather liberal approach with regard to the severity of 
neuropsychological impairment as it may be sufficient for an individual to show scores 
 17 
below 1SD in one test of one cognitive domain to be classified as MCI (providing the 
other criteria are met). It has been argued that such a liberal definition might enhance 
the number of false-positive MCI diagnoses compared to a more strict 
neuropsychological definition of MCI (Bondi et al. 2014). However, one must keep in 
mind that the core-clinical criteria are thought to be combined with biomarker evidence. 
As such, a liberal approach that, at the expense of reduced specificity, maximizes the 
number of potential cases with underlying AD, might be optimal when combined with a 
subsequent biological criterion that has the potential to significantly enhance specificity 
to AD. 
3. Preservation of independence in functional abilities. This criterion basically 
distinguishes the MCI syndrome from dementia. Although individuals with MCI usually 
have mild problems when performing complex instrumental activities of daily living 
(IADL; such as performing financial transactions, shopping, preparing meals etc.), they 
maintain independence of function in daily life, with minimal aids or assistance. 
4. Not demented. As already stated in the third criterion, the cognitive changes should 
be sufficiently mild that there is no interference with social or occupational functioning 
(which if present would warrant a diagnosis of dementia). 
These four criteria together warrant a clinical diagnosis of MCI. In the next step 
of the diagnostic process, it must be determined whether the MCI syndrome is 
consistent with that typically seen in individuals who later progress to AD. Typical 
clinical/cognitive features of MCI patients with underlying AD pathology are a decline 
in episodic memory as the primarily affected domain (“amnestic MCI”). This decline is 
usually a slowly progressive rather than a rapid one. In addition, causes other than AD 
that could account for the decline in cognition (e.g. vascular, traumatic, medical, or 
other neurodegenerative factors) should be ruled out. However, this might be 
challenging since vascular diseases or other neurodegenerative factors might coexist 
with AD pathology in many individuals (Albert et al. 2011; Viswanathan et al. 2009). 
Lastly, the presence of one or two ε4 alleles in the apolipoprotein E (APOE) gene 
increases the likelihood of an AD etiology in a patient who meets the core clinical 
criteria for MCI (Albert et al. 2011). 
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MCI-AD research criteria incorporating biomarkers 
 Based on the core-clinical criteria, MCI-AD criteria incorporating biomarkers 
are proposed to provide increasing levels of certainty for underlying AD in a patient 
meeting the core-clinical criteria for MCI. The NIA-AA criteria employ two types of 
biomarkers, namely biomarkers of Aβ deposition and biomarkers of neuronal injury, as 
already outlined in the previous section on preclinical AD criteria (see section 2.3.1). 
CSF-Aβ42 and CSF-Tau are among the best validated measures of Aβ deposition and of 
neuronal injury respectively (Albert et al. 2011). Based on (1) the core-clinical criteria 
and (2) information on biomarkers of both types named above, the terminology outlined 
in Table 2 has been proposed. 
Table 2. MCI due to AD according to the NIA-AA criteria (Albert et al. 2011). 
Diagnostic 
category 
Biomarker 
probability of  
AD pathology 
Evidence of markers of 
Aβ burden  
(CSF or PET) 
Evidence of markers of 
neuronal injury (e.g. CSF-
Tau, FDG-PET, MRI) 
MCI-core clinical 
criteria 
Uninformative or not 
available 
Conflicting/ 
indeterminate/untested 
Conflicting/          
indeterminate/untested 
MCI due to AD – 
intermediate 
likelihood 
Intermediate 
Positive Untested 
Untested Positive 
MCI due to AD – 
high likelihood 
Highest Positive Positive 
MCI – unlikely 
due to AD 
Lowest Negative Negative 
Note: Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid beta; CSF, cerebrospinal fluid; FDG, 18F-
fluoro-deoxy-glycose; MCI, Mild cognitive impairment; MRI, (structural) magnetic resonance imaging; 
PET,  positron emission tomography. Further information is given in the following text. 
As can be seen in Table 2, the NIA-AA proposes a probabilistic approach to 
diagnose MCI-AD with different levels of likelihood of an AD pathology based on the 
available biomarker information. The diagnostic category of MCI–core clinical criteria 
comprises patients with a syndrome of MCI that is clinically consistent with AD but for 
whom biomarker information is either unavailable or has been uninformative. 
Uninformative biomarker evidence is here defined as either an indeterminate (i.e. falling 
within ambiguous ranges) or a conflicting (i.e. positive Aβ biomarker and a negative 
biomarker of neuronal injury or the reverse) test result. Individuals falling in the 
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category of MCI-AD with intermediate likelihood fulfill the core-clinical criteria and 
have a positive biomarker result for either Aβ deposition or neuronal injury with the 
other category untested. With regard to the probability of AD these individuals are 
supposed to lie between those with conflicting evidence and those in the third category: 
MCI-AD with high likelihood. This category is defined by positivity in both types of 
biomarkers. Individuals in this category have the highest likelihood for underlying AD 
and will likely progress faster to AD dementia compared to the individuals in the 
intermediate and core-clinical group. Finally, there is the category of MCI – unlikely 
due to AD, defined by negative results in both types of biomarkers. In such a case, 
further search for biomarker evidence that suggests other etiologies may be warranted 
(see Albert et al. 2011 for details).  
Further research aims to provide the necessary empirical data to prove the utility 
of these criteria. For the present work the following points are important. In study 1 of 
this work MCI is defined similar to the NIA-AA core-clinical criteria, however, with an 
emphasis on episodic memory decline as the defining cognitive domain. In addition, 
study 1 will subdivide MCI individuals according to the severity of memory impairment 
into “early MCI” with impairment between 1.0-1.5SD below norm and “late MCI” with 
performance of <1.5SD below norm. 
MCI in study 2 and study 3 is defined according to criteria proposed by an 
International Working group in 2004 (Winblad et al. 2004). These are similar to the 
NIA-AA core-clinical criteria and employ a liberal cut-off of 1SD in one or more of the 
tests applied. In addition, study 3 incorporates biomarkers of CSF-Aβ42 and CSF-Tau 
which enables the definition of a subgroup of MCI patients with increased likelihood of 
AD pathology (“MCI due to AD – high likelihood” in the NIA-AA or “prodromal AD” 
in the IWG terminology, respectively). 
2.3.3 AD dementia 
AD dementia describes dementia secondary to the neurodegenerative process of 
AD (McKhann et al. 1984; McKhann et al. 2011). Following the logic of the MCI 
criteria set, the NIA-AA criteria proposes core-clinical criteria for AD dementia, which 
can be applied in all clinical settings, and an additional set of criteria, incorporating 
biomarkers and currently intended for research settings. At this point it should be 
reemphasized that the criteria for AD dementia used in the empirical studies of this 
 20 
thesis are not based on the newer NIA-AA criteria but on the previous version of these 
criteria, namely the NINCDS-ADRDA criteria for clinical AD dementia (McKhann et 
al. 1984). Since the studies presented here used clinical diagnoses as outcomes, the 
core-clinical criteria for probable AD in the newer NIA-AA criteria are the important 
equivalents. Patients diagnosed with “probable AD” by the 1984 NINCDS–ADRDA 
criteria would also meet the core-clinical criteria for probable AD as outlined below 
(McKhann et al. 2011). The NIA-AA first proposes criteria for all-cause dementia to 
characterize the general syndrome of dementia and then presents the core-clinical and 
biomarker-based criteria for probable AD dementia and possible AD dementia as the 
specific dementia syndrome secondary to AD pathology. 
NIA-AA core clinical criteria: All-cause dementia 
All-cause dementia is defined by presence of cognitive or neuropsychiatric 
symptoms that fulfill the following criteria (McKhann et al. 2011): 
1. The symptoms interfere with the ability to function at work or at usual activities. 
2. They represent a decline from previous levels of functioning and performing. 
3. They are not explained by delirium or major psychiatric disorder. 
4. Cognitive impairment is detected and diagnosed through a combination of (1) 
history-taking from the patient and a knowledgeable informant and (2) an objective 
cognitive assessment, i.e. either a “bedside” mental status examination or 
neuropsychological testing (to be employed if the routine history and bedside mental 
status examination cannot provide a confident diagnosis). 
5. The cognitive or behavioral impairment involves a minimum of two of the following 
domains: 
a. Impaired ability to acquire and remember new information – symptoms include: 
repetitive questions or conversations, misplacing personal belongings, forgetting events 
or appointments, getting lost on a familiar route. 
b. Impaired reasoning and handling of complex tasks, poor judgment – symptoms 
include: poor understanding of safety risks, inability to manage finances, poor decision-
making ability, and inability to plan complex or sequential activities. 
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c. Impaired visuospatial abilities – symptoms include: inability to recognize faces or 
common objects or to find objects in direct view despite good acuity, inability to 
operate simple implements, or orient clothing to the body. 
d. Impaired language functions (speaking, reading, and writing) – symptoms include: 
difficulty in thinking of common words while speaking, hesitations; speech, spelling, 
and writing errors. 
e. Changes in personality, behavior, or comportment – symptoms include: 
uncharacteristic mood fluctuations such as agitation, impaired motivation, initiative, 
apathy, loss of drive, social withdrawal, decreased interest in previous activities, loss of 
empathy, compulsive or obsessive behaviors, and socially unacceptable behaviors. 
NIA-AA core-clinical criteria: AD dementia 
Based on the criteria for all-cause dementia, two types of clinical AD dementia 
diagnoses are proposed according to the level of certainty of AD as the primary cause of 
the dementia syndrome: probable AD and possible AD (McKhann et al. 2011).  
Core-clinical criteria for probable AD dementia 
Probable AD dementia according to the core-clinical criteria is diagnosed if the 
following criteria are met (McKhann et al. 2011): 
1. The individual meets criteria for dementia described above, and in addition, has the 
following characteristics: 
A. Insidious onset: Symptoms have a gradual onset over months to years, not sudden 
over hours or days; 
B. Clear-cut history of worsening of cognition by report or observation; and 
C. The initial and most prominent cognitive deficits are evident on history and 
examination in one of the following categories: 
a. Amnestic presentation: It is the most common syndromic presentation of AD 
dementia. The deficits should include impairment in learning and recall of recently 
learned information. There should also be evidence of cognitive dysfunction in at least 
one other cognitive domain, as defined earlier in the text. 
b. Nonamnestic presentations: Language presentation: The most prominent deficits are 
in word-finding, but deficits in other cognitive domains should be present as well. 
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Visuospatial presentation: The most prominent deficits are in spatial cognition, 
including object agnosia, impaired face recognition, simultanagnosia (inability to 
perceive more than one object at a time), and alexia. Deficits in other cognitive domains 
should be present. 
Executive dysfunction: The most prominent deficits are impaired reasoning, judgment, 
and problem solving. Deficits in other cognitive domains should be present. 
D. The diagnosis of probable AD dementia should not be applied when there is 
evidence of one of the following aspects: (a) substantial concomitant cerebrovascular 
disease, defined by a history of a stroke temporally related to the onset or worsening of 
cognitive impairment; or the presence of multiple or extensive infarcts or severe white 
matter hyperintensity burden; (b) core features of Dementia with Lewy bodies other 
than dementia itself; (c) prominent features of behavioral variant frontotemporal 
dementia; (d) prominent features of semantic variant primary progressive aphasia or 
nonfluent/agrammatic variant primary progressive aphasia; or (e) evidence for another 
concurrent, active neurological disease, or a non-neurological medical comorbidity or 
use of medication that could have a substantial effect on cognition. 
In addition to these core-clinical criteria, a diagnosis of probable AD dementia 
with increased level of certainty can be coded for (a) patients in whom cognitive decline 
is documented on subsequent evaluations (through informant reports or 
neuropsychological examination), or (b) patients who are carrier of a causative AD 
genetic mutation (APP, PSEN1, or PSEN2 gene variants). 
Core-clinical criteria for possible AD dementia 
A diagnosis of possible AD dementia should be made when a patient meets the 
core-clinical criteria with regard to the nature of the cognitive deficits described above 
but has characteristics of either an atypical course or evidence of an etiologically mixed 
presentation (McKhann et al. 2011). An atypical course is characterized by a sudden 
(rather than an insidious) onset of impairment or limited information on progressive 
decline. An etiologically mixed presentation is characterized by: (a) concomitant 
cerebrovascular disease, defined by a history of stroke temporally related to the onset or 
worsening of cognitive impairment; or the presence of multiple or extensive infarcts or 
severe white matter hyperintensity burden; or (b) features of Dementia with Lewy 
bodies other than the dementia itself; or (c) evidence for another neurological disease or 
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a non-neurological medical comorbidity or medication use that could have a substantial 
effect on cognition. 
NIA-AA criteria for AD dementia with incorporation of biomarkers 
Following the logic outlined in the criteria schemes of the preclinical AD and 
MCI-AD stage, biomarker information of the two major categories (Aβ deposition and 
downstream neuronal injury) is incorporated in the biomarker-based research criteria for 
probable and possible AD. Table 3 summarizes these diagnostic criteria. 
Table 3. Biomarker-based AD dementia diagnosis according to NIA-AA criteria 
(McKhann et al. 2011). 
Diagnostic 
category 
Biomarker probability 
of AD etiology 
Evidence of markers of 
Aβ burden (CSF or 
PET) 
Evidence of  markers of 
neuronal injury (CSF-
Tau, FDG-PET, MRI) 
1. Probable AD dementia  
1 .a. based on core-
clinical criteria 
Uninformative 
Conflicting/ 
indeterminate/ 
unavailable 
Conflicting/ 
indeterminate/ 
unavailable 
1.b. Intermediate 
level of biomarker 
evidence  
Intermediate 
Positive 
Unavailable or 
indeterminate 
Unavailable or 
indeterminate 
Positive 
1.c. High level of 
biomarker 
evidence 
Highest Positive Positive 
2. Possible AD dementia (atypical clinical presentation) 
2.a. based on 
clinical criteria 
Uninformative 
Conflicting/ 
indeterminate/ 
unavailable 
Conflicting/ 
indeterminate/ 
unavailable 
2.b. with evidence 
for AD 
pathophysiological 
process 
High but does not rule 
out second etiology 
Positive Positive  
3. Dementia – 
unlikely due to AD 
Lowest Negative Negative 
Note: Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid beta; CSF, cerebrospinal fluid; FDG, 18F-
fluoro-deoxy-glycose MCI, Mild cognitive impairment; MRI, (structural) magnetic resonance imaging; 
PET, positron emission tomography. 
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2.4 Subjective Cognitive Decline (SCD) as a clinical symptom of AD 
The following section deals with the concept of Subjective Cognitive Decline 
(SCD). Section 2.4.1 will provide an overview on the SCD concept with regard to 
different terminology in the literature. It will also explain the terminology used in the 
present manuscript. Section 2.4.2 will describe (the heterogeneous) operationalizations 
and assessment methods of SCD in the field of geriatrics. Section 2.4.3 will focus on 
previous research that addresses cross-sectional and prospective associations of SCD 
with other variables in the above outlined stages of AD (preclinical AD, MCI-AD and 
AD dementia). Based on this research overview, a hypothetical working model of the 
temporal development of SCD during the course of AD will be presented and its 
implications discussed (section 2.4.4). 
2.4.1 Overview and terminology 
The concept of SCD has already been introduced more than 30 years ago by 
Berry Reisberg and colleagues in their approach to define stages of AD with the Global 
Deterioation Scale (GDS; Reisberg et al. 1982). In fact, stage 2 of the GDS is defined as 
“normative cognitive functioning, with subjective cognitive impairment” corresponding 
well to the term “SCD in preclinical AD/pre-MCI SCD” introduced by the SCD-
Initiative in 2014 (Jessen et al. 2014a). However, within this 30-year period, SCD has 
developed to a very heterogeneous concept with regard to terminology, specific criteria 
and assessment methods. 
Heterogeneous terminology in the literature 
A review of the relevant literature reveals a variety of terms to describe 
subjectively experienced cognitive worsening. 
Table 4 shows that there are a number of different terminologies used in the 
field. Although these differences seem subtle at a first glance, it is important to point 
them out from the beginning to ensure a better understanding of the implications of each 
of the different wordings. 
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Table 4. Terms for the symptom of SCD in the scientific literature. 
Term abbreviation  
Source  
(selected examples) Comment 
Subjective 
Memory 
Impairment 
SMI Jessen et al. (2010) 
Preferred by the AgeCoDe study group until 
2014. Used in the original publication of 
study 1 of this manuscript. 
Subjective 
Memory 
Complaints 
SMC 
Schmand et al. 
(1997) 
Used in many original articles and reviews 
(Subjective) 
Memory 
Concerns 
MC 
Wolfsgruber et al. 
(2014b); Wolfsgruber 
et al. (2015) 
Term describes a subgroup of patients who 
appraise their memory decline as 
worrying/concerning. Also used in Jessen et 
al. (2010) and Jessen et al. (2014b) as 
“Subjective Memory Impairment with 
worries” or as “Subjective Cognitive 
Decline with concerns (SCD+C). 
Subjective 
Memory 
deterioration 
_ Wang et al. (2004) Seldomly used 
Subjective 
Memory Loss 
_ 
Sinoff & Werner 
(2003) 
Seldomly used 
Subjective 
Cognitive 
Impairment 
SCI Stewart (2012) Used in many original articles and reviews 
Subjective 
Cognitive 
Complaints 
SCC Dufouil et al. (2005) 
Also used simply as “cognitive complaints”. 
Often used in other fields than Geriatrics. 
Subjective 
Cognitive 
Decline 
SCD Jessen et al. (2014a) 
Preferred term of the newly founded 
Subjective Cognitive Decline Initiative. 
Preferred term in this manuscript. 
Note: The Table shows different terms used in the scientific literature for memory-related or global 
Subjective Cognitive Decline. 
In his review on the recent literature on SCD
5
, Stewart (2012) points out two 
sources of variability in the nomenclature. The first refers to the cognitive domain. 
Some terminologies use “cognitive” while “memory” is most often used. In this regard, 
Stewart points out that there is a lack of research regarding the exact nature of the 
impairment itself and the term used to describe it. In other words it is unclear “whether 
persons complaining of problematic forgetfulness are truly describing their perceived 
memory function or whether they are experiencing impairment in a different cognitive 
domain (or multiple domains) for which a complaint of poor memory provides the only 
                                                 
5
 Stewart actually uses the term „Subjective Cognitive Impairment” in his review. 
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recognizable and/or acceptable term available” (Stewart, 2012, p.445). The second 
aspect concerns the use of “complaints” vs. “impairment” to describe the symptom. 
Stewart points out that the term “complaints” implies some form of spontaneous 
reporting and therefore fits to clinical settings where patients actively present for 
memory assessment. However, “impairment” may be the more accurate term for 
defining the symptom on the basis of a positive response to a questionnaire, typically 
employed in epidemiological settings. Further differences, not mentioned by Stewart, 
arise from the usage of a term that directly describes a change in cognition (such as 
“loss”, “deterioration” or “decline”) in contrast to a term that is unspecific with regard 
to this important aspect (“impairment”, “complaints”). As AD-related cognitive deficits 
are slowly progressive, a term describing change seems more accurate (Jessen et al. 
2014a; Abdulrab & Heun, 2008). Studies having used terms like complaints or 
impairment might actually have assessed decline, as the questions applied in the study 
protocols, or at least a portion of those if a summary measure was used, actually 
referred to a change in cognition (e.g. Geerlings et al. 1999). Likewise, studies in 
epidemiological settings have used the word “complaints” while actually measuring 
“impairment” (e.g. Jorm et al. 1997). The respective opposite holds true for some 
studies in clinical settings that used the term “impairment” when, precisely speaking, 
they measured “complaints” (e.g. Erk et al. 2011). 
Description of a symptom vs. labeling of a diagnostic group 
In addition to the above mentioned subtleties regarding SCD terminology, there 
is one important aspect that needs to be pointed out, namely the usage of SCD to 
describe a symptom vs. the usage of SCD to describe a certain group of patients. SCD 
and its related terms (see Table 4) have been used for both purposes. SCD as a symptom 
is not limited to a certain patient group but applies to individuals who present with SCD 
due to several etiologies, of which AD is but one. Even when only referring to AD-
related SCD, it is not limited to a certain disease stage. In contrast to conceptualization 
of SCD as a symptom, the term has also been used to describe patients that present with 
the symptom of SCD in the absence of a cognitive impairment, evidenced by 
neuropsychological test results in the normal range. 
Usage of the broad term of SCD to describe a specific group of patients must be 
seen critically, as it can lead to confusion with other studies that speak of SCD without 
exactly referring to a patient group. The SCD-Initiative has therefore decided to speak 
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of either “pre-MCI SCD” or “SCD in preclinical AD” to specifically address the patient 
group characterized by presence of SCD but absence of cognitive impairment on 
clinical standard tests which would warrant a diagnosis of MCI. The terminology of the 
present manuscript follows this suggestion. 
Terminology used in the present work 
The last section has emphasized the need for a SCD terminology that is as 
consistent as possible throughout the present manuscript. For the main part of the 
present manuscript the term SCD will be used as it is arguably the best to describe the 
symptom of AD-related subjective cognitive worsening over time, comprising both 
memory and non-memory domains (Jessen et al. 2014a). As such, SCD is used as a 
general term throughout the text and will also be used when referring to studies that 
used other terms listed in Table 4. However, whenever there is the need for a more 
precise wording, additional adjectives will be used to describe the exact form of SCD, 
e.g. “memory-related SCD” would specifically describe subjective cognitive decline in 
the memory domain. Note that, although the empirical studies presented in this thesis 
(section 3) focus on such memory-related SCD, the broader term of “SCD” will most 
often be used. This has been done to be more consistent with the most recent term 
introduced by the SCD-Initiative. 
Further, the empirical studies presented herein partly address a specific form of 
memory-related SCD that can be described as “Subjective Cognitive Decline with 
associated concerns” (SCD+C). This term describes a subgroup of individuals who 
report a subjective cognitive decline (in empirical studies 1-3 referring always to the 
memory domain) and, in addition, appraise this self-experienced decline as particularly 
worrying. Individuals who only report memory decline (without associated worries) will 
be termed “Subjective Cognitive Decline without associated concerns” (SCD-C). Note 
that in study 2 and 3 the term “memory concerns” is also used as a synonym of SCD+C 
to keep with the wording of the original publications of these two studies. 
Finally, note that study 1 is a population based study that compares the risk of 
incident AD dementia in patients with MCI to that in individuals with normal cognitive 
test performance but presence of SCD. That means SCD is, as an exception, also used to 
describe a diagnostic subgroup of patients in that study. This group will be labeled with 
the prefix “pre-MCI” to distinguish them from the groups which exhibit SCD but have 
 28 
cognitive impairment in the MCI range. For reference, Table 5 provides an overview of 
the terminology used in this manuscript.  
Table 5. Terminology of SCD used in the present work 
Term Abbreviation  Comment 
Subjective Cognitive 
Decline 
SCD 
General term to describe the symptom of subjective 
cognitive decline throughout the whole manuscript. 
Subjective Cognitive 
Decline with  
associated concerns 
SCD+C 
Describes a subgroup of individuals who appraise their 
subjective cognitive decline as worrying. SCD+C 
refers both to individuals with normal cognitive test 
performance and to MCI patients. 
Subjective Cognitive 
Decline without 
associated concerns 
SCD-C 
Describes a subgroup of individuals with subjective 
cognitive decline but with no concerns regarding the 
self-experienced decline. SCD-C refers both to 
individuals with normal cognitive test performance and 
to MCI patients. 
Memory Concerns MC 
Is used synonymous to “memory-related SCD+C” in 
empirical studies 2 and 3 and reflects the notion of 
worsening memory appraised as worrying. 
pre-Mild Cognitive 
Impairment 
pre-MCI 
Pre-MCI is used as a prefix to SCD. When used in 
conjunction with SCD it describes individuals with 
SCD but  normal cognitive test performance (i.e. the  
term then describes a specific patient group, not the 
symptom per se) 
pre-MCI SCD Individuals with SCD but normal test performance 
pre-MCI 
SCD+C 
Individuals with SCD+C but normal test performance 
pre-MCI 
SCD-C 
Individuals with SCD-C but normal test performance 
Controls CO 
Individuals without report of any subjective cognitive 
decline and with normal cognitive test performance. 
Note: The table contains the Subjective Cognitive Decline terminology used in the different sections of 
the present manuscript. Further explanation of this terminology is given in section 2.4.1. 
2.4.2 Operationalization and assessment of SCD 
The heterogeneity of SCD with regard to terminology is paralleled by an equally 
heterogeneous array of operationalization and assessment methods. These range from 
single questions to detailed quantitative assessment with multi-factorial questionnaires. 
A comprehensive overview of all the different questions, scales and operationalizations 
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used throughout the literature would go far beyond the scope of this work. Rather, the 
different definitional approaches to SCD are presented together with a selection of 
questions and scales. The key point of this selected presentation is to show that SCD has 
been defined rather inconsistently in the past and that the field has just recently begun to 
develop a common set of research criteria. 
Heterogeneous operationalization of SCD in the recent literature 
Abdulrab and Heun (2008) give an overview of the various forms of 
operationalizations of memory-related SCD and list the following common approaches:  
 Use of a single question with “yes/no” response. 
 Use of a single question with “graded” (i.e. ordinal) response categories. 
 Use of scales comprising a set of questions with “yes/no” responses for 
which  
o either a single item or 
o a minimum number of items  
must be answered “yes” in order to categorize a subject as having SCD. 
 Use of questionnaires or subscales of a questionnaire with scored 
responses. A cutoff score is then used to define SCD. 
All these approaches, irrespective of number and characteristics of items, have in 
common that they lead to a categorical definition of either presence or absence of SCD. 
However, there is also a significant amount of papers that measured SCD as a 
continuous variable derived either from a single scale or by aggregation of multiple 
scales without giving a categorical SCD definition. Abdulrab and Heun (2008) 
identified 100 such papers but discarded them from further analysis as they focused on 
the categorical definition of memory-related SCD in their review. In line with this, 
categorical definitions will be discussed first and selected quantitative SCD scales are 
presented at the end of this section. Finally, SCD has also been defined by using 
questions from broader psychopathological symptom check lists (e.g. SCL-90-R, as in 
Grambaite et al. 2013)
6
. 
                                                 
6
 Interestingly, Abdulrab and Heun excluded 12 such papers from their review without further 
explanation. 
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Single-question-operationalizations usually employ more broader questions, 
with regard to context and severity of the memory problems (no questions with regard 
to specific activities) and might not even ask for a specific course of the symptoms 
(example questions: “Do you have problems/trouble with your memory?”; “Do you 
consider yourself as being forgetful?”). Other single questions specifically ask for a 
change in cognitive performance with or without setting a specific time frame (e.g. “Is 
your memory becoming worse” vs. “Have you had memory loss in the past year?”). 
Multiple-question-operationalizations usually ask for difficulties in several 
situations (e.g. remembering names, conversations). Some may also assess a grade of 
subjective severity of the experienced impairment, e.g. by asking for interference with 
daily activities, medical help seeking, perception by others, or associated concerns 
(some example questions are: “Do other people find you forgetful?”, “Are there any 
activities which you are prevented from participating in as a result of these memory 
problems?”, “Have you sought medical help or taken medication for this memory 
problem?”). 
The number and nature of questions in the SCD definitions has varied widely 
and, thus, criteria across studies from different work groups have been inconsistent 
(Abdulrab & Heun, 2008). It is further unclear whether more general vs. specific 
questions, single vs. multiple questions etc. are best to define SCD. One plausible 
argument against single-question and a categorical operationalization is that it might be 
too over-inclusive, i.e. the specificity with regard to identification of subjects with 
underlying AD pathology is limited in this approach. It is similarly unclear whether 
categorical definitions of SCD are better in terms of research and clinical practice utility 
than treatment of SCD as a dimensional variable. A dimensional approach might be 
beneficial for complex statistical analyses. However some kind of cutoff on a 
dimensional measure to classify an individual, either as having SCD or not, is usually 
required for sampling purposes. 
Acknowledgement of the above outlined heterogeneous definitions of SCD has 
recently led to the start of a research initiative to address this apparent deficiency. The 
SCD-Initiative has proposed a conceptual framework for research on pre-MCI SCD 
(Jessen et al. 2014a). Within this framework SCD has been defined as symptomatically 
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without recommendation of specific questions or scales.
7
 However, based on the 
existing small empirical basis, the SCD-Initiative has outlined some specific features 
associated with SCD that might increase the likelihood of underlying preclinical AD 
(termed as “SCD plus”). These features are outlined in the following together with the 
SCD-Initiative’s recommendation of general features to be coded in a study employing 
the concept of SCD (Jessen et al. 2014a): 
 Setting in which SCD is expressed. 
o Medical environment 
 Memory clinic, memory specialist (compare empirical study 2 
and 3) 
 General practitioner 
o Population sample (compare empirical study 1) 
o Volunteer sample (recruitment by advertisement) 
 Association of SCD with medical help seeking (yes/no). 
 Report of SCD (spontaneously/on request; relates to complaints vs. impairment 
in Stewart’s (2012) terminology). 
 Onset of SCD (number of years)  SCD plus if within last 5 years. 
 Age at onset of SCD  SCD plus if age at onset >= 60. 
 Subjective decline in memory (yes/no)  SCD plus if yes. 
 Subjective decline in non-memory domains (yes/no)  if yes, specify. 
 Concerns (worries) associated with SCD (yes/no)  SCD plus if yes (= 
SCD+C). 
                                                 
7
 Rather, the SCD-Initiative has first agreed on SCD as a “best trade-off” concept: “Subjective” (i.e. no 
external validation by objective test or informant needed), “Cognitive” (instead of memory alone) and 
“Decline” (as opposed to “impairment”). The SCD-Initiative further acknowledges that any SCD 
definition is “a trade-off between being overinclusive and being too restrictive”. They chose a sensitive 
and potentially overinclusive definition as the specific features of SCD in preclinical AD are yet unclear 
(Jessen et al. 2014a). 
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 Feeling of worse performance than others of the same age group (yes/no)  
SCD plus if yes. 
 Association of SCD with experience of impairment (yes/no). 
 Confirmation of cognitive decline by an informant (yes/no)  SCD plus if yes. 
 Score on a depression scale, score on an anxiety scale. 
 APOE genotype, if available  SCD plus if carrier of one or more APOE4 
alleles. 
Importantly, Jessen and colleagues highlight the caveat that these features need 
further validation and are subject to modifications (especially those of SCD plus; see 
Jessen et al. 2014a for a list of empirical evidence for each feature). 
Quantitative SCD assessment and selected scales 
Assessment of SCD on a quantitative scale level is nearly as heterogeneous as 
the reported categorical definitions of SCD. Over the last decades a variety of scales has 
been in use in empirical research. These scales range from ad-hoc constructed scales 
(taking items from different item pools; e.g. Rabin et al. 2012) to completely new 
constructed, multi-factorial scales with the specific aim of (improved) SCD assessment 
in mind (e.g. Eckerström et al. 2013). There are also several studies in which authors 
have constructed composite scores for SCD based on items from different 
questionnaires available to them (e.g. Amariglio et al. 2012), thereby merging items 
from validated scales with items not formally validated. Again, a comprehensive 
overview of all the different quantitative approaches would be beyond the scope of this 
manuscript. However, several important points should be mentioned with regard to 
quantitative assessment. Firstly, comparability of studies employing different 
quantitative assessment of SCD is thoroughly limited. This is due to a lack of 
comparative psychometric studies even with regard to the more common scales. The use 
of composite measures also hinders comparability of those studies that used partly the 
same scales. Secondly, the development of many scales is not well documented, their 
psychometric properties either not well studied or unknown. Thirdly, with regard to 
item development, many scales have relied on expert panels or clinical experience. 
However, a systematic phase of qualitative data collection (interviews with patients, 
subsequent qualitative analysis), although recommended as best practice, is rare 
(Eckerström et al. 2013). Fourthly, the available scales were mostly not specifically 
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developed to measure SCD as an early symptom of AD. For example, the “Memory 
Assessment Clinics Questionnaire” (MAC-Q) was initially designed to measure “Age 
Associated Memory Impairment” (a concept different from memory loss due to specific 
diseases; Crook et al. 1986). The MAC-Q consequently asks for change in cognition 
compared to performance in young age (high school) which is arguably suboptimal to 
capture SCD related to AD pathology. However, the MAC-Q has still been used in the 
field of AD-related SCD research with mixed results (Buckley et al. 2013). 
In conclusion, there seems to be large room for improvement in the quantitative 
assessment of SCD which poses a major task for further research (Jessen et al. 2014a). 
To conclude this section, a selection of scales with original sources is presented in Table 
6. The selection was made so that both more recently published scales (ECog, SCD-Q) 
as well as older scales (SMDS, MAC-Q, MMQ) are covered. A short comment on 
general and psychometric properties of each scale is given. 
Table 6. Quantitative scales to measure SCD (examples). 
Name of the 
scale 
abbreviation reference Comment 
Multifactorial 
Memory 
Questionnaire 
MMQ Troyer & 
Rich (2002) 
Assessment of separate dimensions of self-reported 
memory: 1. Contentment (i.e., affect regarding one’s 
memory), 2. Ability (i.e., self-appraisal of one’s memory 
capabilities), 3. Strategy (i.e., reported frequency of 
memory strategy use). The scale is designed for research 
and intervention purposes. It therefore focuses on 
problems with recent memory, not decline in memory.  
 
Psychometric properties, based on a sample of 115 
individuals in initial publication: very good content and 
construct validity, factorial validity, test-retest and intra-
test reliability. 
Memory 
Assessment 
Clinics 
Questionnaire 
MAC-Q Crook et al. 
(1992) 
6 item questionnaire on a 5-point Likert Scale. Subjects 
are asked to rate their memory in comparison to what it 
was like when they were in high school. Higher scores 
reflect greater subjective memory impairment. 5 
questions regarding specific daily activities (e.g. 
remembering a person’s name) and one item asking for 
overall comparison of current vs. earlier memory. 
Summary score of 0-30 points. 
Psychometric Properties, based on 232 subjects meeting 
diagnostic criteria for age-associated memory 
impairment: Satisfactory internal consistency and test-
retest reliability. Concurrent validity supported by a 
significant correlation to another well-validated memory 
questionnaire. 
 34 
Subjective 
Memory 
Decline Scale 
SMDS Jorm et al. 
(1997) 
This scale is used in empirical study 3. It contains four 
questions on self-experienced increasing difficulties in 
everyday memory (e.g. “Do you have more trouble 
remembering things that have happened recently?”; “Are 
you worse at remembering where belongings are kept?”). 
Responses to each question are rated as follows: 0, “no, 
not more difficult than in the past”; 1, “Yes, a bit worse 
than in the past” 2, “yes, much more difficult than in the 
past”. A summary score of 0-8 points can be derived. 
Psychometric properties: Limited data. Cronbach’s alpha 
of 0.71 reported in Jorm et al. (1997). 
Everyday 
Cognition 
Scale 
ECog Farias et al. 
(2008) 
This scale has been designed to capture subtle functional 
abilities that are, however, cognitively mediated. The 
ECog has originally been developed as an informant 
rating scale. It contains 39 items (4-point Likert scale: 1 = 
“better or no change to 4 = “consistently much worse”) 
that ask for performance compared to 10 years ago. The 
ECog has six domain-specific factors: Everyday Memory, 
Language, Visuospatial Abilities, Planning, Organization, 
and Divided Attention. 
Psychometric properties: The original informant rated 
scale has good psychometric properties (Farias et al. 
2008). A self-rated version of the E-Cog, composed of 
identical questions, has been used in SCD studies but 
only the informant version has been formally validated 
(Amariglio et al. 2012). However, in the study of 
Amariglio and colleagues, ECog memory values were 
significantly related to brain amyloid burden in patients 
with pre-MCI SCD and also correlated with episodic 
memory performance. This speaks for good construct 
validity of the self-report version in pre-MCI SCD at least 
for the memory factor. 
Subjective 
Cognitive 
Decline 
Questionnaire 
SCD-Q Rami et al. 
(2014) 
New assessment tool developed by Spanish members of 
the SCD-Initiative. 24-item scale that assesses perceived 
subjective decline in memory, language, and executive 
functions in the last two years. Initial item-pool generated 
by literature review and expert consensus revision. 
Parallel informant version that allows for calculation of a 
discrepancy index between subject and informant. This 
allows for measurement of over- or underreporting of an 
individual’s SCD in comparison to an informant (or vice 
versa depending on research question).   
Psychometric properties, based on an initial validation 
study with 124 CO, 144 pre-MCI SCD, 83 MCI, 46 AD 
dementia patients, and 397 informants: Good internal 
consistency and discriminant validity: SCD-Q scores 
from SCD and MCI differed significantly from controls 
and differed between those SCD who sought help at a 
clinic compared to those who did not. Informant SCD-Q 
scores can differentiate between controls and patients 
with cognitive impairment (MCI, AD dementia) with 
good sensitivity and specificity. 
Note. The table shows a selection of scales that have been used in SCD research.  
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2.4.3 Cross-sectional and prospective associations of SCD across the stages of AD 
This section will give a cohesive overview of the literature on associations 
between SCD and other variables. Again, a selection rather than a complete review of 
the literature will be given
8
. The overview is broken down into several subsections 
according to the temporal relationship (cross-sectional vs. prospective associations with 
subsequent outcomes) and type of variables (behavioral measures, biomarkers). 
The following figure first provides a “timeline” for the antecedents, cross-
sectional associations and sequelae (i.e. subsequent events) of AD-related SCD as the 
biomarker model of AD would suggest (see section 2.2). As it is the case with the 
biomarker model itself, the model in Figure 3 is first of all hypothetical in nature. 
However, it may serve well as a general frame for the remainder of the section.  
Figure 3. Hypothetical timeline model comprising antecedents, cross-sectional 
associations and sequelae of AD-related SCD. 
 
Note. The figure displays antecedents, cross-sectional associations and sequelae (i.e. subsequent events) 
of AD-related SCD. Further information is given in the text.  
Figure 3 is created following a visualization method typically used in structural 
equation modeling (SEM), i.e. unidirectional arrows represent directed regressive 
effects (“variable X influences variable Y”) while bidirectional arrows stand for 
correlations of two variables.
9
 As shown in Figure 3, SCD at a given cross-sectional 
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 There are several extensive reviews on this topic (see e.g. Reid & Maclullich, 2006; Stewart, 
2012; Roberts et al. 2009; Reisberg & Gauthier, 2008) 
9
 For clarity, variables in Figure 3 are considered as latent variables or “constructs”, deliberately 
ignoring the otherwise important measurement part of an SEM model. 
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time of measurement (T0) is depicted as a result of an antecedent cognitive decline from 
the individual’s baseline cognitive performance. When speaking of AD-related SCD, 
this antecedent cognitive decline is itself preceded, and later accompanied, by the onset 
of AD pathology. The unidirectional arrows between these variables indicate that AD 
pathology is the etiological cause for the cognitive decline (deliberately ignoring other 
etiological factors for the sake of simplicity). This decline in performance is then, at 
some point, perceived by the individual and expressed as SCD at T0. If T0 is defined as a 
cross-sectional measurement point in the course of AD development then SCD at T0 
will be influenced by the perceived antecedent cognitive decline which itself is a result 
of AD pathology. However, it will also depend on the individual’s capability to perceive 
and express the cognitive decline at T0. This capability (which relates to the term 
“awareness”, discussed later in this section) might be limited in more progressed stages 
of AD such as MCI and dementia. Objective test performance at T0 similarly depends 
on the extent of preceding AD-related antecedent cognitive decline (from baseline 
performance to T0). Lastly, the biomarker levels at T0 will depend on the time elapsed 
from onset of deviation of the marker away from normality to T0 and the average rate of 
change of the marker over this period of time (see section 2.2). As a result, the 
correlations between test performance, SCD and biomarkers at T0 will largely depend 
on the time elapsed from onset of AD pathology to T0, or, more broadly spoken, on the 
individual’s stage of AD at T0 measurement. As an example, in a study on individuals in 
the pre-MCI stage of AD, a correlation between SCD at T0 and a biomarker of early 
amyloid deposition (e.g. CSF-Aβ42 or brain Aβ PET imaging) might be observed. 
However, correlations between cognitive test performance and SCD or cognitive test 
performance and Aβ might be weaker or even absent (see e.g. Amariglio et al. 2012). 
The correlative pattern for a sample of MCI patients might, however, be different. Here, 
cognitive test performance will likely correlate well with biomarkers (especially those 
reflecting Tau-mediated neuronal injury and degeneration) while a correlation of SCD 
with objective impairment might not be observed. One reason for this absent 
relationship may be that two individuals with the same test performance at T0 may have 
declined from different baseline levels of performance and, thus, report different levels 
of SCD at T0. This relates to the concept of cognitive reserve which describes an 
individual’s relative ability to preserve task performance in the presence of brain 
pathology by use of compensatory mechanisms (Stern, 2012). A second explanation 
may be heterogeneity in symptom awareness among MCI patients. Awareness and 
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cognitive reserve may therefore be considered as influential factors with regard to the 
relationship between SCD and either objective performance or biomarkers of AD. This 
example shows that cross-sectional and prospective associations of SCD with other 
variables of interest (e.g. memory performance, biomarkers, incident AD dementia), as 
well as with possible confounders, may vary across the AD timeline. This thought will 
be picked up again at the end of this section where a working model on the evolution of 
SCD throughout the course of AD will be presented. This model served as a conceptual 
framework for the empirical studies of this work. It might, although hypothetical, also 
serve as a reasonable explanation for the rather heterogeneous findings on the cross-
sectional and prospective associations of SCD which are presented in the following. 
Cross-sectional associations with demographic, clinical, and personality variables 
Cross-sectional studies have related SCD to a range of factors in non-demented 
individuals. These variables include the following demographic factors associated with 
SCD in large population based cohort studies of middle and old aged subjects: higher 
age (Holmen et al. 2013; Reisberg & Gauthier, 2008), lower education (Jonker et al. 
2000; Holmen et al. 2013; however see also van Oijen et al. 2007) and female gender 
(Jonker et al. 2000; however, see also Holmen et al. 2013). Studies have found evidence 
for SCD to be associated with subjective health status, vascular risk factors like 
smoking and hypercholesterolemia (Paradise et al. 2011), and even increased mortality 
among middle-aged individuals after controlling for effects of depression (Singh-
Manoux et al. 2014). Moreover, a number of affective and personality factors such as 
psychological distress and ineffective coping style (Steinberg et al. 2013; Paradise et al. 
2011), negative affect and anxiety sensitivity (Dux et al. 2008), neuroticism, 
conscientiousness, low self-esteem (Pearman & Storandt, 2004; Steinberg et al. 2013), 
increased self-focused attention (Chin et al. 2014) and self-discipline (a sub-facet of 
conscientiousness; Pearman & Storandt, 2005), have been associated with measures of 
SCD. 
The most robust findings, however, have been reported for the association 
between SCD and depressive symptomatology. Depressive symptoms have been 
positively associated with SCD in volunteer (e.g. Buckley et al. 2013), population-based 
(e.g. Benito-León et al. 2010; Paradise et al. 2011), and clinical samples (e.g. Erk et al. 
2011; Chin et al. 2014) with varying age ranges. Some researchers have therefore 
argued that SCD is mainly driven by depressive symptomatology rather than being an 
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indicator of an underlying pathology such as AD. However, in light of the emerging 
evidence that SCD is associated with incident AD dementia and biomarkers of AD 
(reported below) this statement can today be considered as overstated. Furthermore, 
little is known about the temporal (and accordingly the causal) relationship between 
SCD and depressive symptomatology. According to Roberts and colleagues (Roberts et 
al. 2009), the relationship between SCD and depression is most likely reciprocal: One 
individual might endorse subjective cognitive deficits during the course of a depressive 
episode while another individual might develop depression and anxiety due to 
recognition of subjectively worsening cognitive performance. In a novel study, Buckley 
and colleagues found some evidence that depressive symptomatology might contribute 
stronger to SCD symptomatology in individuals with normal test performance than in 
those with MCI (Buckley et al. 2014a). Despite these unresolved issues, depressive 
symptomatology is certainly an important variable that should be recorded and 
controlled for in any SCD study (Jessen et al. 2014a). The same might, for a lesser 
degree of evidence, be true for anxiety and other personality factors. 
Cross-sectional associations with objective cognitive performance, informant 
reports and the potential role of confounding/moderating factors: Awareness, 
affect and cognitive reserve. 
In contrast to the robust findings regarding SCD and depressive 
symptomatology, studies on the association between SCD and concurrent cognitive 
performance have produced inconsistent results. Some studies have reported, albeit 
modest, associations between SCD and objective cognitive performance measures after 
accounting for effects of age and depressive symptomatology (e.g. Jonker et al. 2000; 
Jessen et al. 2007; Snitz et al. 2008; Pearman & Storandt, 2004; Amariglio et al. 2011). 
Other studies, however, have found no such association (Reid & Maclullich, 2006; 
Minett et al. 2008; Lenehan et al. 2012). Lastly, there are studies with findings of an 
association which, however, did not hold up after adjustment for multiple testing and/or 
covariate effects of depressive/affective symptoms (Benito-León et al. 2010; Steinberg 
et al. 2013). 
 Empirical evidence concerning associations between self- and informant-
reported SCD have further shown that correlations between the two sources of 
information are rather poor (Caselli et al. 2014; Jorm et al. 1994; Edmonds et al. 2014). 
Informant reports seem to correlate more consistently with the subject’s cognitive test 
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performance (Rami et al. 2014; Jorm et al. 1994). However, it is also worth mentioning 
that informant reports seem to be equally influenced by affective states of either the 
subject itself or the informant (Rami et al. 2014; Jorm et al. 1994; Caselli et al. 2014). 
The question whether self- vs. informant-reported decline is more predictive of 
prevalent and incident AD dementia is still controversial. For prevalent dementia it 
seems clear that only informant-reported SCD has diagnostic value (Carr et al. 2000). 
The evidence with regard to incident dementia is less clear. Overall, there are few 
studies that specifically compared self- vs. informant reports with consistent 
methodology (i.e. parallel patient-informant questionnaires). Two studies with incident 
dementia as outcome found informant reports to be more predictive (Rabin et al. 2012; 
Tierney et al. 1996). However, in these samples individuals with MCI were included 
and measures were not parallelized. On the contrary, a new study on cognitively normal 
individuals with incident MCI as outcome showed that those who converted to MCI 
self-endorsed decline earlier than informants (Caselli et al. 2014). These seemingly 
inconsistent findings might, as suggested above, be based on the fact that associations 
between SCD and different outcomes depend on the stage of AD in which the 
individual is situated at the time of measurement. 
Potential confounding factors 
Before coming back to the idea of AD stage dependence, other potential confounders, 
leading to inconsistent results across studies, are briefly mentioned in the following. 
The heterogeneity in SCD assessment (the same is true for informant reports) is a 
confounding factor in itself. Further, there might be, according to Vestergren and 
colleagues (Vestergren et al. 2012), other psychometrical factors to name here: 
methodological differences between questionnaires and neuropsychological tests, the 
(memory) introspection paradox
10
, influence from social desirability, and individual 
differences in interpretation and use of self-rating scales. 
Symptom awareness, anosognosia and SCD 
A look back to the ideas outlined with regard to Figure 3 might also help to 
understand the heterogeneous findings. As discussed above, associations between SCD 
and other variables on the individual level may vary across the AD timeline and 
                                                 
10
 „The paradox of introspection stems from the fact that personal experience corresponds to that 
which we know best subjectively, yet least empirically” (Schooler & Schreiber, 2004). 
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therefore depend on the stage of AD in which the individual is situated at the time of 
measurement. An important variable that comes into play as AD progresses is the 
tendency of the affected individual to inadequately judge his/her own memory capacity. 
This is commonly referred to as symptom unawareness or “anosognosia”. Reduced 
awareness and anosognosia are common in individuals with AD dementia (Galeone et 
al. 2011) but have also been observed in individuals with MCI (Galeone et al. 2011; 
Vogel et al. 2004; Vogel et al. 2005; Nobili et al. 2010). However, in MCI, awareness 
of memory deficits is more heterogeneous (Kalbe et al. 2005; Roberts et al. 2009), i.e. 
some patients have reduced insight while others seem to have preserved introspective 
capacity. Importantly, there is evidence of a link between reduced symptom awareness 
and lower concurrent cognitive performance (Grambaite et al. 2013; Vogel et al. 2005; 
Snitz et al. 2008). Furthermore, studies have reported that anosognosia in MCI patients 
is associated with functional and structural brain changes consistent with more 
progressed AD pathology (Nobili et al. 2010; Ries et al. 2007; Vogel et al. 2005; 
Chetelat et al. 2009), with positive AD CSF biomarkers (Edmonds et al. 2014) and with 
more rapid conversion to dementia (Chetelat et al. 2009; Edmonds et al. 2014). In 
summary, this evidence suggests two important aspects: First, reduced awareness is an 
important determinant of whether individuals who truly have objective cognitive 
deficits will report SCD or not. Second, reduced awareness seems to evolve with 
progression of AD and might emerge first in the transitional stage between MCI and 
AD dementia. This might not only contribute to the heterogeneous findings regarding 
the relationship between SCD and other variables. It also has implications for the 
usefulness of SCD as a diagnostic criterion and predictor: The predictive value of SCD 
seems temporally limited across the AD timeline. 
Associations with biomarkers 
Evidence that SCD correlates with biomarkers of AD pathology mostly comes 
from studies that have investigated this relationship in individuals with normal 
cognition, i.e. in the presumed preclinical/pre-MCI stage of AD. Here, different 
qualitative and quantitative operationalizations of SCD have been associated with 
different biomarkers of AD pathology such as brain amyloid burden (Chételat et al. 
2010; Perrotin et al. 2012; Amariglio et al. 2012; Merrill et al. 2012), AD typical CSF 
biomarkers (Visser et al. 2009; Mosconi et al. 2008), as well as AD-related 
hypometabolism and structural brain changes (Saykin et al. 2006; Scheef et al. 2012; 
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Mosconi et al. 2008). Recently, it has also been reported that SCD correlates with post 
mortem amyloid brain pathology in subjects with initial pre-MCI SCD who, however, 
had not progressed to a clinical diagnosis of either MCI or dementia before death 
(Kryscio et al. 2014). Furthermore, functional MRI studies provide evidence that, 
during the performance of cognitive tasks, individuals with SCD show brain activations 
consistent with employment of compensatory strategies of neural networks in order to 
deal with the functional brain changes of early AD (Rodda et al. 2011; Erk et al. 2011). 
Importantly, studies in which SCD has been measured more differentiatedly, found that 
memory-related cognitive complaints/decline had the strongest association to 
biomarkers of AD (Amariglio et al. 2012; Perrotin et al. 2012). To summarize, although 
negative findings have also been reported (e.g. Buckley et al. 2013; Grambaite et al. 
2013), evidence that SCD is related to early AD pathology is growing.  
Importantly, the referenced studies above are based on individuals in the pre-
MCI stage. As suggested by the model in Figure 3, results from these studies are 
inconclusive regarding associations of Aβ biomarkers with objective cognitive 
performance. This indeed suggests that, at the pre-MCI stage, SCD might reflect subtle 
decline which is induced by AD pathology, but is partly compensable and hardly 
detectable on standard tests designed to measure cognitive impairment in MCI. On the 
contrary, there is a lack of studies investigating associations of SCD and AD biomarkers 
within MCI patients. One study (Grambaite et al. 2013) found no association between 
SCD measures and CSF-Aβ42 (or CSF-Tau). However, small sample size (n = 47 MCI) 
was acknowledged as a limitation in this study. Also, the authors of this study 
operationalized SCD with two single items from a scale designed to assess current 
psychopathological symptoms rather than employing a measure specifically designed to 
capture subjective decline in cognition. In a recent and considerably more robust study 
(Edmonds et al. 2014), Edmonds and colleagues reclassified the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) MCI sample based on cluster-analysis-derived 
neuropsychological profiles into amnestic MCI, “mixed MCI” (with most prominent 
impairment in executive functions and language but also mild memory impairment) and 
a “cluster-derived normal” MCI group whose neuropsychological test scores in all 
domains were, on average, not different from normal controls of the ADNI sample. 
Importantly, the memory test used to define MCI in ADNI (story A of the Logical 
Memory test of the Wechsler Memory Scales) was not part of this cluster analysis. All 
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patients (as well as one informant per patient) were also administered the ECog as a 
measure of SCD (see Table 6). Edmonds and colleagues found that patients in the 
amnestic and mixed MCI groups with lower ECog scores compared to their informant’s 
rating (i.e. those that presumably “underestimated” their cognitive deficits relative to 
their informant) were more likely to have an AD like CSF biomarker profile and were 
more likely to develop incident AD dementia. On the contrary, subjects in the “cluster-
derived normal” group overestimated their deficits relative to informants. Importantly, 
the amnestic and mixed MCI groups in this study consisted of MCI patients defined by 
a conservative method, i.e. they can be considered as patients with robust cognitive 
impairment and presumably in a more progressed stage along the continuum of AD. 
Edmonds and colleagues’ results, thus, fit well with the idea that unawareness of 
symptoms is associated with more progressed AD pathology. However, the authors’ 
conclusion that SCD generally contributes to a misdiagnosis of MCI must be seen 
critical, as this result deserves replication in an independent memory clinic sample, and, 
furthermore, the meaningfulness of this statement might depend on how strict the 
neuropsychological criteria of MCI are defined. 
Prospective associations with adverse outcomes 
Similarly to the current state of studies on SCD and biomarkers of AD, most 
studies that found a relationship between SCD and subsequent adverse outcomes are 
based on studies on mostly cognitively unimpaired individuals with long follow-up 
intervals. Overall, compared to the weak associations with concurrent memory 
performance, the literature is far more consistent regarding the relationship between 
SCD and incident AD dementia. Several large cohort studies have demonstrated that 
individuals endorsing SCD while having cognitively normal performance are at an 
increased risk of incident MCI and/or AD dementia (e.g. Geerlings et al. 1999; Reisberg 
et al. 2010; Jessen et al. 2011; Waldorff et al. 2012; see Stewart, 2012 or Jessen et al. 
2014a for a summary of studies). There is also emerging evidence linking SCD to future 
cognitive decline in cohort studies (e.g. Dufouil et al. 2005; Glodzik-Sobanska et al. 
2007; Hohman et al. 2011; Samieri et al. 2014). However, negative results have also 
been reported (e.g. Tierney et al. 1996; Jorm et al. 1997; Reid & Maclullich, 2006; 
Hollands et al. 2014). While estimates for excess in risk differ between the studies, a 
recent meta-analysis has reported that, across all included studies, individuals with pre-
MCI SCD are at a two-fold increased risk to develop dementia over time (Mitchell et al. 
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2014). An analogous meta-analysis with rate of decline as the variable of interest has 
not been published yet. 
One cohort study of elderly with white matter changes (LADIS study; Verdelho 
et al. 2011) found SCD predictive for incident AD dementia but not for vascular 
dementia. There has also been evidence that the relationship between SCD and 
increased risk of incident AD dementia is moderated by education (van Oijen et al. 
2007). Other studies found a moderating role of ApoE4 status (Samieri et al. 2014) on 
the relationship between SCD and subsequent cognitive decline. Finally, van Harten and 
colleagues demonstrated that the best predictor of memory decline and clinical 
progression in subjects with pre-MCI SCD is a positive AD biomarker profile, which 
provides evidence for SCD as a phenotypic feature of preclinical AD (van Harten et al. 
2013a; van Harten et al. 2013b). 
Again, studies of SCD as a predictor of incident AD dementia or future 
cognitive decline in subjects with cognitive impairment at the MCI level are rare 
(Edmonds et al. 2014). There are some older longitudinal studies that did not explicitly 
exclude MCI patients as the MCI concept was not yet developed at that time (Tierney et 
al. 1996; Jorm et al. 1997; Schmand et al. 1997). It would be hard to retrospectively 
determine which participants of the sample would receive a diagnosis of MCI and often 
no subgroup analysis has been conducted. Geerlings and colleagues (Geerlings et al. 
1999), however, excluded demented individuals from their study and classified 
participants based on the MMSE score as either “normal” (>= 26 points) or 
“borderline/impaired” (<= 25 points). The authors found SCD associated with incident 
AD dementia but this effect was modified by cognitive baseline level, such that SCD 
predicted incident AD only in those with normal cognition but not in those with 
borderline/impaired cognition. This may again speak towards the hypothesis that the 
predictive value of SCD may level off in samples of more progressed individuals.  
Another moderator of the relationship between SCD and future cognitive decline 
in MCI may be depressive symptoms as suggested by a population-based cohort study 
with psychometrically defined amnestic MCI (Crowe et al. 2006). This study found an 
association of SCD with steeper cognitive decline over time in MCI subjects with lower 
depressive symptoms but not in those with higher depressive symptoms (the sample was 
divided via median split on a self-report depression scale). 
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2.4.4 Relationship of objective and subjective cognitive decline across the time 
line of AD progression: A working model for the present studies 
This section will sum up empirical evidence and ideas already discussed in the 
last section by presenting a working model on the temporal development of SCD and its 
interaction with objective cognitive decline across the timeline of AD progression. 
Implications of this model for prediction of AD biomarker pathology and future AD 
dementia will then be given. The model is depicted in Figure 4. 
Figure 4. Working model for the temporal development of SCD across progression of 
AD (adapted from Jessen et al. 2014a) 
Note. The figure depicts the evolvement of SCD and its relation to objective cognitive decline in the 
course of AD progression from preclinical AD to AD dementia. Further information is given in the text. 
Figure reused in this dissertation with permission by Elsevier (RightsLink Licence number: 
3512451165092). 
Depicted on the y-axis in Figure 4 is the presumed trajectory of objective 
cognitive decline in relation to the progression of AD pathology. Progression of AD is 
projected on the x-axis and broadly segmented in the three clinical stages outlined 
earlier, i.e. preclinical AD, MCI-AD/prodromal AD and AD dementia. It is assumed 
that after a phase of stable cognitive performance in the presence of increasing AD 
pathology (i.e. preclinical AD stage 1 and 2 according to NIA-AA criteria), cognitive 
decline occurs in the late preclinical stage of AD (NIA-AA preclinical AD stage 3). The 
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trajectory for cognitive decline in Figure 4 represents that of an average performing 
individual, as it lies in the middle of the green-shaded bar representing the range of age-
, sex- and education adjusted normal performance. Risk- or protective factors like 
cognitive reserve, genetic factors, comorbid conditions, or lifestyle factors will likely 
moderate both the intercept and slope of this trajectory. After falling below the 
threshold of normal age-, sex-, and education-adjusted performance, the MCI-
AD/prodromal AD stage with measurable cognitive deficits is reached. Cognitive 
decline then progresses onward and, in addition, functional decline (not shown in this 
figure) will evolve as a consequence of increased cognitive impairment. Once functional 
decline has reached a level of impairment that significantly interferes with the ability to 
function at work or in usual activities, the stage of dementia is reached.  
The evolvement of SCD is depicted by a bar that is shaded from white (absence 
of SCD) to red (presence of SCD) across the disease stages. According to Figure 4, it is 
assumed that SCD occurs first as a symptom of the late stage of preclinical AD (NIA-
AA preclinical AD stage 3), reflecting the individual’s notion of subtle cognitive 
decline and increasing compensatory cognitive efforts. This is illustrated by the bar 
having the most strong red shade in the zone where objective cognitive performance 
deviates from baseline but is still within normal limits. SCD is, thus, proposed as a key 
feature of the late preclinical AD stage when the cognitive impairment threshold of MCI 
has not yet been reached. However, as cognitive impairment progresses into MCI, the 
red bar slowly fades out and turns into a white shade again. This represents that the 
subjective experience of cognitive impairment may vanish as disease progresses into the 
more advanced stage of MCI and finally dementia. 
Implications for the significance of SCD and objective cognitive impairment 
with regard to prediction of AD arise from the differential temporal involvement of both 
symptoms and their relation to each other across the progression of AD. The working 
model proposes that the predictive power of SCD is most valuable at the late preclinical 
stage of AD when SCD is not influenced by anosognosia and the validity of detecting 
objective cognitive impairment is low due to limited sensitivity of standard cognitive 
tests. However, on the other hand, the validity of SCD might decrease as AD progresses 
due to evolvement of anosognosia which itself is related to progression of objective 
cognitive impairment. In addition, the validity to detect objective cognitive impairment 
increases with progression of AD into the MCI stage and is high at more advanced 
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stages. This increasing predictive validity of objectively measured cognitive impairment 
is indicated by the yellow shaded area that fades in from white to yellow as AD 
progresses
11
. The increasing validity of the standard cognitive tests is a result of lower 
false-negative and false-positive classification compared to cognitive testing at earlier 
stages. This has direct implications for definition of cognitive impairment thresholds in 
the MCI diagnosis illustrated by the right vertical bar in Figure 4. The more left the bar 
is placed, i.e. the more liberal the cognitive impairment threshold, the more red shade 
(i.e. more predictive value) has the bar representing SCD and the less yellow shade (less 
accuracy) has the area representing objective cognitive impairment. If the cognitive 
impairment threshold is, however, shifted to the right side of the picture, SCD fades out 
and objectively measured cognitive impairment becomes a valid predictor for AD 
dementia. In conclusion, according to the model, there is a “time window” (encircled by 
the ellipse in Figure 4), expanding from the NIA-AA stage 3 of preclinical AD to the 
MCI stage, where both SCD and objective cognitive impairment may complement each 
other as predictors of incident AD dementia or underlying AD biomarker pathology. 
The relative importance of the two predictors, however, shifts from SCD to objective 
cognitive impairment as AD progresses. Importantly, although the existing literature, 
outlined in the previous sections, might partly support the general principles of this 
model, its implications for AD dementia prediction have not yet been formally tested. 
The empirical studies presented in the present thesis were conceptually based on this 
proposed working model and aim to provide further empirical evidence for it. 
2.5 Conclusions and hypotheses addressed in the present studies 
In the previous sections, a general framework for the development of AD was 
outlined and stages of AD from preclinical AD to AD dementia were described. SCD 
was then defined for the present work and a comprehensive overview of the rather 
heterogeneous literature on SCD was given. Finally, a working model, describing how 
SCD might evolve and interact with objective cognitive decline throughout the course 
of AD, was presented. Implications from this working model for SCD as a predictor of 
either future AD dementia or higher likelihood of AD pathology were briefly discussed. 
                                                 
11
This is the interpretation of the author and not explicitly mentioned in the original paper of 
Jessen et al. (2014a).  
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Based on the present literature it can be cautiously concluded that SCD is 
associated with future cognitive decline, higher risk of AD dementia, and higher 
likelihood of AD pathology. Thus, it is potentially useful as an indicator of incipient AD 
with implications both for clinical practice and research. However, although there is a 
growing body of evidence, there are also studies that have not found associations with 
longitudinal outcomes or biomarker profiles. Furthermore, there has been a wide 
heterogeneity both in the samples studied (preclinical AD, MCI, mixed samples) and in 
the definition of SCD (see section 2.4.2). This two-fold heterogeneity (samples and 
assessment) might explain some of the equivocal findings in the research literature 
(section 2.4.3), especially as the validity of SCD may vary depending on the stage of 
AD, as outlined above (section 2.4.4.). The aspects just mentioned pose a serious 
difficulty to compare results across studies and there are many questions not fully 
answered yet. These questions refer to the proposed working model in section 2.4.4 and 
to the measurement aspect of SCD outlined in section 2.4.2. Such questions may be: 
 Is SCD a valid feature specifically in the early clinical phase of AD?  
 How strong is the predictive validity of SCD in subjects with MCI? Does 
it vary across different levels of objective cognitive impairment? 
 What factors influence SCD and/or moderate its association to incident 
AD dementia or biomarkers of AD pathology? 
 Are there certain aspects of SCD which are more closely related to AD 
and thus of a higher predictive value than others? If yes, are these aspects 
the same for different stages of AD? 
Section 3 of this thesis contains empirical research that addresses some of these 
questions. In the following subsections, the study aims and hypotheses of the three 
empirical studies presented herein are described. Study 1 is based on a population based 
sample of the German “Study on Ageing, Cognition and Dementia (AgeCoDe)” while 
study 2 and 3 are based on a memory-clinic MCI sample of the German Competence 
Network for dementia (DCN). 
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2.5.1 Study 1 (longitudinal study, AgeCoDe sample): Memory-related SCD (with 
vs. without concerns) as a predictor of AD dementia in individuals with 
normal cognition, early and late MCI. 
Building on previous research that showed associations of SCD with higher risk 
of future AD dementia, study 1 (previously published; Jessen et al. 2014b) addresses 
two aspects. First, it compares the AD dementia risk of subjects with pure memory-
related SCD (but no cognitive impairment; i.e. pre-MCI SCD) to that of patients with 
either early or late MCI. Early MCI comprises patients with evidence of very mild 
objective memory impairment on neuropsychological tests (memory performance 
between 1.0 to 1.5 SD below the norm) while late MCI patients are more advanced in 
their objective memory impairment (more than 1.5 SD below the norm). Both MCI 
groups have SCD as defined in the MCI criteria. Second, the study evaluates whether 
SCD with concerns/worries (SCD+C) is associated with a higher risk of developing 
incident AD dementia compared to SCD without concerns (SCD-C). It is hypothesized 
that the qualitative appraisal of a self-experienced cognitive decline as worrisome (i.e. 
SCD+C) is important and might further elevate the risk of AD compared to SCD-C. 
2.5.2 Study 2: (longitudinal study, DCN sample): Significance of memory-related 
SCD in a clinical sample of MCI patients: Interaction with objective 
memory impairment. 
Study 2 (previously published; Wolfsgruber et al. 2014b) deals with a key aspect 
of the working model presented in the previous section. The model stated that, during 
the early course of symptomatic AD, SCD might evolve as a result of self-perceived, 
intra-individual decline that is difficult to detect on cross-sectional neuropsychological 
tests. However, with the evolvement of more severe cognitive impairment, SCD might 
wane as a result of reduced insight into symptoms. If these assumptions from the 
working model were true, then the predictive value of SCD should be most predictive in 
very mildly impaired MCI patients and then decrease with increasing levels of memory 
impairment. Study 2 tests this hypothesis derived from the working model by examining 
the risk of incident AD dementia by SCD+C, objective memory performance and the 
proposed interaction of both factors in a large sample of memory clinic MCI patients 
with different levels of cognitive impairment. Some of these patients could be 
considered as early MCI patients (see definition in 2.5.1.) while others have more 
advanced, multi-domain cognitive impairment in the range of late MCI. 
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2.5.3 Study 3 (cross-sectional biomarker study, DCN sample): Biomarker 
correlates of memory-related SCD in MCI patients. 
Study 3 (Wolfsgruber et al. 2015) finally addresses an under-researched topic, 
namely the relationship between measures of SCD and biomarkers of AD in the stage of 
MCI. While most research on SCD and biomarkers has focused on the pre-MCI stage, 
the MCI stage has been somewhat overlooked presumably due to the equivocal findings 
regarding the presence or absence of SCD in this patient group and the importance of 
objective cognitive testing in MCI. SCD might be influenced by several confounding 
factors in MCI: depressive symptoms, objective impairment level (interaction 
hypothesis proposed in section 2.5.2 applies here too) and education (as a cognitive 
reserve proxy). This study examines whether measures of SCD may predict abnormal 
CSF biomarkers of AD in a sample of MCI patients while taking into account the 
aforementioned factors as covariates. 
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3 Empirical Studies 
3.1 Study 1: AD dementia risk in late MCI, in early MCI, and in pre-MCI SCD 
(Jessen et al. 2014b) 
3.1.1 Abstract 
Objective 
To compare the risk of developing Alzheimer’s disease (AD) dementia in late 
mild cognitive impairment (LMCI), early MCI (EMCI), and subjective cognitive  
decline with normal test performance (pre-MCI SCD). 
Methods 
The baseline sample (n = 2892) of a prospective cohort study in non-demented 
individuals (German Study on Aging, Cognition and Dementia in Primary Care 
Patients) was divided into LMCI, EMCI, pre-MCI SCD, and control subjects by delayed 
recall performance. These groups were subdivided by the presence of self-reported 
concerns associated with experienced memory decline. AD dementia risk was assessed 
over 6 years. 
Results 
Across all groups, risk of AD dementia was greatest in LMCI. In those with self-
reported concerns regarding their memory decline, pre-MCI SCD and EMCI were 
associated with a similarly increased risk of AD dementia. In those subgroups without 
concerns, pre-MCI SCD was not associated with increased risk of AD dementia, but 
EMCI remained an at-risk condition. 
Conclusions 
Pre-MCI SCD and EMCI with self-reported concerns were associated with the 
same risk of AD dementia, suggesting that risk conditions earlier than LMCI should be 
extended to pre-MCI SCD with concerns. 
3.1.2 Introduction 
Defining at-risk stages of dementia resulting from Alzheimer’s disease (AD) is 
crucial for biomarker-based predementia AD detection, which in turn is the requirement 
for future predementia AD treatment (Aisen et al. 2011; Hampel et al. 2010). The 
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Alzheimer’s Disease Neuroimaging Initiative (ADNI) and other large-scale multicenter 
studies have demonstrated that individuals with mild cognitive impairment (MCI) are at 
increased risk of developing AD dementia, particularly if they display biomarker 
evidence of AD (Buchhave et al. 2012; Koivunen et al. 2011; Mitchell, 2009). MCI in 
these studies is defined as amnestic MCI by reported memory concerns, memory 
impairment on standard tests, absence of significant impairment in activities of daily 
living, and the absence of dementia (Winblad et al. 2004). Impairment on cognitive 
testing is usually defined as performance below 1.5 standard deviations (SD) of the age-
, sex- and education-adjusted normative mean in a standardized test. In the attempt to 
define an even earlier point in time for disease detection, the recent extensions of ADNI 
(ADNI go, ADNI 2) have introduced the distinction of MCI into early and late MCI. 
Late MCI (LMCI) refers to the original definition (performance of 1.5 SD below the 
normative mean), whereas in early MCI (EMCI), impairment is defined as performance 
between 1.0 SD and 1.5 SD below the normative mean on a standard test (Aisen et al. 
2011). 
Epidemiologic studies further propose that the pure report of memory decline 
with normal cognitive performance (subjective cognitive decline [pre-MCI SCD]) is an 
at-risk condition of developing AD (Geerlings et al. 1999; Jessen et al. 2010; Reisberg 
et al. 2010). It has been shown that SCD with self-reported concerns/worries (SCD+C) 
is associated with a two-fold risk of AD dementia in comparison with SCD without 
concerns (SCD-C; Jessen et al. 2010). 
In the study presented here, we investigate the risk of AD dementia over 6 years 
for the three categories LMCI, EMCI, and pre-MCI SCD. In addition, we tested the risk 
of AD dementia in these groups after subdivision based on the presence of self-reported 
concerns associated with experienced memory decline. The investigation was performed 
within the German study on Aging, Cognition and Dementia in primary care patients 
(AgeCoDe). 
3.1.3 Methods 
Participants 
The AgeCoDe study is a general practice (GP) registry-based longitudinal study 
in elderly individuals designed to identify predictors of cognitive decline and dementia 
(Jessen et al. 2007; Luck et al. 2007). The study recruitment was undertaken in six 
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German cities (Bonn, Düsseldorf, Hamburg, Leipzig, Mannheim, and Munich) with a 
total of 138 GPs connected to the study sites. The inclusion criteria for this study were 
an age of 75 years and older, absence of dementia according to GP judgment, and at 
least one contact with the GP within the past 12 months. Exclusion criteria were GP 
consultations by home visits only, living in a nursing home, severe illness with an 
anticipated fatal outcome within 3 months, language barrier, deafness or blindness, and 
lack of ability to provide informed consent. Baseline recruitment was performed in 2002 
and 2003.  
The study was approved by the local ethical committees of the Universities of 
Bonn, Hamburg, Düsseldorf, Heidelberg/Mannheim, and Leipzig, and the Technical 
University of Munich.  
A total of 3327 subjects provided informed consent for participation after being 
provided with a complete description of the study protocol. The study assessments were 
performed by trained interviewers at the subjects’ home. Seventy individuals were 
excluded after baseline interview because of the presence of dementia according to 
standard assessment, and 40 subjects were excluded for age less than 75 years. For the 
current analysis, 16 subjects were excluded as a result of a lack of follow-up 
information on conversion to dementia, and 171 subjects were excluded as a result of 
conversion to non-AD dementia because the focus of the current analysis was on AD 
dementia only. In addition, 24 subjects were excluded because of incomplete 
neuropsychological test data for classification into subgroups of pre-MCI SCD and 
EMCI and LMCI. Because we also included the apolipoprotein E genotype (ApoE) in 
the analyses, another 114 subjects without information on ApoE status were excluded. 
After exclusion of these subjects, 2892 individuals remained in the database for 
analysis.  
Four follow-up visits with 18-month intervals were the basis for the analyses. 
The personal interview rates and the rates of informant-only information (described 
later), respectively, at follow-up were 2503 and 389 at follow-up 1 (100% total), 2215 
and 286 at follow-up 2 (86.5% total), 1797 and 409 at follow-up 3 (76.3% total), and 
1509 and 225 (60.0% total) at follow-up 4. The main reasons for lack of follow-up and 
informant-only information were incident dementia and death. Also, those subjects with 
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only informant-based information at one follow-up were excluded from further follow-
ups. 
Assessment Procedures 
SCD was assessed by the question: “Do you feel like your memory is becoming 
worse?” Possible answers were “no”; “yes, but this does not worry me”; and “yes, this 
worries me”. The expression of worries was rated as self-reported concerns (SCD+C) to 
stay in accordance with the nomenclature of the current MCI definition.  
Neuropsychological assessment included the Structured Interview for Diagnosis 
of Dementia of Alzheimer type, Multi-infarct Dementia and Dementia of other 
Aetiology according to the Diagnostic and Statistical Manual of Mental Disorders, 
version IV (DSM-IV) and the International Classification of Diseases, version 10 (ICD-
10) (SIDAM; Zaudig et al. 1996). The SIDAM is specifically designed to diagnose 
dementia according to the named criteria. It contains a 55-item neuropsychological test 
battery, a 14-item scale for the assessment of activities of daily living (ADL; SIDAM-
ADL scale), and the Hachinski Rosen Scale. The neuropsychological battery includes 
the Mini-Mental State Examination.  
The verbal memory test of the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD; Morris et al. 1989) neuropsychological battery (10-item 
word list, three presentations, delayed recall after 10 minutes) was administered during 
all assessments. Subjects also performed the semantic verbal fluency task of the 
CERAD battery. Depressive symptoms were assessed with the 15-item version of the 
Geriatric Depression Scale (Yesavage et al. 1982). 
Level of education was classified by the Comparative Analysis of Social 
Mobility in Industrial Nations classification system into low, middle, and high (König et 
al. 1988). 
For those subjects, who could not be interviewed in person at follow-up, the 
Global Deterioration Scale (Reisberg et al. 1982) and the Blessed Dementia Rating 
Scale (Blessed et al. 1968) were completed by the interviewer with an informant and 
with the GP. 
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Definition of LMCI, EMCI and pre-MCI SCD at baseline 
The CERAD verbal memory delayed recall performance was used to define the 
level of impairment at baseline. Independent age-, sex-, and education-adjusted German 
normative data for this test are available (www.memoryclinic.ch). The groups were 
classified as follows: LMCI, reported memory decline (memory has become worse) and 
performance on the CERAD delayed recall task of more than 1.5 SD below the 
normative mean; EMCI, between 1.5 SD and 1.0 SD below the normative mean; or pre-
MCI SCD, less than 1.0 SD below the normative mean. In addition, all groups were 
subdivided by the association of self-reported concerns (worries) with regard to the 
reported memory decline. Individuals without the report of memory decline and with a 
performance of less than 1.0 SD below the normative mean on the CERAD delayed 
verbal recall task served as the reference group (control subjects; CO group). Subjects 
without the report of memory decline but with a performance below 1.0 SD of the 
normative mean on the CERAD delayed verbal recall task (n = 359) were not 
considered for the primary analyses because they neither met the criteria of MCI or pre-
MCI SCD nor of the CO. They were only included in a secondary exploratory analysis 
(discussed later).  
Applying these classification rules, 358 subjects were classified as having 
LMCI; 251 subjects, EMCI; 1061 subjects, pre-MCI SCD; and 863, CO (total, 2533). 
Subgroup classification was performed post hoc during data analysis and was not fed 
back to interviewers. Interviewers thus were unaware of group membership, ruling out 
surveillance bias in the detection of incident dementia across the groups. 
Definition of dementia at follow-up 
Dementia was diagnosed in a consensus conference with the interviewer and an 
experienced geriatrician or geriatric psychiatrist according to the criteria set of DSM-IV, 
which is implemented as a diagnostic algorithm in the SIDAM. The etiological 
diagnosis of dementia due to in AD was established according to the National Institute 
of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria for probable AD (McKhann 
et al. 1984). Mixed dementia was diagnosed in cases of cerebrovascular events without 
temporal relationship to cognitive decline. For all analyses, mixed dementia and 
dementia in AD were combined. Dementia diagnosis in subjects who were not 
interviewed personally was based on the Global Deterioration Scale (score >= 4 points). 
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In these cases, an etiological diagnosis was established if the information provided was 
sufficient to judge etiology according to the criteria just described. 
Statistical Analyses 
Multivariate Cox proportional hazard regression analyses were performed to 
evaluate the influence of selected predictors on the time to onset of AD dementia. The 
predictors were group membership (LMCI, EMCI, pre-MCI SCD, or CO), age, sex, 
education (low, medium, high), depressive symptoms (Geriatric Depression Scale 
scores <6 points or >= 6 points), and ApoE4-status.  
We performed three separate analyses. The first analysis was performed with the 
total sample (n = 2533). During the second analysis, we restricted the sample to the 
LMCI, EMCI, and pre-MCI SCD groups with self-reported concerns plus the CO group 
(n = 1327). The third analysis was performed in the LMCI, EMCI, and pre-MCI SCD 
groups without concerns plus the CO group (n = 2069). For the exploratory assessment 
of the difference in risk between the pre-MCI SCD group and the other two groups of 
interest (LMCI, EMCI) all analyses were also performed with the pre-MCI SCD group 
as the reference instead of the CO group.  
To describe further the relevance of the subjective report, an exploratory 
analysis was performed in which subjects without report of impairment, but below 
normal performance on verbal delayed recall (EMCI–noSCD, between 1.0 SD and 1.5 
SD below the normative mean; LMCI–noSCD, below 1.5 SD of the normative mean) 
were integrated in the model of the second analysis (subjects with SCD+C). We chose 
the model of the second analysis to include both “ends” of subjective report (i.e., no 
SCD and SCD+C). 
3.1.4 Results 
The number of subjects excluded at follow-up 1, followup 2, follow-up 3, and 
follow-up 4, respectively, were 0, 125, 82, and 143 (n = 350) in the CO group; 0, 111, 
99, and 160 (n = 370) in the pre-MCI SCD group; 0, 33, 27, and 40 (n = 100) in the 
EMCI group; 0, 57, 43, and 69 (n = 169) in the LMCI group; 0, 34, 17, and 19 (n = 70) 
in the EMCI–noSCD group; and 0, 31, 27, and 41 (n = 99) in the LMCI–noSCD group. 
The number of conversions to AD dementia at follow-up 1, follow-up 2, follow-up 3, 
and follow-up 4, respectively, were in 0, 6, 15, and 11 (n = 32; rate of conversion, 
3.7%) in the CO group; 4, 17, 22, and 23 (n = 66; rate of conversion, 6.2%) in the pre-
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MCI SCD group, 2, 7, 11, and 7 (n = 27; rate of conversion, 10.8%) in the EMCI group; 
26, 24, 24, and 15 (n = 89; rate of conversion, 24.9%) in the LMCI group; 0, 2, 1, and 1 
(n = 4; rate of conversion, 2.5%) in the EMCI–noSCD group; and 7, 4, 5, and 8 (n = 24; 
rate of conversion, 12.1%) in the LMCI–noSCD group. 
The descriptive data of the analyses are listed in Table 7. The number of incident 
AD cases with respective hazard ratio (HR) for each group throughout the course of the 
study are listed in Table 8. For the entire sample, the AD dementia risk in subjects with 
LMCI was increased (HR = 7.27; p < .001). The risk was increased also in subjects with 
EMCI (HR = 3.10; p < .001) and with pre-MCI SCD (HR = 1.55; p = .04) in 
comparison with the control subjects. Figure 5A shows the survival curves. In addition, 
age (HR = 1.13; p < .001) and positive ApoE4 carrier status (HR = 1.88; p < .001) were 
associated with an increased risk of AD dementia. With the pre-MCI SCD group as the 
reference group, both LMCI (HR = 4.69; p < .001) and EMCI (HR = 2.0; p = .003) were 
associated with a significantly greater risk of AD dementia. 
In the second analysis, all three categories were restricted to those participants 
reporting concerns regarding their memory decline (SCD+C). In this analysis, the risk 
of AD dementia was increased in the LMCI group (HR = 11.13; p < .001). The EMCI 
group (HR = 2.46; p = .06) and the pre-MCI SCD group (HR = 2.44; p < .001) showed 
a very similar increase in risk. The increase in risk in the EMCI group did not reach 
significance, most likely because of the limited size of the group (Figure 5B). In this 
analysis there was also an increased risk of AD dementia associated with greater age 
(HR = 1.15; p < .001) and with positive ApoE4 carrier status (HR = 2.2; p < .001). 
Compared with the pre-MCI SCD group, there was a difference in risk of incident AD 
dementia in the LMCI group (HR = 4.56; p < .001), but not in the EMCI group (HR = 
1.01; p = .99). 
In the third analysis, all three categories were restricted to subjects who reported 
no concerns regarding their memory decline (SCD-C). Here, the risk of incident AD 
was increased in LMCI (HR = 5.64; p < .001) and EMCI (HR = 3.35; p < .001), but not 
significantly in the pre-MCI SCD group (HR = 1.25; p = .343; Figure 5C). Age (HR = 
1.14; p < .001) and positive ApoE4 carrier status (HR = 1.72; p = .004) were also 
associated with a greater risk of incident AD dementia. In addition, depressive 
symptoms (HR = 1.81; p = .025) were associated with increased risk of incident AD 
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dementia in this analysis. When the pre-MCI SCD group was treated as the reference 
group, both LMCI (HR = 4.51; p < .001) and EMCI (HR = 2.67; p < .001) were 
associated with a greater risk of incident AD dementia.  
In an exploratory analysis, we included the groups of EMCI-noSCD and LMCI-
noSCD in the second model (individuals with SCD+C). Four subjects (2.5%) in the 
EMCI-noSCD group and 24 subjects (12.1%) in the LMCI-noSCD group converted to 
AD dementia. In comparison with the CO group, the risk of AD dementia for EMCI-
noSCD was not increased (HR = 0.85; p = .765), whereas the risk for LMCI-noSCD 
was increased (HR = 3.87; p < .001). 
Table 7. Study 1: Sample description for all groups. 
    CO 
pre-MCI 
SCD Early MCI Late MCI all 
total 
sample 
N 863 1061 251 358 2533 
age: years (mean, SD) 79.7 (3.47) 79.8 (3.48) 79.4 (3.79) 79.9 (3.93) 79.7 (3.58) 
female: n (%) 584 (67.7) 618 (58.3) 162 (64.5) 277 (77.4) 1641 (64.8) 
level of education 
     low: n (%) 530 (61.4) 604 (56.9) 167 (66.5) 229 (64) 1530 (60.4) 
middle: n (%) 249 (28.9) 308 (29) 60 (23.9) 96 (26.8) 713 (28.1) 
high: n (%) 84 (9.7) 149 (14) 24 (9.6) 33 (9.2) 290 (11.4) 
depressive *: n (%) 41 (4.8) 98 (9.2) 24 (9.6%) 58 (16.2) 221 (8.7) 
ApoE4+: n (%) 163 (18.9) 210 (19.8) 44 (17.5) 100 (27.9) 517 (20.4) 
subjects 
with 
concerns 
only 
N 863 261 70 133 1327 
age: years (mean, SD) 79.7 (3.47) 79.6 (3.42) 78.7 (3.05) 79.7 (4.22) 79.6 (3.52) 
female: n (%) 584 (67.7) 180 (69.0) 46 (65.7) 110 (82.7) 920 (69.3) 
level of education 
     low: n (%) 530 (61.4) 162 (62.1) 50 (71.4) 86 (64.7) 828 (62.4) 
middle: n (%) 249 (28.9) 61 (23.4) 15 (21.4) 33 (24.8) 358 (27.0) 
high: n (%) 84 (9.7) 38 (14.6) 5 (7.1) 14 (10.5) 141 (10.6) 
depressive *: n (%) 41 (4.8%) 49 (18.8) 13 (18.6) 30 (22.6) 133 (10.0) 
ApoE4+: n (%) 163 (18.9) 54 (20.7) 10 (14.3) 40 (30.1) 267 (20.1) 
subjects 
without 
concerns 
only 
N 863 800 181 225 2069 
age: years (mean, SD) 79.7 (3.47) 79.8 (3.5) 79.7 (4.02) 80.0 (3.76) 79.8 (3.56) 
female: n (%) 584 (67.7) 438 (54.8) 116 (64.1) 167 (74.2) 1305 (63.1) 
level of education 
     low: n (%) 530 (61.4) 442 (55.3) 117 (64.6) 143 (63.6) 1232 (59.5) 
middle: n (%) 249 (28.9) 247 (30.9) 45 (24.9) 63 (28.0) 604 (29.2) 
high: n (%) 84 (9.7) 111 (13.9) 19 (10.5) 19 (8.4) 233 (11.3) 
depressive *: n (%) 41 (4.8%) 49 (6.1) 11 (6.1) 28 (12.4) 129 (6.2) 
 ApoE4+: n (%) 163 (18.9) 156 (19.5) 34 (18.8) 60 (26.7) 413 (20.0) 
Note. *depressive symptoms were defined as a score of 6 or higher on the Geriatric-Depression-Scale. 
CO, control subjects group; pre-MCI SCD, group with subjective cognitive decline but normal test 
performance; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment. 
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Table 8. Conversion to AD dementia for different risk groups. 
  CO 
pre-MCI 
SCD 
EMCI LMCI All 
total sample 
(first 
analysis) 
conversion to AD 
dementia (n, %) 
32 
(3.7) 
66 (6.2) 27 (10.8) 89 (24.9) 
214 
(8.4) 
risk*  
(Hazard-Ratio, CI) 
1.0 
1.55 
(1.02-2.37) 
3.1 
(1.86-5.18) 
7.27 
(4.82-10.97) 
- 
subjects with 
concerns only 
(second 
analysis) 
conversion to AD 
dementia (n, %) 
32 
(3.7) 
25 (9.6) 5 (7.1) 45 (33.8) 
107 
(8.1) 
risk*  
(Hazard-Ratio, CI) 
1.0 
2.44 
(1.44-4.14) 
2.46 
(0.95-6.36) 
11.13 
(6.92-17.89) 
- 
subjects 
without 
concerns only 
(third 
analysis) 
conversion to AD 
dementia (n, %) 
32 
(3.7) 
41 (5.1) 22 (12.2) 44 (19.6) 
139 
(6.7) 
risk*  
(Hazard-Ratio, CI) 
1.0 
1.25 
(0.786-2.0) 
3.35 
(1.94-5.77) 
5.64 
(3.55-8.97) 
- 
Note. CO, control subjects group; pre-MCI SCD, group with subjective cognitive decline but normal test 
performance; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, 
Alzheimer’s disease; CI, confidence interval. *Risk in comparison with CO. Covariates: age, sex, 
education (low, medium, high), depressive symptoms (Geriatric Depression Scale scores < 6 points or >= 
6 points), and apolipoprotein E4 status. 
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Figure 5. Survival Curves across late MCI, early MCI and pre-MCI SCD groups with and without concerns respectively. 
Note. Survival curve (A) across all subjects, (B) across all subjects with concerns regarding their experienced memory decline, and (C) across all subjects without concerns 
regarding their experienced memory decline. AD, Alzheimer’s disease; pre-MCI SCD, individuals with experienced memory decline but normal test performance; EMCI, 
early mild cognitive impairment; LMCI, late mild cognitive impairment. 
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3.1.5 Discussion 
We tested the risk of AD dementia in a large sample of dementia-free elderly 
subjects who were categorized into three groups according to their baseline report on 
memory-related SCD and their performance in a verbal memory task. These categories 
were (1) LMCI defined by the report on memory-related SCD and performance on 
delayed verbal recall below 1.5 SD of the norm, (2) EMCI defined by the report on 
memory-related SCD and performance on delayed verbal recall between 1.0 SD and 1.5 
SD below the norm, and (3) pre-MCI SCD defined by the report on memory-related 
SCD with performance on delayed verbal recall within the norm (better than 1.0 SD 
below the normative mean). The distinction of LMCI and EMCI was made specifically 
because these two stages of MCI have recently been proposed, and EMCI is now used 
as an inclusion criterion in early AD recognition studies (e.g. ADNI; Aisen et al. 2010). 
The rationale for this approach is to move the biomarker-based identification of AD in 
individuals to an even earlier point in time before the originally used definition of MCI, 
which is now termed LMCI. The reference in our analysis was individuals who reported 
no memory-related SCD and who performed within the unimpaired range (better than 
1.0 SD below the normative mean) on delayed verbal recall. 
Across all individuals, we observed increasing risk of AD dementia in an 
ordered fashion, with highest risk in LMCI followed by EMCI and pre-MCI SCD. This 
result substantiates the concept of MCI as a risk factor of AD and shows that risk 
increases with increasing levels of impairment (Gomar et al. 2011). 
In a second analysis, we restricted the groups to those who reported memory-
related SCD associated with self-reported concerns (SCD+C). This approach was 
chosen because LMCI and EMCI are defined by the presence of impairment on tests 
and by reported concerns regarding memory impairment (http://adni.loni.ucla.edu/) 
(Winblad et al. 2004). The second reason for restricting the analysis to subjects with 
SCD+C relates to the finding of a doubling in risk of AD dementia in SCD+C compared 
with SCD without concerns (Jessen et al. 2010). In this analysis, subjects with LMCI 
had a very high risk of incident AD dementia. Subjects with pre-MCI SCD, however, 
had the same risk of incident AD dementia as subjects with EMCI. Thus, if both the 
pre-MCI SCD and EMCI groups report memory-related SCD with concerns, the fact 
that the subjects with EMCI performed between 1.0 SD and 1.5 SD below the norm on 
verbal delayed recall had no additional effect on the risk of AD dementia in our data. 
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This suggests that a categorical definition of minimal impairment (EMCI) is of limited 
sensitivity and specificity to detect individuals at the earliest disease stages. The lack of 
sensitivity is most likely associated with misclassification of high-performing subjects 
as normal. The lack of specificity is caused by false classification of actually 
unimpaired subjects as impaired, who perform poorly in a particular testing situation. 
To the contrary, the subjective report on decline, which is present in both pre-MCI SCD 
and EMCI, reflects the overall longitudinal development of cognitive performance 
within the recent time and may be a more robust indicator of minor changes than a 
single time point measurement. 
In the third analysis, which was restricted to individuals who report memory-
related SCD but not associated concerns, the effect was different. Here, individuals with 
pre-MCI SCD were only at a mild, non-significant increased risk of AD dementia 
compared with the CO group. In contrast, individuals with LMCI and EMCI were still 
at increased risk of AD dementia. It needs to be pointed out that, in this case, LMCI and 
EMCI definitions differed from the currently proposed MCI definitions 
(http://adni.loni.ucla.edu/; Winblad et al. 2004) because those require concerns 
associated with experienced memory impairment. 
The second and third analyses show that pre-MCI SCD becomes predictive only 
if the self-evaluation of the experienced impairment causes concerns. If the experienced 
impairment was evaluated by the individuals as being of no concern, there was no 
prediction of dementia. This suggests that SCD without concerns may actually 
correspond to normal age-associated decline (Burke & Barnes, 2006) rather than to the 
first manifestation of AD. The concept of concerns regarding the experienced decline is 
most likely different from an increased intensity of perceived decline. One study found 
that subjective impairment was associated with cognitive decline; the increasing 
intensity of the experienced impairment assessed through a self-report questionnaire, 
however, did not contribute further to the prediction of decline (Glodzik-Sobanska et al. 
2007). The presence of concerns was not assessed explicitly in this study. 
The results of our study suggest that explicitly assessed self-reported concerns 
have predictive value. This suggests that if SCD corresponds to initial disease 
manifestation, the specific characteristic of experienced memory impairment might be 
different from normal aging and therefore cause such concerns. If this assumption was 
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true, it might explain the discrepant findings in SCD in the prediction of cognitive 
decline and dementia across studies (prediction or no prediction; Reid & Maclullich, 
2006) because most studies do not address the specific self-evaluation of SCD (e.g. 
association with concerns), but address SCD in general (Abdulrab & Heun, 2008). 
We found a higher rate of depressive symptoms in all groups with concerns 
associated with SCD compared with those with no concerns associated with SCD or 
without SCD at all. We accounted for this statistically in the analyses and it did not 
change the effects of SCD on prediction of AD dementia. However, the slightly 
increased level of depressive symptoms may also represent a very early sign of AD 
(Barnes et al. 2012). 
Conceptually, our data strengthen the importance of the subjective experience of 
memory decline in dementia prediction. As pointed out earlier, the subjective 
experience and evaluation of memory decline (concerns) may actually be an indicator of 
early disease-related impairment. As an indicator of longitudinal change, it adds 
information to the cross-sectional measures of performance obtained by tests. 
Accordingly, it has been shown that SCD and objective measures of cognitive 
performance both contribute independently to dementia prediction, and that the 
prediction is improved by the combination of both rather than either one alone (Jessen 
et al. 2011). This is of particular importance for prediction models because not all 
individuals with cognitive impairment report SCD (Mitchell, 2008). It can be speculated 
that the predictive power of the subjective report increases, and the predictive power of 
objective cognitive test performance decreases, as prediction moves to the earliest 
disease stages. This assumption is supported by the lack of risk increase of AD 
dementia in individuals with very mild performance impairment (1.0–1.5 SD below the 
norm), but without the report on memory impairment (EMCI-noSCD) in opposition to 
the risk increase in subjects with SCD and concerns but normal performance on testing. 
The greater relevance of subjective report rather than of test measures at the earliest 
symptomatic stage of AD may be related to effects of compensation. At this early 
disease stage, increased compensatory neuronal effort may facilitate still normal 
performance on tests, but may be experienced subjectively and interpreted as evidence 
for impairment (Erk et al. 2011). 
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Obviously, SCD with concerns alone or in combination with cognitive testing is 
not sufficient for individual prediction of AD dementia. It has, however, great heuristic 
value for identification of subjects, which may undergo biomarker-based predementia 
AD detection (Scheef et al. 2012). 
On a practical level, our data suggest that current biomarker-based early disease 
recognition research (such as ADNI) should consider expansion from EMCI to pre-MCI 
SCD with concerns because these subjects carry a similar risk of AD dementia as 
subjects with EMCI. By keeping the requirement for minor cross-sectional impairment 
on tests (EMCI), those subjects who are classified falsely as not impaired will be missed 
(e.g. those with high premorbid performance levels or with very effective compensatory 
mechanisms). For these individuals, however, early disease recognition may be of the 
highest value because they are still at a largely normal level of function.  
Our exploratory analysis also showed that individuals with slight memory 
impairment without subjective report (EMCI-noSCD) had no increased risk of future 
AD dementia, but those with more severe impairment and no subjective report (LMCI-
noSCD) were at increased risk. The LMCI-noSCD individuals may represent a group 
with cognitive decline resulting from AD pathology, but lack of awareness. One recent 
FDG-PET study found evidence that LMCI patients who were unaware of their memory 
deficits exhibited a more severe and AD-typical hypometabolic pattern than LMCI 
individuals who were aware of their deficits (Nobili et al. 2010). 
This study has limitations. The design of this study is not identical to biomarker-
based studies that focus on MCI (e.g. ADNI). The participants in our study are not seen 
in specialist centers, but rather resemble a population-based sample. In addition, the 
neuropsychological and clinical assessments were not extensive. It has been 
demonstrated in other studies that the stage of pre-MCI may also be associated with 
very mild impairment in executive function and increased apathy scores (Duara et al. 
2011), which were not addressed specifically in this study. 
One potential confound may be related to the inclusion criterion of at least one 
visit in the GP office within the past 12 months. This may exclude very healthy subjects 
or those who do not go to a GP office. In Germany, however, the vast majority of 
persons older than 75 years of age visit the GP regularly. Thus, we consider the data 
externally valid. The high age at entry in the study (average, 80 years) does not allow 
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generalization to younger subjects with SCD, in whom other factors such as 
psychosocial distress may be of great relevance for the presence of SCD (Paradise et al. 
2011). Because we did not use biomarkers, we applied the NINCDS-ADRDA 
(McKhann et al. 1984) and DSM-IV criteria for AD dementia rather than recently 
proposed criteria that involve biomarkers (McKhann et al. 2011). Also, our definition of 
MCI was restricted to amnestic MCI. It is uncertain how subjective report and 
performance impairment in other cognitive domains are related to dementia prediction. 
In a number of cases, only informant-based information could be obtained, mostly 
because of death or morbidity-related reasons. In an exploratory analysis, we 
recalculated the models after exclusion of those with informant-based information only. 
The prediction results were similar across the entire sample (data not shown). Thus, we 
think that the results are not biased by this approach. 
Residual confounding of the data is unlikely because we used well-defined 
categories for level of education and ApoE4 status. Depressive symptoms were 
dichotomized according to an established cutoff (Gauggel & Birkner, 1999). In 
addition, we have also repeated our analyses with the Geriatric Depression Scale as a 
continuous predictor with similar results (data not shown). Last, the subjective report 
was based on interview with the participants only. Reports from informants were not 
considered for classification of SCD. 
Overall, our data provide evidence that stages of very mild impairment may not 
be well captured by standard neuropsychological testing and also highlight the 
relevance of subjective reports as an indicator of individual change over time and 
predictor of AD dementia. 
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3.2 Study 2: Memory concerns, memory performance and risk of dementia in 
patients with MCI (Wolfsgruber et al. 2014b) 
3.2.1 Abstract 
Background 
Concerns about worsening memory (“memory concerns”; MC) and impairment 
in memory performance are both predictors of Alzheimer’s disease (AD) dementia. The 
relationship of both in dementia prediction at the pre-dementia disease stage, however, 
is not well explored. Refined understanding of the contribution of both MC and memory 
performance in dementia prediction is crucial for defining at-risk populations. We 
examined the risk of incident AD dementia by MC and memory performance in patients 
with mild cognitive impairment (MCI). 
Methods  
We analyzed data of 417 MCI patients from a longitudinal multicenter 
observational study. Patients were classified based on presence (n = 305) vs. absence (n 
= 112) of MC. Risk of incident AD dementia was estimated with Cox Proportional-
Hazards regression models. 
Results 
Risk of incident AD dementia was increased by MC (HR = 2.55, 95%CI: 1.33 – 
4.89), lower memory performance (HR = 0.63, 95%CI: 0.56 – 0.71) and ApoE4-
genotype (HR = 1.89, 95%CI: 1.18 – 3.02). An interaction effect between MC and 
memory performance was observed. The predictive power of MC was greatest for 
patients with very mild memory impairment and decreased with increasing memory 
impairment. 
Conclusions  
Our data suggest that the power of MC as a predictor of future dementia at the 
MCI stage varies with the patients’ level of cognitive impairment. While MC are 
predictive at early stage MCI, their predictive value at more advanced stages of MCI is 
reduced. This suggests that loss of insight related to AD may occur at the late stage of 
MCI. 
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3.2.2 Introduction 
The syndrome of mild cognitive impairment (MCI; Petersen, 2004) has been 
established as a risk state for Alzheimer’s disease (AD) dementia. Patients with MCI 
show cognitive impairment objectified by neuropsychological testing while their 
functional activities are largely intact. In addition, current criteria for MCI (Petersen, 
2004; Winblad et al. 2004; Albert et al. 2011) require report on cognitive decline, 
provided either by the patient and/or by an informant or clinician who knows the patient 
well. 
Compared to the current knowledge and standards of neuropsychological testing, 
the criterion of subjective report about cognitive decline in the definition of MCI is less 
elaborated. It is unknown whether more precise operationalization (either quantitatively 
or qualitatively) of this criterion may increase the predictive accuracy for AD dementia 
in MCI patients. In fact, in everyday clinical practice, the criterion of experienced or 
observed cognitive decline might often be considered fulfilled by the fact that a patient 
consults the medical system for diagnostic workup of cognitive impairment. Studies that 
investigated the role of individual and informant reports for the prediction of AD 
dementia in MCI are rare. One early study (Tierney et al. 1996) found informant reports 
but not the individual’s memory complaints associated with future AD dementia in 
memory impaired patients. A recent study (Rabin et al. 2012) in a non-demented elderly 
community sample found both self and informant reports to be predictive, while in a 
combined predictive model only informant reports together with neuropsychological 
tests remained a significant predictor. 
Other studies, based on pre-MCI samples, showed elevated risk of future AD 
dementia (Geerlings et al. 1999; Reisberg et al. 2010; Jessen et al. 2011) as well as 
associations with biomarkers of AD in individuals who report self-experienced 
cognitive decline (Saykin et al. 2006; Mosconi et al. 2008; Visser et al. 2009; Chételat 
et al. 2010; Scheef et al. 2012; Amariglio et al. 2012; Mielke et al. 2012). However, 
there are also studies that did not find associations of self-reported cognitive decline 
with either incident AD dementia (Reid & Maclullich, 2006) or biomarkers of AD 
(Buckley et al. 2013; Grambaite et al. 2013) in pre-MCI samples. Importantly, 
comparability of results across studies is limited due to heterogeneity of samples and 
assessment of self-experienced cognitive decline. Further, it was  recently reported that, 
in individuals with normal cognitive test performance (pre-MCI), those who are 
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particularly concerned about their experienced memory decline have a higher risk of 
developing AD dementia, as compared to those who report a self-experienced memory 
decline without concerns (Jessen et al. 2010; Jessen et al. 2014b). Thus, the appraisal of 
the experienced decline as worrying may be of specific predictive value when assessing 
an individual’s report. 
Based on the existing data, the significance of self-reported concerns about 
worsening memory (hereafter: “memory concerns” (MC)) in MCI is yet unclear and it is 
largely unknown what factors might influence the report or denial of MC in MCI 
patients (Mitchell, 2008). Reduced self-awareness is one factor that might influence the 
report of MC in this patient group (Roberts et al. 2009). Self-awareness often becomes 
impaired during the progression of AD. Hence, unawareness (also termed anosognosia) 
concerning the memory impairment is frequently observed in AD dementia (Vogel et al. 
2004). Reduced self-awareness and anosognosia are also observed in MCI patients 
(Vogel et al. 2004; Vogel et al. 2005; Galeone et al. 2011). However, levels of 
awareness are heterogeneous among these patients (Roberts et al. 2009). This might 
contribute to the fact that MC are not consistently present in patients with MCI (Vogel 
et al. 2004; Vogel et al. 2005; Kalbe et al. 2005). 
The heterogeneity in self-awareness may originate from the fact that 
anosognosia as a core symptom of AD dementia manifests at the stage of MCI and that 
the likelihood of its occurrence rises with increasing cognitive impairment. Evidence for 
this assumption comes from studies that investigated self-awareness in patients with AD 
dementia and patients with amnestic MCI (i.e. with clinical impairment in the memory 
domain, evidenced by neuropsychological testing (Petersen, 2004; Winblad et al. 2004). 
Patients with advanced amnestic MCI, scoring lower than two standard deviations (SD) 
below age-corrected norms on a memory test (Vogel et al. 2005), showed symptoms of 
anosognosia similarly severe compared to the AD dementia group. In a study on 
amnestic MCI patients, Nobili and colleagues found that low awareness of memory 
deficits was associated with more progressed AD pathology (Nobili et al. 2010). 
Moreover, results from a recent study showed that cognitive complaints decreased with 
decreasing cognitive performance in MCI patients, while the relationship was opposite 
(i.e. reported complaints increased with decreasing memory performance) in individuals 
with only subjective memory impairment but no MCI (Grambaite et al. 2013). These 
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results suggest that, within the stage of MCI, those patients with more severe cognitive 
impairment tend to have reduced insight into their cognitive deficits. 
Based on the empirical evidence a hypothetical model of AD dementia 
prediction in MCI can be formulated: At the earliest stage of impairment (early MCI) 
self-awareness of the patient is mostly unaffected. Here, MC should reflect the true self-
perceived, longitudinal intra-individual decline and should contribute to AD dementia 
prediction in addition to cross-sectional impairment on tests. At later stages of MCI, 
self-awareness is waning and the predictive value of MC is declining. MC as defined in 
this model comprises two important aspects, i.e. the specific notion of (1) a decline in 
memory performance and (2) the appraisal of this self-perceived decline as worrying. 
The appraisal as worrying extends beyond the subjective report about cognitive decline 
as part of the general MCI criteria and has been found to be of higher predictive value 
than the notion of a worsening memory without worries (Jessen et al. 2010; Jessen et al. 
2014b). This clearly separates the definition of memory concerns in our study from 
subjective memory decline in general. 
In the present study, we tested the proposed model in a sample of MCI patients 
whose memory impairment ranged from very mild to advanced severity.  
3.2.3 Methods 
Ethics Statement  
The protocol of the study was approved by the Institutional Review Board (IRB) 
of the Medical Faculty, University of Erlangen (coordinating study center) and by IRBs 
at each individual participating study center, listed in the following: IRB Medical 
Faculty, University of Hamburg; IRB Charité – University Medicine Berlin; IRB 
Medical Faculty, University of Göttingen; IRB Medical Faculty, University of 
Düsseldorf; IRB Medical Faculty, University of Bonn; IRB Medical Faculty, University 
of Leipzig; IRB Medical Faculty, University of Frankfurt (am Main); IRB Medical 
Faculty, University of Heidelberg; IRB Medical Faculty, Saarland University; IRB 
Medical Faculty, University of Mannheim; IRB Medical Faculty, University of 
Freiburg; IRB Medical Faculty, Ludwig Maximilian University Munich; IRB Medical 
Faculty, Technical University Munich. 
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The study was conducted in accordance with the Declaration of Helsinki. After 
complete description of the study to the patients, written informed consent was 
obtained. 
Participants 
Subjects were recruited between 2003 and 2007 at 14 specialized university 
memory clinics collaborating within the German Dementia Competence Network 
(DCN). The general procedures for assessment and selection of subjects have been 
reported in detail previously (Kornhuber et al. 2009). Briefly, patients over 50 years of 
age who were referred to or sought help at one of the participating memory clinics 
underwent a clinical, neuropsychological and laboratory assessment and brain imaging.  
Patients with either MCI or mild dementia were asked to participate in this longitudinal 
observational study.  
Clinical and neuropsychological assessment 
Patients were assessed annually by experienced physicians and 
neuropsychologists for up to three years with standardized diagnostic procedures as 
described in detail previously (Kornhuber et al. 2009). This assessment included the 
neuropsychological test battery of the Consortium to Establish a Registry for 
Alzheimer's Disease (CERAD-NP; Morris et al. 1989). The CERAD-NP consists of 
various subtests, including the Mini-Mental State Examination (MMSE) (Folstein et al. 
1975), and is specifically designed to assess the cognitive domains most commonly 
affected in AD. The subtests are (in order of administration) (1) Verbal Fluency, (2) 
modified Boston Naming Test (15 item version), (3) the MMSE, (4) Word List 
Learning of a 10-item word list (sum of three learning trials; maximum score of 30), (5) 
Figure Copying (maximum score of 11), (6) Word List Delayed Recall (maximum score 
of 10), (7) Word List Recognition (maximum score of 10 or 100%), and (8) Figure 
Recall (maximum score of 11). We used the Word List Delayed Recall subtest 
(CERAD-DR) as a measure of objective memory impairment as delayed recall of word 
lists is considered among the tests that are most sensitive to incipient AD (Albert et al. 
2001). In addition, high levels of diagnostic accuracy for the CERAD-DR have been 
reported regarding cross-sectional detection (Sotaniemi et al. 2012) and prediction of 
AD dementia (Wolfsgruber et al. 2014a).  
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Depressive symptoms were rated by the interviewer with the Montgomery 
Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979). The 
MADRS consists of 10 items which are scored from 0 to 6 after a clinical interview. It 
is well established in psychogeriatric and AD studies (Müller-Thomsen et al. 2005). A 
cutoff score of 13 points is suggested for mild depression. Instrumental activities of 
daily living were assessed with the Bayer-Activities of Daily Living Scale (BADL), a 
25-item, informant-rated questionnaire developed to assess deficits in the performance 
of everyday activities in patients with MCI or mild-to-moderate dementia (Hindmarch 
et al. 1998). 
Definition of MCI and incident AD dementia 
All diagnoses were established in a consensus conference between physicians 
and neuropsychologists at each site. The diagnosis of MCI was made according to the 
consensus criteria proposed in 2004 by the International Working Group on MCI 
(Winblad et al. 2004): (1) subjective and/or informant report about cognitive decline, 
(2) evidence of an impairment on objective cognitive test, (3) no or only minor 
impairments in instrumental activities of daily living (BADL score < 4), and (4) not 
demented. Criterion (2) was met if patients showed a cognitive deficit of more than 1SD 
below age- and education-adjusted norms in at least one subtest of the CERAD-NP 
battery or in the Wechsler-Memory-Scales Logical Memory II subtest. The diagnosis of 
incident AD dementia was made according to the NINCDS/ADRDA criteria for 
probable AD
 
(McKhann et al. 1984). 
Classification of participants into “MCI with memory concerns” vs. “MCI without 
memory concerns” 
Patients were classified as “MCI with memory concerns” (MC+) or “MCI 
without memory concerns” (MC-) according to their response to the following 
standardized question (Geerlings et al. 1999): “Do you feel like your memory has 
become worse”. Possible answers were: (1) “No”, (2) “Sometimes, but this does not 
worry me”, (3) “Yes, that worries me”, (4) “Yes, that worries me seriously”. Answers 
(1) and (2) were combined to the MC- and answers (3) and (4) to the MC+ group, 
respectively. 
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The question and response categories were read aloud to patients by the 
interviewer as part of the initial assessment prior to neuropsychological testing. 
Duration of MC was not assessed in this study. 
The standardized question on memory concerns was not used for the initial 
diagnosis of MCI but only for division into groups of MC+ and MC- patients 
respectively. The criterion of subjective report on cognitive decline required for the 
diagnosis of MCI could be provided either by the subject and/or by an informant 
according to the criteria of the International Working Group on MCI (Winblad et al. 
2004). Thus the MC+ group constitutes a subgroup of MCI patients who themselves, 
when questioned in person with a standardized item, report memory decline which they 
appraise as particularly worrying. MC as operationalized here thus extend beyond the 
subjective report about cognitive decline as part of the general MCI criteria. Patients in 
the second response category “sometimes, but this does not worry me” were therefore 
assigned to the MC- group. We also refrained from keeping the four categories separate 
as this would have prevented the detailed analysis and straightforward interpretation of 
moderating effects between categorical (MC+ vs. MC-) and continuous (memory 
performance) variables, also due to limited number of participants answering “No” to 
the question on experienced memory decline. However, we report descriptive statistics 
of interest (conversion rates and memory performance) for all subgroups. 
Statistical analysis 
Differences between groups were evaluated using independent sample t-tests for 
continuous and Chi
2
-test for categorical variables, respectively. Risk of incident AD 
dementia was evaluated using stepwise Cox Proportional-Hazards regression analyses 
(SPSS-Version-20). Hazard Ratios (HR) with corresponding 95% Confidence Intervals 
(CI) are reported. Continuous predictors were age, years of education and the CERAD-
NP delayed recall score (CERAD-DR). These were mean-centered prior to analysis by 
subtracting the respective sample mean from each observed value. Categorical 
predictors were gender, ApoE4-status (no E4 allele vs. presence of one or two E4 
alleles) and group-status (MC- vs. MC+ group). In step 1 we entered age, gender, 
education, ApoE4 plus the CERAD-DR in the model. In step 2 we added group-status 
as an additional variable, to test the hypothesis that MC contribute to the risk of incident 
AD dementia over time after controlling for objective memory impairment. In step 3 we 
added the linear interaction term of group-status and memory performance (group-
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status*CERAD-DR) to the model to test the hypothesis that the impact of MC on risk of 
future AD dementia is moderated by the level of objective memory impairment. In an 
additional analysis we added the MADRS score in step 1 to control for depressive 
symptoms as a possible confounder. 
Eight hundred and thirteen MCI patients were included at baseline in the 
longitudinal observational study. For the present analyses we included patients with a 
MMSE score between 24 and 30 (inclusive) and excluded patients with incomplete 
clinical or neuropsychological data required for the classification of subgroups and for 
statistical analysis. We further excluded those without information on ApoE4 genotype 
and those who withdrew early from the study without at least one follow-up visit at 12 
months after baseline. Application of these criteria resulted in a sample of 454 MCI 
patients eligible for the present analyses. Thirty-seven patients (8.1%) converted to 
dementia other than AD during follow-up. We excluded these cases for the present 
analysis as our focus was on the impact of MC on incident AD dementia. The final 
sample had a size of n = 417 MCI patients. Dropout analysis revealed that the group of 
patients excluded due to missing baseline data or lack of follow-up were older on 
average (Mexcluded = 68.8, SD = 8.73; Mincluded = 65.6, SD = 7.93; p < 0.05) but had only 
slightly lower MMSE mean scores (Mexcluded = 27.3, SD = 1.72; Mincluded  =  27.7, SD = 
1.66;  p < 0.05). The two groups did not differ regarding years of education, gender 
distribution and expression of memory concerns (i.e. distribution of MC+ vs. MC-). 
3.2.4 Results 
Descriptive statistics of the sample  
Of the 417 included patients, 19 patients (4.6%) responded “No” to the question 
on experienced memory decline, 93 (22.3%) answered “Sometimes, but this does not 
worry me”, 211 (50.6%) answered “Yes, that worries me” and 94 (22.5%) answered 
“Yes, that worries me seriously”. Thus, 112 (26.9%) patients were classified as MC- 
and 305 (73.1%) as MC+. The two groups did not differ in demographical variables, 
frequency of ApoE4 status, MMSE score, memory- or overall cognitive impairment on 
the CERAD-NP and mean follow-up time. MC+ patients showed higher scores on the 
MADRS scale and slightly higher BADL scores (Table 9). 
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Table 9. Study 2: Sample description. 
  
Total Sample  
(n = 417 MCI subjects) 
MC- group  
(n = 112 MCI subjects) 
MC+ group  
(n = 305 MCI subjects) Group comparison 
  M (SD) M (SD) M (SD) MC- vs. MC+ group 
         Cohen's d p-value 
Age (years) 65.6 7.93 66.3 8.70 65.4 7.63 0.11 0.341 
Education (years) 12.6 2.84 12.8 2.81 12.5 2.85 0.12 0.270 
MMSE-Score 27.6 1.66 27.6 1.62 27.7 1.67 -0.06 0.617 
CERAD 
Delayed Recall 5.3 2.21 5.3 2.15 5.4 2.23 -0.03 0.766 
CERAD 
Total Score 73.3 10.8 73.4 10.9 73.2 10.7 0.02 0.888 
MADRAS 7.93 6.34 5.13 5.01 8.95 6.47 -0.63 < 0.001 
B-ADL-Score 2.16 1.29 1.96 1.37 2.23 1.26 -0.21 0.061 
Follow-Up time 
(months) 27.6 9.85 28.5 10.5 27.3 9.61 0.12 0.304 
Time to Conversion  
(months) 19.1 7.80 20.8 7.42 18.8 7.87 0.27 0.422 
 n % n % N % Chi
2
 p-value 
Female gender 170 40.8 42 37.5 128 42.0 0.68 0.411 
Positive  
ApoE4-status 158 37.9 44 39.3 114 37.4 0.13 0.722 
Conversion to AD 
dementia  74 17.7 11 9.8 63 20.7 6.59 0.010 
Note. P-values are derived from independent sample t-tests (2-sided) for comparison of continuous variables, and from Chi
2
-tests for categorical variables. AD, Alzheimer’s 
disease; BADL, Bayer-Activities of Daily Living Scale; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; M, Mean; MADRS, Montgomery Asberg 
Depression Rating Scale; MMSE, Mini-Mental State Examination; MCI, Mild Cognitive Impairment; MC-, MCI patients without Memory Concerns; MC+, MCI patients 
with Memory Concerns; SD, Standard deviation. 
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Risk of AD dementia 
Seventy-four patients (17.7%) developed incident AD dementia within a mean 
follow-up time of 27.6 months. The incidence rate differed significantly between groups 
(9.8% vs. 20.7% for the MC- and MC+ group respectively). Incidence rates according 
to the individual response categories of the question on experienced memory decline 
were 6 out of 19 (31.6%) in the “No” category, 5 out of 93 (5.4%) in the category 
“Sometimes, but this does not worry me”, 42 out of 211 (19.9%) in the category “Yes, 
that worries me”, and 21 out of 94 (22.3%) in the category “Yes, that worries me 
seriously”. With regard to memory performance, the patients answering “No” had the 
lowest mean CERAD-DR scores (M = 4.37, SD = 2.63) while patients in the other 
categories displayed better and similar mean CERAD-DR scores (category “Sometimes, 
but this does not worry me”: M = 5.48, SD = 2.01; category “Yes, that worries me”: M 
= 5.29, SD = 2.16; category “Yes, that worries me seriously”: M = 5.53, SD = 2.21). 
Mean CERAD-DR performance in the group of patients answering “No” was 
significantly lower compared to that of patients in the other three response categories (t 
= 1.99, df = 415, p = 0.048). 
Results of the Cox Proportional-Hazards regression models are presented in 
Table 10. In step 1, positive ApoE4 status (HR = 1.89, 95% CI: 1.18 – 3.02) and lower 
CERAD-DR performance (HR = 0.63, 95% CI: 0.56 – 0.71) were associated with 
higher risk of developing incident AD, yielding acceptable model fit (Nagelkerkes R
2 
= 
0.262). Group-status (MC- vs. MC+) was entered in step 2 of the analysis. In addition to 
CERAD-DR and ApoE4, presence of MC (i.e. belonging to the MC+ group) was also 
associated with an increased risk of future AD (HR = 2.55, 95% CI: 1.33 – 4.89) and 
significantly increased model fit (Δ-Chi2 = 9.5, df = 1, p = 0.002, change in 
Nagelkerke’s R2 = 2.1%). Thus, the hypothesis that presence of MC does individually 
contribute to the risk of future AD dementia after controlling for objective memory 
impairment, was supported by the results of the regression analyses. 
The third step of the regression model included the interaction term of group-
status and CERAD-DR. The overall model fit was again improved by inclusion of the 
interaction term (Δ-Chi2 = 4.8, df = 1, p = 0.028, change in Nagelkerke’s R2 = 1%), 
supporting the hypothesis that the impact of MC on risk of future AD varies with the 
severity of objective memory impairment. The HR-value of the interaction term is 
greater than one (HR = 1.51, 95% CI: 1.01 – 2.25), which means that the impact of MC 
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on the risk of future AD increases with higher memory performance and decreases with 
lower memory performance with an estimated factor of 1.5 per word. This moderating 
effect is depicted in Figure 6 (black solid line) where on the y-axis the estimated HR of 
MC is plotted as a function of memory performance (CERAD-DR). As can be seen 
here, the HR of MC decreases with decreasing memory performance, i.e. when moving 
from left to right along the x-axis. 
The additional analysis with the MADRS score as a predictor added in step 1 of 
the modelling process revealed that depressive symptoms were not associated with risk 
of future AD dementia (p = 0.56) and did not alter the results reported above. 
Figure 6. The impact of memory concerns on the risk of future AD dementia is 
moderated by objective memory performance at baseline. 
 
 
 
 
 
 
 
 
 
Note. The impact of memory concerns on the risk of future AD dementia, expressed in terms of the 
Hazard Ratio (HR) for the predictor ‘‘memory concerns’’, is plotted as a function of objective memory 
performance at baseline, i.e. the interaction effect between memory concerns and objective memory 
performance is depicted. Values are derived from the multivariate Cox-proportional Hazard Regression 
analysis (see Table 10, model step 3: HR of the interaction-term = 1.51, 95% Confidence Interval: 1.01–
2.25). The black solid line corresponds to the estimated HR-value = 1.51 of the interaction effect. The 
two dotted lines represent the functional curves that result when the boundary HR-values of the lower 
95% Confidence Interval (= 1.01) or upper 95% Confidence Interval (= 2.25) respectively, are inserted as 
numbers to plot the interaction effect. CERAD-DR, Delayed Recall of the Consortium to Establish a 
Registry for Alzheimer’s Disease Neuropsychological Assessment Battery. 
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Table 10. Differential risk for incident AD dementia across follow-up time (Results of Cox proportional hazard regression models). 
  Model Statistics Predictor Statistics 
  M2LL 
Chi
2
 
Δ-Chi2 
(df) 
p-
value 
Nagelkerke 
R
2 
(%) 
B SE Wald-Chi
2
 p-value HR 
95% C.I. for HR 
  Lower Upper 
Step 1:  
Model with covariates 
and CERAD-DR as 
predictors 
Model variables 723.5 107.2  (5) 0.000 26.2        
Age     0.03 0.02 2.33 0.127 1.03 0.99 1.06 
Female gender     0.26 0.24 1.17 0.279 1.29 0.81 2.05 
Education     -0.05 0.04 1.52 0.218 0.95 0.88 1.03 
Positive ApoE4 status     0.63 0.24 6.95 0.008 1.89 1.18 3.02 
CERAD-DR     -0.47 0.06 56.1 < 0.001 0.63 0.56 0.71 
Step 2: 
 MC added as 
predictor 
Model variables 713.9 9.5 (1) 0.002 28.3        
Age     0.03 0.02 3.34 0.068 1.03 1.00 1.07 
Female gender     0.11 0.24 0.22 0.641 1.12 0.70 1.80 
Education     -0.05 0.04 1.77 0.183 0.95 0.88 1.03 
Positive ApoE4 status     0.61 0.24 6.39 0.011 1.85 1.15 2.97 
CERAD-DR     -0.46 0.06 55.9 < 0.001 0.63 0.56 0.71 
Presence of MC     0.93 0.33 7.87 0.005 2.55 1.33 4.89 
Step 3:  
added Interaction 
between  
CERAD-DR and MC 
Model variables 709.1 4.8 (1) 0.028 29.3        
Age     0.03 0.02 2.97 0.085 1.03 1.00 1.07 
Female gender     0.16 0.24 0.44 0.506 1.18 0.73 1.90 
Education     -0.05 0.04 1.31 0.252 0.95 0.88 1.03 
Positive ApoE4 status     0.64 0.24 6.95 0.008 1.89 1.18 3.05 
CERAD-DR     -0.83 0.20 17.4 < 0.001 0.44 0.30 0.65 
Presence of MC     1.95 0.70 7.73 0.005 7.01 1.78 27.7 
Linear Interaction:  
CERAD-DR * MC 
    0.41 0.21 4.00 0.046 1.51 1.01 2.25 
Note. M2LL of the Intercept model = 830.6. Details of the modeling process are given in the methods section. The HR for the CERAD-DR is below one as it represents the 
HR for a one unit increase in CERAD-DR scores (i.e. for better memory performance). Lower CERAD-DR scores are therefore associated with a higher risk for developing 
incident AD dementia. B, Beta-Coefficient of the predictor; C.I., Confidence Interval; CERAD-DR, Delayed Recall of the Consortium to Establish a Registry for Alzheimer's 
Disease Neuropsychological Assessment Battery; HR, Hazard Ratio; M2LL, Minus-Two-Log-Likelihood; SE, Standard Error for B; MC, Memory Concerns.
 77 
3.2.5 Discussion 
In the present study we found that MC, which extend beyond the subjectively 
experienced memory decline that is part of the general MCI criteria set, were associated 
with an increased risk of incident AD dementia. This main effect of MC is of 
importance as it suggests that reported concerns regarding self-perceived memory 
decline (rather than just self-report without associated concerns) are predictive for 
future AD dementia in the MCI stage. We suggest that the magnitude of this main effect 
(about two-fold increased risk in the MC+ group) is of clinical relevance. Our findings 
are in line with results from an independent population-based study which found that 
self-perceived memory decline with reported concerns is associated with a higher risk of 
incident AD dementia than the mere notion of worsening memory without concerns 
(Jessen et al. 2010; Jessen et al. 2014b). These results also suggest that AD-related 
memory decline might be experienced in a different quality (i.e. as more serious and 
therefore worrying) compared to memory decline related to other factors such as normal 
aging. As an alternative hypothesis, proneness to psychological distress, a trait which 
has been reported as a risk factor for AD dementia (Wilson et al. 2003), might also be 
associated with a higher proneness to worry about self-perceived memory decline. If 
true, this could also explain the higher risk of incident AD dementia associated with 
endorsing worries about worsening memory. We also stress that the main effect of MC 
does not imply that MCI patients without concerns about worsening memory are of no 
risk of future AD dementia, but our data suggest that their risk is lower at a group level. 
Interestingly, in the small patient group who answered “No” to the question on 
experienced memory decline the conversion rate was highest and the memory 
performance level was lowest. 
We also observed an interaction effect between MC and objective memory 
performance. The impact of MC on risk of future AD dementia was highest for patients 
with very mild memory impairment and decreased with increasing memory impairment. 
Compared to the main effect of MC, this interaction effect was less strong. While this 
impedes a direct clinical applicability (e.g. for prediction in the individual case), it still 
highlights that at a group level MC and objective memory impairment interact in the 
course of AD. We suggest that this interaction between MC and memory performance is 
meaningful in several ways. Firstly, at the stage of very mild memory impairment, the 
assessment of self-perceived and worrying intra-individual decline might further 
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contribute to AD dementia prediction in addition to cross-sectional impairment on tests. 
This is of relevance as it highlights the particular value of self-reported memory decline 
with associated worries at the stage of very mild impairment (Jessen et al. 2014b). 
Secondly, the effect of decreasing predictive validity of MC with increasing 
memory impairment may be caused by the reduction of self-perceived insight into 
symptoms at later stages of MCI.  In this regard, we observed the highest conversion 
rate (31.6%) in the group answering “No” to the MC question, i.e. in those patients who 
were neither concerned about worsening memory nor reported any experienced memory 
decline at all. These patients also had the lowest CERAD-DR performance in the 
studied sample which is consistent with this potential explanation. Our observation is in 
line with results from a recent brain FDG-PET imaging study in a sample of single- and 
multidomain amnestic MCI patients (memory performance of < 1.5 SD below norm), 
which also included an assessment of awareness (Nobili et al. 2010). Patients with poor 
awareness of their memory deficits showed a hypometabolic pattern similar to that of 
patients with early AD dementia, suggesting that unawareness of memory deficits in 
MCI is linked to a more progressed pathology. Vogel and colleagues
 
(Vogel et al. 2004) 
studied a group of amnestic MCI patients with more severe memory impairment (< 2SD 
below norm). They found similar levels of reduced awareness for this MCI group 
compared to a group of AD dementia patients and observed lower MMSE scores to be 
associated with lower levels of awareness. Furthermore, one recent study has shown 
that, in the group of MCI patients, subjective cognitive complaints decreased with 
increasing cognitive impairment (Grambaite et al. 2013). Based on these empirical data, 
we propose that anosognosia, which is a well-known clinical sign of AD dementia, 
might occur at the stage of late MCI. At the stage of very mild MCI, before this loss of 
valid self-perception, the presence of MC is predictive of future AD dementia. This is in 
agreement with several studies showing that subjective memory decline in individuals 
with normal cognitive function is also predictive for AD dementia (Geerlings et al. 
1999; Reisberg et al. 2010; Jessen et al. 2011; Jessen et al. 2010; Jessen et al. 2014b).
 
Depressive symptoms did not predict risk of future AD dementia in the present 
study and inclusion of depressive symptoms as a possible confounding variable did not 
alter the effects for objective memory impairment and MC. It is important to note, that 
although the MC+ group scored higher on the MADRS, their mean MADRS score 
reflected only very mild depressive symptoms and did not correspond to the clinical 
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diagnosis of a major depression. ApoE4 status was associated with a higher risk of 
incident AD dementia which is in line with recent studies (Xu et al. 2013; Espinosa et 
al. 2013). However, frequencies of ApoE4 did not differ between the MC+ and MC- 
group. Results remained similar when ApoE4 was not accounted for in the models and 
we did not observe an interaction between MC and ApoE4 with regard to risk of 
incident AD dementia in additional post-hoc analyses (data not shown). ApoE4 and MC 
thus independently contributed to risk of AD dementia in the present sample. We also 
controlled for level of education in our analysis. Regarding the interplay of education 
and memory concerns, results from a large population based cohort study of non-
demented elderly suggest that the clinical relevance of subjective memory complaints 
might be higher in individuals with higher educational background (van Oijen et al. 
2007). We also tested for an interaction between memory concerns and level of 
education in our analysis but did not find such an effect (data not shown). Differences in 
samples and design (i.e. community based cohort of non-demented elderly vs. memory 
clinic MCI sample in our study) might have contributed to these discrepant findings. 
Our results are different to those of other studies which did not find a clear 
association between self-reports of memory decline and incident AD dementia (Tierney 
et al. 1996; Rabin et al. 2012). However, besides differences regarding samples and 
assessment of self-reported memory decline, these studies did also include informant 
reports in their predictive models. Therefore the comparability of our results to these 
studies is limited and we acknowledge the lack of informant reports in our study as a 
limitation. 
A strength of the present study is the large number of neuropsychologically well 
characterized patients who met criteria for MCI (Winblad et al. 2004). Within these 
criteria we set the cutoff for cognitive impairment at 1.0SD below the normative mean. 
This procedure is in line with recently established study protocols of large studies, e.g. 
ADNI-2 where recruitment was extended to early (amnestic) MCI patients with very 
mild memory impairment (< 1.0 SD below the norm; Aisen et al. 2010). The present 
sample therefore enabled us to test the specific contribution of MC for risk of AD 
dementia at different stages of memory impairment within the MCI spectrum.  
This study has limitations. The present sample reflects MCI patients with at least 
very mild impairment in one cognitive domain. Therefore the present results concerning 
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the prognostic value of MC at different levels of memory impairment only refer to the 
MCI spectrum and not to cognitively unimpaired individuals (pre-MCI). Secondly, we 
focused on memory concerns only (rather than concerns about other cognitive domains 
or cognition in general) and on AD dementia as the outcome. It is important to note that 
other cognitive domains beyond memory can also be affected in MCI due to AD (Albert 
et al. 2011). Thirdly, data on duration of MC and on discrepancies between the 
informant and the patient regarding the report of MC was not available to us. Finally, 
our sample reflects a memory clinic population and the transfer to population-based 
cohort or volunteer samples may not be valid. Dropout analysis also revealed that the 
patients included in this study were three years younger on average compared to those 
excluded due to baseline missing data or lack of follow-up. However the two groups 
differed only slightly regarding baseline cognitive functioning and, more importantly, 
the groups did not differ in the expression of MC (73.1% MC+ in the study sample vs. 
74.8% MC+ in those excluded from the analysis; p = 0.661). Thus, although a small 
selection bias was observed in our data, we consider the main results of our study not 
confounded by this bias. 
In conclusion, the present study highlights a dynamic of the impact of MC as a 
predictor for incident AD dementia in MCI patients. The results may have implications 
for clinicians working with elderly patients at risk of AD dementia, but also for the 
design of early intervention trials in AD. MC should be taken seriously as a risk 
indicator for future AD dementia, especially in cases where neuropsychological test 
results are at the border between normal and impaired. 
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3.3 Study 3: SCD is related to CSF biomarkers of AD in MCI patients 
(Wolfsgruber et al. 2015) 
3.3.1 Abstract 
Objective  
To test whether, in individuals with mild cognitive impairment (MCI), different 
measures of subjective cognitive decline (SCD) in the memory domain predict 
abnormal CSF biomarkers of Alzheimer’s disease (AD). 
Methods  
We analyzed the multi-center baseline (cross-sectional) data of 245 MCI 
patients. SCD was measured quantitatively with the Subjective-Memory-Decline-Scale 
(SMDS) and qualitatively by assessing particular concerns associated with self-
experienced worsening of memory. Logistic regression models were used to examine 
associations between SCD and abnormal CSF biomarkers, taking into account objective 
memory impairment, depressive symptoms and education as covariates. 
Results  
Abnormal CSF-Aβ42 and more depressive symptoms were associated with 
higher SMDS scores and with the report of memory concerns. Risk of abnormal CSF-
Aβ42 increased by an estimated 57% for a one standard deviation increase in SMDS 
scores and was doubled in patients who had SMDS scores > 4 or who reported memory 
concerns, respectively. In addition, both SCD measures predicted risk of having a 
biomarker signature indicative of prodromal AD defined as presence of low CSF-Aβ42 
together with either high CSF-Tau or CSF-pTau181 levels. 
Conclusions 
 In MCI, specific aspects of SCD severity and quality are related to CSF 
biomarkers indicative of AD. This extends findings in pre-MCI samples and calls for an 
improved operational assessment of SCD in MCI. This might be useful for sample 
enrichment strategies for increased likelihood of AD pathology. 
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3.3.2 Introduction  
The subjective report of cognitive decline is part of the mild cognitive 
impairment (MCI) diagnostic criteria (Winblad et al. 2004) and can be provided, 
unstandardized, either by the patient and/or by a close informant, or by a clinician 
familiar with the patient. However, self-reported subjective cognitive decline (SCD) is 
neither a mandatory criterion nor is there a standardized SCD assessment in current 
MCI criteria sets (Winblad et al. 2004; Petersen, 2004; Albert et al. 2011). It has been 
established that specific qualitative and quantitative neuropsychological deficits (e.g. 
marked episodic memory deficits) increase the likelihood of Alzheimer’s disease (AD) 
in MCI (Albert et al. 2011; Wagner et al. 2012; Dubois et al. 2014). 
It is yet unclear whether quantitative and qualitative features of self-reported 
SCD may also improve the prediction of underlying AD pathology in MCI patients, 
however, studies in the presumed preclinical stage of AD (Sperling et al. 2011) suggest 
that this may well be the case. These studies have associated various measures of SCD 
with increased likelihood of abnormality in biomarkers of AD pathology (Visser et al. 
2009; Mosconi et al. 2008; Amariglio et al. 2012; Mielke et al. 2012; Saykin et al. 
2006; Rami et al. 2014) including CSF biomarkers. Thus, SCD measures may serve as 
indicators of AD pathology in the stage of preclinical AD (Jessen et al. 2014a). 
The present study examines whether this association of SCD with AD 
biomarkers extends into the stage of MCI. We tested whether different measures of 
SCD in the memory domain predict CSF biomarker abnormality indicative of AD. We 
took several factors into account which could affect this association: objective memory 
performance (because in advanced MCI awareness of own cognitive deficits may 
vanish; Roberts et al. 2009; Vogel et al. 2004; Snitz et al. 2008; Grambaite et al. 2013), 
depressive symptoms (because they may relate to SCD independent of AD pathology; 
Roberts et al. 2009; Reid & Maclullich, 2006) and education (as a cognitive reserve 
proxy; Stern, 2012). 
3.3.3 Methods 
Standard Protocol Approvals, Registrations, and Patient Consents 
The study protocol was approved by Institutional Review Boards of all 
participating study centers of the German Dementia Competence Network (DCN; 
Kornhuber et al. 2009). All patients provided written informed consent. 
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Participants 
We analyzed data from a multi-center longitudinal observational study of the 
German DCN. Sample selection and assessment procedures of this study have been 
reported in detail previously (Kornhuber et al. 2009). Eight hundred and thirteen MCI 
patients were included at baseline of which 702 had complete clinical and 
neuropsychological data. For the present analyses we used cross-sectional baseline data 
from a subsample of 245 of these patients with available biomarker data. 
We investigated missing data pattern by comparing the study sample with the 
group of patients excluded due to missing CSF, clinical, or neuropsychological data. 
The two groups did not differ regarding age, education, Mini-Mental State Examination 
(MMSE) score, gender or APOE4 status, suggesting that the assumption of a missing at 
random data pattern was not violated. 
CSF measures 
We collected CSF according to previously described standard operating 
procedures (Lewczuk et al. 2006) by lumbar puncture from the L3/L4 or L4/L5 inter-
vertebral region,  into polypropylene test tubes with intermediate storage at site (–
80°C). Samples were then shipped to a central biobank without undergoing any 
thawing/re-freezing cycles. We measured CSF-Aβ42, CSF-Tau and CSF-pTau181 
(Innogenetics, Ghent, Belgium) with ELISA (Lewczuk et al. 2004) in an ISO 9001-
certified laboratory under routine quality control regime (intra-assay coefficients of 
variation: 2.3–5.9%; inter-assay coefficients of variation: 9.8–13.7%). We performed all 
analyses in duplicate and used the mean of the two. 
We defined abnormally low CSF-Aβ42 (< 600 pg/ml), abnormally high CSF-
Tau (> 300 pg/ml) and abnormally high CSF-pTau181 (> 60 pg/ml) based on our own, 
previously published cutoff values (Lewczuk et al. 2006; Lewczuk et al. 2004), as is 
currently best practice. We defined a biomarker signature indicative of AD pathology 
(hereafter: “CSF-AD signature”) as presence of low CSF-Aβ42 together with either 
high CSF-Tau or CSF-pTau181 levels (Dubois et al. 2014). 
Clinical, neuropsychological assessment  
Standardized diagnostic procedures have been described previously (Kornhuber 
et al. 2009). Assessment included the German version of the neuropsychological 
assessment battery of the Consortium to Establish a Registry for Alzheimer's Disease 
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(CERAD; Morris et al. 1989), which contains the MMSE and is extended with the 
Trail-Making-Test (TMT) A and TMT-B (Reitan, 1958). Additional memory tests 
administered were the Wechsler-Memory-Scale Logical Memory II (WMS-LM-II; 
Wechsler, 1987) and the Free and Cued Selective Reminding Test (FCSRT; Buschke, 
1984). We used the CERAD Word List Delayed Recall subtest (CERAD-DR), to 
quantify objective memory performance in our main analysis. This free delayed recall 
measure has good diagnostic accuracy for prevalent and incident AD dementia 
(Wolfsgruber et al. 2014a). We assessed depressive symptomatology with the 
Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) 
consisting of 10 items scored from 0 to 6 based on a clinical interview. A score >= 13 
suggests at least mild depression (Müller et al. 2003). We assessed instrumental 
activities of daily living (IADL) with the Bayer-Activities of Daily Living Scale 
(BADL; Hindmarch et al. 1998). 
Definition of MCI 
MCI diagnosis was made according to criteria proposed by Winblad et al. 
(2004): (1) subjective and/or informant report about cognitive decline (2) evidence of 
objective cognitive impairment (3) no or only minor IADL impairment (BADL score < 
4), and (4) not demented. Criterion (2) was met if patients’ test scores (cognitive 
domains in parentheses) fell more than 1SD below age- and education-adjusted norms 
on the WMS-LM-II (verbal memory) or on one or more of the following subtests of the 
CERAD battery: Word List Immediate Recall, Word List Delayed Recall (both verbal 
memory); Figure Copying (visuoconstruction); Verbal Fluency, Boston Naming Test 
(both language); Figure Recall (visual memory); TMT-A (processing speed); TMT-B 
(executive functions). We considered MCI patients with deficits in one of the verbal 
memory tests as amnestic MCI and those without deficits in verbal memory as non-
amnestic MCI. We will further report on a subgroup of patients who met amnestic 
impairment at a more conservative cutoff (< -1.5SD below norm) in at least one of the 
verbal memory tests. 
SCD assessment 
The quantitative and qualitative SCD assessment outlined below was not used 
for initial MCI diagnosis. Rather, the diagnosis of MCI required “evidence of cognitive 
decline measured either by self- and/or informant report in conjunction with deficits on 
objective cognitive tasks” according to the applied MCI criteria (Winblad et al. 2004). 
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Thus, the operational SCD assessment as outlined below extends beyond the general 
(self- or informant-based) SCD report required by the MCI criteria. 
We assessed SCD quantitatively with the Subjective-Memory-Decline-Scale 
(SMDS; Jorm et al. 1997) which contains four questions related to self-experienced, 
increasing difficulties in everyday memory (e.g. “Do you have more trouble 
remembering things that have happened recently?”; “Are you worse at remembering 
where belongings are kept?”). Responses to each question were rated as follows: 0, “no, 
not more difficult than in the past”; 1, “Yes, a bit worse than in the past” 2, “yes, much 
more difficult than in the past”. We summed item ratings to obtain a score from 0 to 8. 
In addition, we assessed particular concerns regarding self-experienced memory 
decline. This qualitative aspect of SCD might be associated with higher risk to develop 
AD dementia compared to report of self-experienced memory decline without concerns 
(Jessen et al. 2014b). We classified subjects as “MCI with memory concerns” (MC+) or 
“MCI without memory concerns” (MC-) according to their response to the following 
standardized question: “Do you feel like your memory has become worse”. Possible 
answers were: 1, “No”; 2, “Sometimes, but this does not worry me”; 3, “Yes, that 
worries me”; 4, “Yes, that worries me seriously”. We classified patients who did not 
specifically endorse memory concerns (response category 1 and 2) as MC- and those in 
categories 3 and 4 as MC+. 
Statistical analysis 
Descriptive statistics of the sample 
Statistical analyses were conducted with SPSS-Version-20. As part of 
descriptive sample statistics we examined relationships between CSF measures, 
objective memory performance, depressive symptoms and both SCD measures. We 
conducted Pearson correlations for quantitatively measured SCD (SMDS scale), while 
performing independent sample t-tests and Chi
2
 tests for the categorical memory 
concerns measure (MC+ vs. MC- group). 
Prediction of abnormal CSF biomarkers: Main analysis 
We conducted a series of stepwise logistic regression analyses with abnormality 
in CSF-Aβ42 and CSF-AD signature (Dubois et al. 2014) as dependent variables in 
separate models. We performed separate analyses for both SCD measures. In step 1, we 
 86 
entered one of the SCD measures as a single predictor. In step 2 we then adjusted for 
covariates, by adding the terms age, gender, education, memory performance (CERAD-
DR score), MADRS depression score, and dropped insignificant terms from the model. 
Prediction of abnormal CSF biomarkers: Additional analyses 
After this main analysis, we conducted a series of additional analyses. Firstly, 
we added both the SMDS scale and the predictor “memory concerns” together in a 
single model in step 1 of the modeling process to check for additional effects of both 
SCD measures. Secondly, we included APOE4 status as an additional predictor (n = 26 
cases with missing APOE4 data). Thirdly, we repeated the main analysis but substituted 
the CERAD-DR with the Total Recall score of the FCSRT, which we previously found 
to be most closely related with AD biomarkers (Wagner et al. 2012). Fourthly, we 
extended the main analysis by adding an interaction term of CERAD-DR and either 
SCD measure in a separate analysis. With this analysis we tested whether the predictive 
power of the SCD measures might decrease with increasing memory impairment as 
reported recently for incident AD dementia as an outcome (Wolfsgruber et al. 2014b). 
As an alternative approach to the interaction analysis, we repeated the main analysis but 
restricted the sample to patients with more pronounced amnestic impairment at the        
< -1.5SD cutoff. Lastly, we modeled an interaction effect between SCD measures and 
education to check for a moderating effect of education (as a proxy for cognitive 
reserve) on the relationship between SCD measures and abnormal CSF biomarkers. 
3.3.4 Results 
Descriptive statistics of the sample  
Table 11 contains descriptive statistics of the whole sample, the number of 
patients classified as “MCI without memory concerns” (MC-) vs. those classified as 
“MCI with memory concerns” (MC+), and results of group comparison of these 
subgroups. MC+ patients showed higher MMSE, CERAD total score (Chandler et al. 
2005), MADRS and SMDS mean values. Individuals with higher SMDS scores showed 
more depressive symptomatology and lower CSF-Aβ42 values while SMDS was 
uncorrelated to objective memory performance, CSF-Tau and CSF-pTau181 levels 
(Table 12). 
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Prediction of abnormal CSF biomarkers: Main analysis 
Both measures of SCD were significant predictors of abnormal CSF-Aβ42 and 
of a CSF-AD signature according to IWG2 criteria when treated in separate models 
(Table 13). Lower memory performance also predicted abnormal CSF biomarkers and 
was the strongest predictor for abnormal CSF in terms of p-value and relative 
contribution to the R
2
 of the covariate adjusted models. In addition, more years of 
education were slightly associated with higher likelihood of abnormal CSF biomarkers. 
The likelihood of abnormal CSF biomarkers was increased by 57% (CSF-Aβ42) to 73% 
(CSF-AD signature) for patients scoring 1SD above the sample mean in SMDS scores. 
Risk of abnormal CSF-Aβ42 or CSF-AD signature was about two times higher in 
patients who reported memory concerns. 
Prediction of abnormal CSF biomarkers: Additional analyses (not shown in Table 
13). 
When both measures of SCD were added simultaneously, only the SMDS 
remained a significant predictor of abnormal CSF-Aβ42 and of a CSF-AD signature 
together with objective memory performance and education. 
Inclusion of APOE4 status or substitution of the CERAD-DR with a measure of 
cued recall (FCSRT Total Recall score) did not alter the results reported above. SCD 
measures remained significant predictors with similar ORs. As expected, APOE4 
carriers had higher risk of abnormal CSF-Aβ42 (OR = 2.34, 95%CI: 1.28-4.29) and 
CSF-AD signature (OR = 3.05, 95%CI: 1.57-5.91). There was no interaction of APOE4 
and SCD measures. 
There were no significant interaction effects between CERAD-DR and SCD 
measures. SCD measures remained significant predictors with similar ORs when only 
the subgroup of patients with amnestic impairment at the < -1.5SD cutoff was analyzed. 
The same was true when an even more conservative amnestic MCI subsample with 
impairment at the < -1.5SD cutoff in at least two of the three verbal memory tests was 
selected (n = 116, 47.3% of the sample, prevalence of CSF-AD signature = 42.2%). 
Lastly, there was no moderating effect of education on the association between 
SCD measures and abnormal CSF biomarkers. 
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Table 11. Study 3: Sample description of demographical, clinical and biomarker data. 
 
Total Sample  
(n = 245) 
MCI without memory concerns 
(MC-, n = 53, 21.6% ) 
MCI with memory concerns 
(MC+, n = 192, 78.4%) 
Group comparison 
 M (SD) M (SD) M (SD) MC- vs. MC+ 
        Cohen's d T-value p 
Age (years) 66.8 8.32 68.3 9.20 66.3 8.03 0.24 1.52 0.130 
Education (years) 12.4 3.00 12.4 3.31 12.5 2.92 -0.01 -0.08 0.935 
MMSE-Score 27.4 1.73 27.0 1.52 27.5 1.78 -0.29 -2.05 0.043 
CERAD Delayed Recall 4.9 2.26 4.4 2.27 5.03 2.25 -0.27 -1.71 0.089 
CERAD Total Score 70.8 11.2 68.1 10.9 71.5 11.2 -0.31 -1.99 0.048 
MADRAS 8.30 6.37 6.57 4.92 8.77 6.64 -0.35 -2.25 0.025 
SMDS-Score 4.29 2.29 2.47 2.05 4.80 2.09 -1.12 -7.20 < 0.001 
B-ADL-Score 2.51 1.48 2.69 1.71 2.46 1.41 0.16 0.98 0.330 
CSF Abeta-42 (pg/ml) 777 338 840 329 759 340 0.24 1.54 0.125 
CSF Tau (pg/ml) 420 257 428 234 418 263 0.04 0.23 0.814 
CSF pTau181 (pg/ml) 62.5 30.0 62.7 30.0 62.4 30.1 0.01 0.24 0.954 
 n % n % n %  Chi
2
 p 
Female Gender 100 40.8 18 34.0 82 42.7  1.32 0.251 
APOE4+ (n = 26 missing) 89 36.3 22 41.5 67 34.9  0.94 0.331 
MADRAS >= 13 54 22.0 7 13.2 47 24.5  3.02 0.080 
Amnestic MCI (< -1.0SD cutoff) 217 88.6 48 90.6 169 88.0  0.26 0.606 
Non amnestic MCI 28 11.4 5 9.4 23 12.0  
Amnestic MCI (< -1.5 SD cutoff) 188 76.7 44 83.0 144 75.0  1.5 0.221 
Low CSF Aβ-42 (< 600pg/ml) 91 37.1 13 24.5 78 40.6  4.61 0.032 
High CSF Tau (> 300pg/ml) 148 60.4 36 67.9 112 58.3  1.60 0.206 
High CSF pTau181 (> 60pg/ml) 105 42.9 22 41.5 83 43.2  0.05 0.823 
CSF-AD signature* 71 29.0 11 20.8 60 31.3  2.22 0.136 
Note: *CSF-AD signature (biomarker signature indicative of AD pathology) defined as presence of low CSF-Aβ42 together with either high CSF-Tau or CSF-pTau181 levels (Dubois et al. 
2014). Group comparison statistics are derived from independent sample t-tests (2-sided p-value).  Definition of amnestic and non-amnestic MCI is given in the method section. M, Mean; B-
ADL, Bayer Activities of Daily Living Scale; CERAD, Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery; MADRS, Montgomery Asberg 
Depression Rating Scale; MC-, “MCI without memory concerns”; MC+, “MCI with memory concerns”. SMDS, Subjective-Memory-Decline-Scale. 
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Table 12. Correlation-Matrix of predictor variables for the whole study sample. 
 
Note: *<= 0.05 **<= 0.01 2-sided p-value. CERAD-DR, Delayed recall task of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery; MADRS, 
Montgomery Asberg Depression Rating Scale; SMDS, Subjective Memory Decline Scale. 
. 
  
 SMDS Age 
Education 
(years) 
MADRS 
score 
CERAD-
DR 
CSF-
Abeta42 
CSF-Tau 
Age .044       
Education (years) -.108 -.017      
MADRS score .228
**
 -.172
**
 -.117     
CERAD-DR -.012 -.438
**
 .087 .062    
CSF-Aβ42 -.209
**
 -.212
**
 -.047 .126
*
 .258
**
   
CSF-Tau .091 .320
**
 -.005 -.066 -.307
**
 -.375
**
  
CSF-pTau181 .080 .299
**
 .022 -.050 -.305
**
 -.310
**
 .880
**
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Table 13. Prediction of abnormal CSF biomarkers in MCI patients by measures of objective memory performance and SCD. 
  Abnormal CSF-Abeta42 (< 600pg/ml) AD typical CSF signature* 
  OR (95% C.I.) p-value R2
†
 OR (95% C.I.) p-value R
2
 
Model 1: with SMDS scale as a  predictor        
Unadjusted model   .045   .059 
SMDS scale (per one standard deviation increase) 1.47 (1.12 - 1.93) 0.006  1.61 (1.19 - 2.14) 0.002  
Covariate adjusted model   .168   .221 
SMDS scale (per one standard deviation increase) 1.57 (1.17 - 2.10) 0.002 .045 1.73 (1.26 - 2.37) 0.001 .059 
CERAD-DR (per one standard deviation decrease) 1.92  (1.43 - 2.60) < 0.001 .098 2.36 (1.66 - 3.28) < 0.001 .143 
Education (1 year increase) 1.11  (1.01 - 1.22) 0.027 .025 1.10 (.998 -1.22) 0.056 .019 
Model 2: with Presence of memory concerns as a  predictor  
      
Unadjusted model   .026   .028 
Presence of memory concerns 2.08 (1.05 - 4.16) 0.037  1.79 (.861 - 3.72) 0.119  
Covariate adjusted model   .157   .185 
Presence of memory concerns 2.69 (1.29 - 5.63) 0.009 .026 2.42 (1.10 - 5.37) 0.028 .028 
CERAD-DR (per one standard deviation  decrease) 2.00 (1.48 - 2.72) < 0.001 .113 2.38 (1.69 -3.33) < 0.001 .145 
Education (1 year increase) 1.09 (.997 - 1.20) 0.058 .018 1.08 (.980 - 1.19) 0.118 .012 
Note: SMDS and CERAD-DR raw scores were rescaled as z-scores on the basis of mean and SD of the whole sample. Thus, the odds ratios for these predictors correspond to one SD increase 
(SMDS) or decrease (CERAD-DR) in the z-score. * defined as low CSF-Abeta42 together with either high CSF-Tau or high CSF-pTau181 (see Dubois et al. 2014 and method section),  
† 
numbers in bold are R2 values for the whole model, values in the predictor lines are each predictor’s relative contribution of R2 to the R2 of the whole model, C.I., Confidence Interval; CERAD-
DR, delayed recall task of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery; OR, Odds Ratio; SMDS, Subjective-Memory-Decline-Scale. 
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3.3.5 Discussion 
In patients with MCI, we found that quantitative and qualitative aspects of SCD 
significantly predicted abnormal CSF-Aβ42 levels, as well as a CSF biomarker 
signature indicative of prodromal AD (Dubois et al. 2014), in addition to the prediction 
possible with objective memory performance. This complements other findings which 
related subjective memory decline in MCI patients to increased risk of incident AD 
dementia (Wolfsgruber et al. 2014b) and future cognitive decline (Crowe et al. 2006).  
Memory performance was not consistently related to measures of SCD, in line 
with previous findings (Snitz et al. 2008; Reid & Maclullich, 2006). While there was no 
correlation of memory performance with SMDS scores, we found that patients who did 
not report memory concerns (MC- group) performed worse on cognitive measures than 
those who reported concerns. This counter-intuitive observation is in line with the 
hypothesized link between lower memory performance, reduced awareness and lower 
probability of self-reported SCD in the MCI stage (Vogel et al. 2004; Snitz et al. 2008; 
Grambaite et al. 2013; Wolfsgruber et al. 2014b). Reduced insight in more severely 
impaired MCI patients might limit the significance of SCD as a predictor of underlying 
AD pathology. In the present study we found no evidence that SCD was less predictive 
for AD biomarkers in those patients with more severe memory impairment. However, 
this could be due to limited statistical power as we previously found, in a larger sample 
of the DCN MCI cohort, that the predictive power of SCD for incident AD dementia 
decreased with decreasing memory performance (Wolfsgruber et al. 2014b). 
We observed a small effect of higher education being associated with higher risk 
of CSF pathology. This might reflect that patients with higher education can tolerate 
more AD pathology due to higher cognitive reserve (Stern, 2012; Dumurgier et al. 
2010). We did, however, not observe a moderating effect of education on the 
relationship between SCD measures and abnormal CSF biomarkers. 
The prevalence of abnormal CSF-Aβ42 and CSF-AD signature in our sample 
seems lower than in other MCI samples (Visser et al. 2009), however, it was higher 
than in cognitively normal individuals with SCD (van Harten et al. 2013b). Differences 
in cutoffs for biomarker abnormality and algorithms to define a CSF-AD signature are 
likely sources of prevalence variability across samples. The lower prevalence in our 
sample might also originate from inclusion of non-amnestic MCI and from setting the 
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cognitive impairment cutoff at 1SD below the normative mean. The present sample, 
thus, contains a broad spectrum of (early and late) memory clinic MCI patients which is 
important both in terms of external validity and as a comparison to other well 
established MCI samples, such as the ADNI sample, which included early (amnestic) 
MCI patients characterized by very mild memory impairment (Aisen et al. 2010). 
This study has limitations. We did not explicitly measure cognitive reserve 
(although education is a reasonable proxy; Stern, 2012) and a direct measure of 
awareness was unavailable to us. We had to focus on subjective decline in the memory 
domain due to lack of questionnaire data measuring subjective decline in other cognitive 
domains. Executive dysfunctions also evolve early in the process of AD and are 
predictive of future AD dementia (Dickerson et al. 2007). SCD regarding executive 
functioning therefore might also be related to amyloid pathology in MCI, as has been 
found in cognitively normal elderly (Amariglio et al. 2012). Finally, while our multi-
center sample reflects a large memory clinic population, the results might not be 
generalizable to population-based cohorts or volunteer samples. 
We here demonstrated that SCD is related to AD biomarkers in MCI, thereby 
extending findings in pre-MCI samples (Amariglio et al. 2012; Mielke et al. 2012). At 
the pre-MCI stage, SCD might reflect Aβ induced subtle impairment that is partly 
compensable and hardly detectable on standard tests (Amariglio et al. 2012). However, 
this does not imply a reduced significance of SCD at the MCI stage, where the 
emergence of objectively measurable cognitive deficits offers additional predictive 
value. In fact, effect sizes of the association between SCD and amyloid pathology were 
very similar in our MCI sample as compared to those reported in a pre-MCI sample 
(Mielke et al. 2012). This suggests that SCD remains an equally strong predictor of AD 
pathology in the MCI stage irrespective of the increasing predictive validity of objective 
memory performance from pre-MCI to MCI samples.  
In sum, our results show that specific aspects of SCD severity and quality are 
related to CSF biomarkers indicative of AD pathology in MCI. This calls for a refined 
and improved SCD assessment to complement the broad clinical SCD criterion in 
current MCI definitions. This might eventually contribute to improved prediction of AD 
and could also be useful for enrichment of MCI samples regarding underlying AD 
pathology. Steps towards improved SCD assessment have recently been taken in the 
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context of preclinical AD (Jessen et al. 2014a) including research on qualitative features 
of SCD (Buckley et al. 2014a). Our results suggest that further research on refinement 
and validation of SCD in preclinical AD might also improve the assessment of SCD in 
the MCI stage. This is especially true as the border between the late preclinical AD 
stage, where individuals might experience SCD (Sperling et al. 2011), and the early 
MCI stage of AD, as regards neuropsychology, depends on how the threshold of 
cognitive impairment is defined. Thus, as the field strives to better identify and 
ultimately treat individuals at the earliest clinical stages of AD, we believe that research 
aimed at improving the understanding and assessment of AD-related SCD can make 
significant contributions. Our findings suggest that self-reported subjective memory 
decline and associated concerns are important features to consider for SCD assessment.
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4 General Discussion 
In the course of normal aging processes, development of cognitive performance 
in most domains, including memory, follows a descending trajectory already beginning 
from middle age (Schaefer & Bäckman, 2007). Thus, it is not surprising that reports of 
SCD are quite common in the elderly general population. SCD can be defined as an 
individual’s perception of worsening cognitive function compared to his/her earlier 
performance level (Jessen et al. 2014a). Depending on assessment methods and sample 
characteristics, the prevalence of SCD in elderly people of 65 years and older is about 
25-50%, increases with age, and may reach values over 80% in persons aged 80 years 
and older (Stewart, 2012). Considering these numbers, subjective reports on cognitive 
decline in the elderly may often represent the subjective notions of declining cognitive 
performance due to normal aging processes.  
However, SCD can also be associated with significant concerns about cognitive 
functioning in daily life and is then often the reason for consulting a general practitioner 
or a specialized memory clinic for diagnostic evaluation of possible causes for the 
subjectively experienced symptoms. The perceived cognitive deterioration may also be 
corroborated by family members and physicians and/or the concurrent performance on 
objective neuropsychological tests is below what would be expected according to the 
individual’s age, gender and level of education. In the latter case, a diagnosis of mild 
cognitive impairment (MCI) is justified, provided that daily function and independence 
is still largely preserved, i.e. a dementia diagnosis can initially be ruled out (Winblad et 
al. 2004). 
MCI, especially with amnestic deficits, is considered a well-established risk 
stage for AD dementia (Petersen, 2004). Recent research criteria for AD include the 
MCI spectrum and speak of "MCI due to AD" or "prodromal AD" if, in addition to the 
clinical phenotype of MCI, biochemical or imaging diagnostics are positive for AD 
pathology. SCD is part of the MCI criteria to further characterize the clinical phenotype 
of cognitive deficits. As there is usually only one measurement point at the time of 
diagnosis, SCD provides information about a previous deterioration of cognitive 
performance, i.e. presence of SCD supports that the cross-sectionally measured 
cognitive deficit is the result of a decline from higher performance (instead of being a 
life-long existing deficit). Within the MCI criteria this information can be obtained 
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either from the patient and/or from a close informant or a clinician familiar with the 
patient. The usefulness of the criterion of (self-reported) SCD has been questioned in 
the literature (Edmonds et al. 2014), not least because symptoms of reduced insight into 
cognitive deficits, a typical characteristic of the dementia stage of AD, can already 
occur in more progressed stages of MCI (Galeone et al. 2011) and will then reduce the 
reliability and validity of self-reported SCD (Roberts et al. 2009). Furthermore, the lack 
of operationalization of this criterion has been criticized (Abdulrab & Heun, 2008) and 
there are currently no common standards for the assessment of SCD. It therefore 
remains to be determined to what extent the phenomenon of SCD is adequately captured 
by today’s approaches and whether its full potential in terms of diagnosis and prognosis 
in the context of AD is utilized. 
Research on SCD has gained new impetus in recent years in the field of early 
diagnosis of AD. Since many pharmacological intervention studies for the prevention of 
AD in the MCI stage showed no significant effects, the scientific field now endeavors to 
detect incipient AD before the MCI stage (Sperling et al. 2011). Several large studies 
have shown that people with SCD but objective cognitive performance in the normal 
range, have significantly increased risk of incident AD dementia and biomarker 
abnormality indicative of AD (Jessen et al. 2014a). SCD could therefore be considered 
as a very early symptom of incipient AD and offer a starting point for risk enrichment 
of samples or as a dependent measure over time for intervention studies and naturalistic 
observational studies. Because of these recent findings, SCD has been taken into 
account as an early clinical symptom in the research criteria of the final stages of 
preclinical AD (Sperling et al. 2011). This last phase of preclinical AD marks the 
transition from the preclinical phase to the early clinical phase of MCI.  However, also 
for this transitional stage, the optimal characterization and measurement methods of 
SCD are still insufficiently determined. 
This thesis presented three empirical studies that addressed aspects of 
characterization and measurement of SCD in individuals with objectively normal 
cognitive function and MCI patients. These studies were conceptually based on a 
current working model for the temporal development of SCD in the course of AD 
(Jessen et al. 2014a). This model assumes that the predictive power of SCD is most 
valuable at the late preclinical stage of AD when SCD is not influenced by reduced 
insight as a confounding factor and, at the same time, the validity of detecting objective 
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cognitive impairment is low due to limited sensitivity of standard cognitive tests. 
However, as AD progresses, the validity of SCD might decrease due to evolvement of 
reduced symptom insight which itself is related to progression of objective cognitive 
impairment. At the same time the validity to detect objective cognitive impairment 
increases with progression into the MCI stage and is high at more advanced MCI stages. 
In the remainder of this section, a brief summary of the results of the three 
studies is given and their contributions to the field of AD research are discussed (section 
4.1). In section 4.2, further thoughts regarding limitations, implications and directions 
for future research on AD-related SCD are outlined. 
4.1 Contributions of the presented studies to the field of AD research 
The present studies have made a number of contributions to the field of AD-
related SCD research. Study 1 has highlighted the fact that cognitively unimpaired 
elderly General Practice patients, a sample highly relevant to the health care sector, who 
report SCD with associated concerns (SCD+C) are of a 2.5-fold increased risk to 
develop AD dementia over a period of 6 years compared to individuals with normal 
cognition and without SCD. Study 1, thus, suggests that SCD in the memory domain 
might be useful as a predictor of incident AD dementia, even in the absence of overt 
neuropsychological testing deficits. This finding confirmed earlier findings of the 
AgeCoDe study with shorter follow-up time (Jessen et al. 2010) and is in line with 
recent findings from other epidemiologic studies investigating SCD as a risk factor for 
dementia (Mitchell et al. 2014). 
Beyond these confirmatory results, study 1 suggested that the qualitative feature 
of concerns/worries about the self-perceived memory decline might be of specific 
predictive value as the risk in the SCD+C group was also significantly increased 
compared to those individuals with SCD but without associated concerns. Study 1, thus, 
provided strong evidence for the recent inclusion of concerns regarding experienced 
cognitive decline, especially in the memory domain, as one of several features that may 
increase the likelihood of underlying AD in subjects with SCD (Jessen et al. 2014a). As 
an open question for future research it remains to be determined why the appraisal of 
self-experienced cognitive decline as worrying is associated with such an elevated risk 
of AD dementia compared to SCD without concerns. The results suggest that AD-
related memory decline is experienced in a different quality (i.e. as more serious and 
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therefore worrying) compared to memory decline related to other factors such as normal 
aging. Following this idea, further research should try to determine what specific 
qualitative aspects of the self-experienced cognitive decline (and what other factors) 
may determine the emergence of patients’ concerns. Research in this regard will 
contribute to better operationalization and measurement of AD-related SCD. 
Importantly, in study 1 the AD dementia risk in individuals with SCD+C was 
not substantially different from those individuals whose memory performance fell in the 
range of early amnestic MCI (risk of AD dementia in this group was also about 2.5-fold 
increased compared to the cognitively normal control group). It, thus, seems that the 
transition of pre-MCI SCD to early MCI is fluent and the definition of a strict border 
between these two stages is arbitrary. This clearly highlights the problems associated 
with neuropsychological cutoffs to define, and differentiate from one another, the 
presumed late preclinical stage of AD (clinically manifesting as “only SCD”) and the 
early MCI stage. 
Study 2 focused on the interplay between objective and subjective cognitive 
decline with regard to risk of AD dementia in a large memory clinic sample and was the 
first study to directly test a prediction hypothesis derived from the recently proposed 
working model of the temporal evolution of SCD in the course of AD (Jessen et al. 
2014a). From a statistical point of view, the assumptions on the interplay between 
objective memory performance and SCD outlined above can be modeled by a 
moderating effect of objective memory performance on the relationship between SCD 
and incident AD dementia: The predictive value of SCD for incident AD dementia 
should be highest at subtle memory impairment and should decrease as memory 
impairment progresses. Results of study 2 showed a significant main effect of SCD+C 
on incident AD dementia. Across the whole sample MCI patients with memory 
concerns were of 2.5-fold increased risk to convert to AD dementia compared to those 
MCI patients without concerns about their experienced memory decline. The 
hypothesized relationship between objective and subjective cognitive decline with 
regard to risk of AD dementia could also be demonstrated by a significant moderating 
effect as proposed above. This finding has also relevance for the widely received 
dynamic biomarker model for the development of AD (Jack et al. 2013). In this model, 
biomarkers of AD pathology as well as cognitive and functional performance are 
modeled as sigmoid-shaped, ascending curves of pathology/impairment. However, the 
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development of AD-related SCD seems to markedly differ from these trajectories. The 
SCD trajectory may rather divert from the trajectory of objective impairment in the 
stage of late MCI/early AD dementia and may be better modeled as an inverse U-shaped 
function. Thus, the association of SCD with biomarkers and cognitive/functional status 
is variable throughout the course of AD. Since SCD is gaining even further interest in 
the scientific field of AD, a revised biomarker model of AD should incorporate the 
aforementioned diverging trajectory of SCD and support this hypothesized trajectory 
with empirical, longitudinal data on intra-individual changes in SCD. 
Study 3 demonstrated that, in a memory clinic sample, specific aspects of SCD 
quantity and quality were predictive of a CSF profile indicating AD pathology, i.e. 
presence of “prodromal AD” according to the IWG2 (Dubois et al. 2014) and NIA-AA 
(Albert et al. 2011) criteria. Risk of a prodromal AD CSF profile increased by 73% for 
a one standard deviation increase in scores on a quantitative SCD scale and was 
approximately doubled in those MCI patients that reported memory concerns, 
respectively.  These results, thus, highlighted, together with the longitudinal findings of 
study 2, the usefulness of SCD operationalizations that extend beyond the broad clinical 
SCD criterion as part of the general MCI diagnostic procedures. This argues for a 
refined SCD assessment in MCI and might again be especially important in the early 
stage of MCI. 
In practice, clinicians are indeed often confronted with cases that fall on the 
border between normal test performance and early mild cognitive impairment. The 
DCN memory clinic cohort, initially drawn from patients that actively sought evaluation 
at one of the DCN memory clinics, contains a substantial number of such mildly 
impaired patients. Therefore, not only has the DCN MCI sample a high external 
validity. It follows from this that the diagnostic entity of SCD without clearly 
determinable cognitive impairment is highly relevant for memory clinic routine 
practice. While such patients have long been considered “the worried well” or those 
with depression related complaints, the recent literature provides growing evidence that 
this clinical entity of pre-MCI SCD should be taken seriously and better characterized in 
future studies (Jessen et al. 2014a). 
This, however, also implies that the definition of objective impairment at the 
MCI level, which will serve as an exclusion criterion for studies on pre-MCI SCD, 
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needs to be sharpened as well as harmonized across those studies. It can be argued here 
that, for the purpose of distinguishing a group of individuals with pre-MCI SCD from 
those with MCI, a more robust neuropsychological MCI definition, compared to that 
applied in studies such as the DCN cohort should be chosen (Edmonds et al. 2014; 
Bondi et al. 2014). Recently proposed neuropsychological MCI criteria which balance 
reliability (i.e. stability of the MCI diagnosis across time) and sensitivity to incipient 
AD (Jak et al. 2009; Bondi et al. 2014) could be used to define such a robust MCI 
group from which a pre-MCI SCD group could then be distinguished by not meeting 
these neuropsychological MCI criteria. 
Following the logic from the working model outlined above, in such a pre-MCI 
SCD patient group, measures of SCD should be predictive of incident AD dementia and 
of biomarker abnormality indicative of AD while associations between memory 
performance and these outcomes should be weak or even absent. Indeed, application of 
the proposed neuropsychological MCI criteria of Jak and colleagues (2009) to the DCN 
MCI sample leads to 39% patients not meeting these more robust criteria, i.e. they 
would be classified as pre-MCI SCD. In these patients, short term rate of conversion to 
incident AD dementia, within the average 28 months follow-up interval of the DCN 
study, is low in (only 4%). However, a substantial number (30%) of these patients have 
a CSF profile indicative of AD suggesting that, given a longer follow-up, a high number 
of these will eventually develop robust MCI or AD dementia. In addition, as proposed 
above, presence of an AD biomarker signature in these patients is predicted by SCD 
measures while both neuropsychological measures and informant reports are not 
predictive (unpublished data). 
An implication of these results is that new studies with longer follow-up 
intervals and a more extensive SCD assessment are needed to contribute further to the 
characterization of the pre-MCI SCD stage. In these new prospective studies it could 
then be examined whether more precise SCD operationalizations together with 
innovative objective tests (Rentz et al. 2013) can help to detect those individuals among 
the pre-MCI SCD patient group who have truly underlying AD pathology and will later 
convert to AD dementia. Such studies have only recently been set up (e.g. DELCODE 
or the ADNI-2 cohort), so there is only limited data today. 
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4.2 Limitations of today’s SCD studies and future directions 
Over the course of the present work it became clear that the nature of SCD is 
extremely complex, both in regard to its phenomenology, its determinants, its evolution 
over time and finally the subsequent outcomes it is associated with. The empirical 
studies here, thus, only focused on small aspects of the whole SCD picture.  
One limitation of all studies is that, while study 1 and 2 deal with longitudinal data 
on the level of outcome (incident AD dementia), the symptom of SCD itself was always 
measured on a single time point. In general, there is still a lack of empirical data on the 
longitudinal evolution of SCD over the course of AD. It needs to be acknowledged that 
the hypothesized temporal evolution of SCD in the working model outlined above is 
based on inference from cross-sectional data across studies of individuals situated at 
different time points along the AD continuum (stages of pre-MCI, MCI, AD dementia). 
In addition, these studies have rarely employed the same measures of SCD. Hypotheses 
can be derived and empirically tested from the proposed working model based on cross-
sectional SCD measurement, as was done in study 2 and 3 of this work. However, a 
more refined understanding of the development of SCD in relation to objective 
cognitive decline (and biomarkers of AD) will certainly require large longitudinal data 
on intra-individual change in self- and informant reported SCD
12
, objective cognitive 
performance, and biomarkers. A long follow-up time frame is needed to monitor the 
trajectories of theses AD-related variables from the earliest symptoms to overt 
dementia. As a consequence, such data is both difficult and expensive to collect. 
Further, to effectively monitor SCD longitudinally, reliable and change-sensitive SCD 
scales are needed. However, the existing scales have not been thoroughly evaluated in 
this regard. It should also be mentioned that even the assessment of change in objective 
cognitive performance at the earliest AD stages is, at the current state of knowledge, not 
optimal and therefore subject to extensive research (e.g. Ayutyanont et al. 2014). It 
would, thus, be helpful to connect the research on longitudinal assessment at both levels 
(subjective and objective) of cognition. 
                                                 
12
 The degree of discrepancy between both sources of information might serve as a measure of 
over- or underestimation of SCD by the patient relative to his/her informant. An underestimation could be 
interpreted as a sign of a patient’s reduced insight into his/her own cognitive deficits (Edmonds et al. 
2014). 
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Good news is that, from a statistical point of view, powerful techniques for the 
analysis of complex longitudinal data have recently been developed, are continuously 
advanced and have been made more accessible to applied researchers (Duncan et al. 
2013). These structural equation modeling techniques for longitudinal data are 
commonly referred to as Growth Curve Modeling (GCM) or Latent Growth Curve 
Modeling (LGCM; Duncan et al. 2013). They allow to model longitudinal trajectories 
of phenomena on the basis of single test scores (GCM) or latent constructs (LGCM). 
Furthermore, it is possible to model trajectories of different constructs simultaneously 
and test hypotheses on the relationship between those trajectories. Such models, 
commonly referred to as “Parallel Process GCM”, could be used to simultaneously 
study the trajectories of the above named, AD-related variables. It is further possible to 
incorporate categorical outcomes (“sequelae of change”; Duncan et al. 2013) in these 
modeling approaches and to adjust them to non-ignorable, “not at random” missing data 
patterns that are often present in longitudinal studies on neurodegenerative diseases 
(Gottfredson et al. 2014). 
With regard to the aim of optimized SCD assessment, future research will also have 
to focus on a better phenomenological characterization of, and distinction between, AD-
related vs. non-AD-related SCD. One can assume that there will be overlap between 
both types of SCD but also distinctive features pertaining more to one or the other. 
There are generally two possible approaches to this goal, a quantitative and a qualitative 
approach. Optimally, both should inform each other (Buckley et al. 2014a; Buckley et 
al. 2014b).  
The quantitative approach may employ advanced statistical and psychometric 
methods, such as item response theory (IRT) and co-calibration techniques, with the 
aim to identify those SCD items most closely related to AD and to make currently 
available SCD measures more comparable (see Crane et al. 2008 for an analogous IRT 
example with objective cognitive test data). Such techniques can rely on existing data 
sets that can be merged together for a simultaneous psychometric analysis. Latent Class 
Analysis (LCA) could be used as an alternative quantitative approach to a better 
characterization of SCD. LCA is a structural equation modeling technique that can be 
used to find distinct classes of individuals based on a set of multivariate variables. In the 
field of AD, LCA has been used for empirically driven subtyping of samples of 
individuals with dementia (Libon et al. 2014) and AD dementia (Davidson et al. 2010) 
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according to their neuropsychological test performance, or presence of neuropsychiatric 
symptoms (Lyketsos et al. 2001). The same approach has also been applied to non-
demented memory clinic patients at risk for incident dementia. Köhler and colleagues 
(Köhler et al. 2013) submitted the neuropsychological data of a large memory clinic 
sample to LCA and extracted distinct neuropsychological profiles that were 
differentially associated with clinical progression to dementia. Similar to its application 
to neuropsychological test score data, LCA could also be applied to rich SCD 
questionnaire data, e.g. in a sample of patients with SCD and normal cognition. It could, 
thus, be used to find possible subtypes within the heterogeneous phenotypic 
presentation of individuals with SCD. Linked with association analyses on multiple 
levels (e.g. depressive symptoms, biomarkers, risk factors, clinical progression) it might 
be possible to further describe the characteristics of potential SCD subtypes and test 
whether certain types might be more closely associated than others with AD-related risk 
factors and outcomes such as ApoE4 genotype, abnormal biomarkers and subsequent 
decline/clinical progression to MCI and dementia. It would then be of further interest 
which SCD items best characterize these subtypes. 
Besides those quantitative approaches mentioned above, there are also efforts to 
employ qualitative research strategies for the refinement of the SCD concept (Buckley 
et al. 2014a). The main idea behind the qualitative research approach is that the 
experience of the working mind is inherently subjective and of a high 
phenomenological complexity. An entirely quantitative approach to characterize such 
experiences of mental function will, thus, inevitably result in loss of useful information. 
In other words: "not everything that counts can be counted" (Cameron, 1963). 
Qualitative research could help to characterize different phenomenological profiles of 
SCD that relate to different conditions underlying the subjective experience of cognitive 
decline. This idea is similar to LCA, however, the type of data is different. LCA 
requires numerical data of preferably interval or ordinal scale type (i.e, questionnaire 
data in case of SCD). This kind of data has already been reduced in its informative 
value due to the act of quantification of a subjective experience into numerical values 
representing the item responses of the questionnaire. In contrast, qualitative research 
will deal with less reduced data in form of directly communicated experiences of the 
individual under study. The idea now is that, although the subjective experience of 
cognitive decline and its communication is certainly subject to variable factors (such as 
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personality traits or intercultural differences), there will likely be an overlap of 
phenomenological experience (a “phenomenological profile”) that may be more closely 
related to a condition such as AD than to other conditions, e.g. depressive symptoms.  
Phenomenological profiling is in fact well established in clinical psychiatry, e.g. in 
differential diagnosis of different psychiatric disorders. For example a patient with 
obsessive compulsive disorder and a schizophrenic patient may both experience 
recurring, intrusive and obsessive thoughts which are experienced as uncontrollable 
(American Psychiatric Association, 2013). Both patients might further engage in 
compulsive behavior. Patients with obsessive compulsive disorder generally recognize 
there obsessive thoughts and compulsive behavior as their own and judge them as 
irrational. However, a schizophrenic patient might experience the intrusive thoughts as 
not of his own but rather to be induced by some external power (e.g. by way of “brain 
manipulation” in paranoid psychosis). In this example, a qualitative difference in the 
experience of the source of origin of the intrusive thoughts distinguishes different 
psychiatric phenotypes. In principle, this qualitative information could be obtained via 
questionnaire. However, this is only possible due to the established knowledge about 
qualitative similarities and differences (i.e. a phenomenological profile) of both 
disorders that has been gathered by clinicians by observation of and communication 
with patients, i.e. a qualitative research approach was the starting point. 
With regard to SCD assessment, development of most items and questionnaires was 
based on expert panels or clinical experience. A formal phase of qualitative data 
collection, although recommended as best practice, has usually not been conducted 
(Eckerström et al. 2013). A notable exception constitutes the development of the 
Sahlgrenska Academy Self-reported Cognitive Impairment Questionnaire (SASCI-Q; 
Eckerström et al. 2013) which had a qualitative open format interview phase with MCI 
patients, their relatives as well as a third group of surviving cancer patients as a starting 
point for item generation. The initial open format interview was centered on questions 
about various functional difficulties experienced in participants’ everyday lives. 
Importantly, the authors took care that questions were “not limited to the interviewees’ 
personal understandings of cognition or memory”. Rather, they were “deliberately 
designed to address everyday activities and behaviors instead of referring to specific 
cognitive domains” (Eckerström et al. 2013).  The first interview phase was then 
followed by transcription of the interview material and a content analysis with focus on 
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identifying those everyday difficulties that could be related to cognition. These 
interview aspects were then categorized into meaningful concepts (e.g. “forgetfulness”), 
rephrased into questions with selection of an appropriate response scale (yes/no vs. 
Likert scale etc.), revisited and subject to a face validation phase with practitioners and 
patients of a memory clinic. Results of this phase lead to cancellation of further items as 
well as to addition of new ones. In a final development phase, around 100 remaining 
items were administered to healthy individuals and to individuals who attended a 
memory clinic for diagnostic work-up but for whom cognitive impairment could not be 
objectified. The authors then examined which items were most capable of 
distinguishing between those diagnostic groups. As expected, many items that 
distinguished well were related to decline in memory. However, a rather interesting 
finding for the authors was that also items related to social activities and social 
communication where among the distinguishing ones. One possible explanation for this 
finding is that social activities are omnipresent in everyday life and, therefore, hardly 
avoidable by the patient without consequences. Thus, items, which relate to difficulties 
in performing these activities, may be more salient and thereby “more useful as 
indicators when investigating subjective cognitive impairment and compromised 
functioning in a clinical sample” (Eckerström et al. 2013). This study example 
demonstrates how qualitative and quantitative approaches to item and questionnaire 
development can work hand-in-hand to derive a well thought out SCD questionnaire.  
In conclusion, much work remains to develop the SCD concept and its optimal 
assessment. However, fortunately, international research groups are now combining 
their efforts to take up this challenge. 
Finally, it should be noted that the concept of SCD is one out of several possible 
approaches to better study the characteristics of (and possible interventions in) the  
preclinical AD stage. It may well be the case that one day, if highly accurate biomarkers 
of preclinical AD were easily available and early symptomatic treatments were 
developed, the assessment of SCD would no longer be necessary. Thus, the SCD 
concept may be seen as a temporarily limited research approach to study preclinical AD 
and may be abandoned once better objective markers of preclinical AD are at hand. 
However, today, in a state where there is a lack of objective markers that are both easily 
accessible and reliable in predicting disease risk (Henriksen et al. 2014), SCD may 
prove as useful a research approach to preclinical AD as has the MCI concept been to 
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generate knowledge on the earliest clinical features of AD (Petersen et al. 2009). SCD 
as a research approach to preclinical AD has several key advantages. Firstly, assessment 
of SCD is very feasible, cost-effective and non-invasive. Secondly, due to the non-
invasiveness but also because individuals with SCD are often actively help-seeking, it is 
less hampered by ethical consideration and very relevant to the health care system. This 
sets it apart from other current approaches to study preclinical AD which either rely on 
extensive biomarker assessment to enrich samples for risk of AD (e.g. A4-Trial, 
Sperling et al. 2014) or study preclinical AD in dominantly inherited early-onset AD 
samples (e.g. the DIAN study, Morris et al. 2012). The combined advantages of low 
costs, non-invasiveness and high relevance to care make enrichment via SCD especially 
appealing for low-cost/low-risk intervention approaches, e.g. concerning nutritional 
behavior, physical/cognitive activity and other lifestyle factors. However, more 
invasive, e.g. pharmacological treatments should better be studied in more thoroughly 
enriched (biomarker-defined) preclinical AD samples bearing more clearly increased 
risk of cognitive decline and incident AD dementia (Sperling et al. 2011; Sperling et al. 
2014). Importantly, as long as biomarker assessment is not widely available, SCD may 
complement biomarker-based enrichment strategies as a pre-selection criterion due to its 
positive association to biomarker abnormality in cognitively normal individuals (Mielke 
et al. 2012). In a similar way, assessment of SCD may help to enrich samples for studies 
on new objective markers of preclinical AD, such as blood-based biomarkers 
(Henriksen et al. 2014) or more sensitive neuropsychological tests (Rentz et al. 2013). 
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5 German Summary (Deutsche Zusammenfassung) 
Die Leistungsfähigkeit in den meisten kognitiven Domänen, insbesondere auch 
im Gedächtnis, zeigt im Zuge normaler Alterungsprozesse bereits ab dem mittleren 
Erwachsenenalter einen abfallenden Verlauf (Schaefer & Bäckman, 2007). Aus diesem 
Grund verwundert es nicht, dass Berichte über Subjektive Kognitive 
Verschlechterungen (engl. “Subjective Cognitive Decline”, SCD)  in der älteren 
Allgemeinbevölkerung durchaus häufig anzutreffen sind. Als SCD bezeichnet man 
dabei die subjektive Wahrnehmung sich verschlechternder kognitiver 
Leistungsfähigkeit einer Person in Bezug auf ein früheres Leistungslevel (Jessen et al. 
2014a). Je nach Art der Erfassung und der untersuchten Stichproben liegt die Prävalenz 
von SCD im Bereich des Gedächtnisses bei älteren Menschen ab dem 65ten Lebensjahr 
bei ca. 25-50% (Stewart, 2012). Die Prävalenz solcher Beschwerden steigt mit dem 
Alter an und erreicht Werte über 80% bei Personen von 80 Jahren und älter (Stewart, 
2012). 
Diese Zahlen verdeutlichen zunächst, dass subjektive Empfindungen über 
nachlassende kognitive Leistungsfähigkeit zu Phänomenen des regulären kognitiven 
Alterungsprozesses gehören können. Dennoch kann eine solche Wahrnehmung auch mit 
ausgeprägten Sorgen um die kognitive Leistungsfähigkeit einhergehen und ist dann 
meist Anlass für das Aufsuchen eines Allgemeinarztes oder einer Fachambulanz zur 
Abklärung möglicher Ursachen für die subjektiv erlebten Symptome. Häufig, aber nicht 
immer, wird die wahrgenommene Verschlechterung auch von Angehörigen und 
behandelnden Ärzten berichtet und/oder es zeigt sich bei Abklärung der 
Leistungsfähigkeit mittels objektiver neuropsychologischer Testverfahren auch ein 
tatsächlich bestehendes Defizit, d.h. eine Leistung, die unterhalb des aufgrund von 
Alter, Geschlecht und Bildung der Person zu erwartenden Niveaus liegt. In einem 
solchen Fall ist die Diagnose einer leichten kognitiven Einschränkung (engl. „Mild 
Cognitive Impairment“, MCI) gerechtfertigt, sofern Alltagsfunktion und 
Unabhängigkeit der Lebensführung noch weitgehend erhalten ist, d.h. eine 
Demenzdiagnose zunächst ausgeschlossen werden kann (Winblad et al. 2004).  
MCI gilt als gut etabliertes Risikostadium für eine später eintretende Demenz, 
zumeist aufgrund der Alzheimer Krankheit und dies besonders wenn es sich um 
amnestische Defizite (amnestic MCI) handelt (Dubois et al. 2014). Personen mit MCI 
weisen ein deutlich erhöhtes Risiko für inzidente Alzheimer Demenz auf, mit jährlichen 
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Übergangsraten von ca. 10-15% (Petersen, 2004). Neuere Forschungskriterien für die 
Alzheimer Krankheit umfassen auch das MCI Spektrum und sprechen von „MCI 
aufgrund Alzheimer Krankheit“ oder „prodromaler Alzheimer Krankheit“ wenn neben 
dem klinischen Phänotyp des MCI zusätzlich biochemische oder Bildgebungsdiagnostik 
(„Biomarker“ Diagnostik) positiv für eine ursächliche Alzheimer Krankheit sprechen 
(Albert et al. 2011; Dubois et al. 2014). SCD ist Teil der MCI Kriterien um den 
klinischen Phänotyp des kognitiven Defizits näher zu charakterisieren. Da für 
gewöhnlich nur ein Messzeitpunkt zum Zeitpunkt der Diagnose vorliegt, gibt SCD 
Information über eine vorangegangene Verschlechterung und erhärtet damit den 
Befund, dass die objektiv defizitäre Leistung Ursache einer neurodegenerativen 
Erkrankung (anstatt eines lebenslang bestehenden Defizits) ist. Innerhalb der MCI 
Kriterien kann diese Information entweder vom Betroffenen selbst, einem Angehörigen 
oder einem mit dem Patienten vertrauten Kliniker gegeben werden.  
Die Nützlichkeit des Kriteriums der (selbst-berichteten) subjektiven 
Gedächtnisbeschwerden wurde in der Literatur mehrfach in Frage gestellt (Edmonds et 
al. 2014), nicht zuletzt deshalb, weil bereits im MCI Stadium Symptome von reduzierter 
Einsichtsfähigkeit, wie sie für das Stadium der Alzheimer Demenz charakteristisch sind, 
auftreten können (Galeone et al. 2011). Das Auftreten dieser Symptome kann die 
Verlässlichkeit subjektiver Information hinsichtlich einer kognitiven Verschlechterung 
negativ beeinflussen (Roberts et al. 2009). Weiterhin wurde die mangelhafte 
Operationalisierung von SCD kritisiert (Abdulrab & Heun, 2008) und es gibt derzeit 
noch keine einheitlichen Standards zur Erfassung selbstberichteter subjektiver 
kognitiver Verschlechterung. Es stellt sich daher für die Forschung die Frage, in wie 
weit das Phänomen des SCD adäquat erfasst ist und seine Informationskraft in Hinblick 
auf Diagnostik und Prognostik im Rahmen der Alzheimer Krankheit ausgeschöpft 
wurde. 
Neuen Auftrieb hat die Forschung um das Phänomen der subjektiven 
Gedächtnisbeschwerden in den letzten Jahren im Bereich der Frühdiagnostik der 
Alzheimer Krankheit erfahren. Da viele pharmakologische Interventionsstudien zur 
Prävention von Alzheimer Demenz im MCI Bereich keine durchschlagenden 
signifikanten Effekte zeigten, ist das wissenschaftliche Feld darum bemüht, die 
Alzheimer Krankheit noch vor dem MCI Stadium zu detektieren (Sperling et al. 2011). 
Mehrere große Studien konnten zeigen, dass Personen mit SCD aber objektiver 
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kognitiver Leistung im Normalbereich ein signifikant erhöhtes Risiko für inzidente 
Alzheimer Demenz und Biomarkerpositivität für die Alzheimer Krankheit aufweisen 
(Jessen et al. 2014a). SCD könnte daher als ein frühes Symptom einer sich anbahnenden 
Alzheimer Demenz gelten und bietet Ansatzpunkte für die Risikoanreicherung von 
Stichproben oder als abhängiges Maß über die Zeit für Interventionsstudien und 
naturalistische Beobachtungsstudien. Aufgrund dieser neueren Befundlage ist SCD im 
Sinne eines klinischen Frühsymptoms auch in den Forschungskriterien der letzten Phase 
der präklinischen Alzheimer Krankheit aufgenommen wurden („preclinical AD stage 
3“; Sperling et al. 2011). Diese letzte Phase markiert den Übergang von stummer 
präklinischer zur frühen klinischen Phase des MCI. Auch für diesen Übergangsbereich 
gilt jedoch, dass die genaue Charakterisierung von SCD, der Verlauf über die Zeit und 
die Messmethoden noch unzureichend erforscht sind. 
Die vorliegende Arbeit enthält drei Studien, die sich mit SCD im Bereich 
objektiv normaler kognitiver Leistungsfähigkeit sowie im MCI Bereich beschäftigen. 
Die Studien orientierten sich dabei an einem derzeit gängigen Arbeitsmodell (Jessen et 
al. 2014a) für den temporären Verlauf subjektiver Gedächtnisbeschwerden im Zuge der 
Entwicklung der Alzheimer Krankheit. SCD wird dabei als ein frühes Symptom der 
Krankheit aufgefasst und bildet ein Kernsymptom im Übergangsbereich der 
präklinischen Phase der Alzheimer Krankheit zur frühen klinischen Phase des MCI. Im 
Verlaufe der Alzheimer Krankheit können subjektive Gedächtnisbeschwerden wieder 
abnehmen bzw. die Verlässlichkeit des Urteils sinken, da reduzierte Einsichtsfähigkeit 
und/oder Leugnung der Beschwerden seitens des Patienten aufgrund fortschreitender 
Krankheit und damit einhergehender Verschlechterung der kognitiven 
Leistungsfähigkeit zunehmen. Andererseits ist die Sensitivität objektiver kognitiver 
Testdiagnostik gerade im eben angesprochenen Übergangsbereich zwischen 
präklinischer und MCI Phase begrenzt. Gerade hier könnte daher die Erhebung von 
SCD als zusätzliche Informationsquelle prognostischen Zugewinn bringen.  
Desweiteren explorieren die hier vorliegenden Studien, quantitative und qualitative 
Aspekte von SCD (z.B. das „sich Sorgen“ um die erlebte Gedächtnisverschlechterung) 
hinsichtlich ihrer prognostischen Informationskraft.  
Datengrundlage der Studien ist zum einen die deutsche „Study on Ageing 
Cognition and Dementia in primary care“ (AgeCoDe), eine multizentrische 
Kohortenstudie von ca. 3200 älteren Hausarztpatienten (nicht dement und mindestens 
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75 Jahre zu Studienbeginn) mit derzeit bis zu 7.5 Jahren Verlaufsbeobachtung (Studie 
1). Als weitere Stichprobe diente eine, ebenfalls multizentrische, 
Gedächtnisambulanzkohorte von nicht-dementen Patienten des deutschen 
Kompetenznetzes Demenzen, ein Zusammenschluss von forschenden Uniklinik-
Gedächtnisambulanzen in Deutschland. Aus dieser Kohorte konnten Stichproben von 
ca. 450 MCI Patienten mit Verlaufsdaten von bis zu 36 Monaten (Studie 2), sowie von 
ca. 250 MCI Patienten mit querschnittlichen Biomarkerdaten (Studie 3) genutzt werden.  
Studie 1 untersuchte innerhalb der AgeCoDe Kohorte das Risiko für inzidente 
Alzheimer Demenz bei Personen mit SCD (genauer: subjektiver 
Gedächtnisverschlechterung) aber noch normaler Testleistung in einem Gedächtnistest. 
Desweiteren wurde der qualitative Aspekt von Sorgen über den erlebten 
Gedächtnisabbau im Hinblick auf das Alzheimer Demenz Risiko exploriert. Beide 
Personengruppen (SCD mit bzw. ohne Sorgen bei normaler Gedächtnistestleistung) 
wurden mit zwei MCI Gruppen („frühes MCI“ mit leichtem objektivem 
Gedächtnisdefizit; „spätes MCI“ mit stärkerem objektivem Gedächtnisdefizit) 
hinsichtlich des Alzheimer Demenz Risikos verglichen. Als Referenzgruppe in diesem 
Design diente eine Kontrollgruppe von Personen ohne SCD und ohne objektives 
Defizit. Es zeigte sich hierbei, das SCD mit Sorgen mit einem ca. 2.5-fach erhöhten 
Alzheimer Demenz Risiko verglichen zur Kontrollgruppe einherging. Das Risiko in 
dieser Gruppe entsprach dem der Gruppe „frühes MCI“. Die Gruppe der Personen, die 
subjektive Gedächtnisverschlechterung ohne Sorgen berichteten, wies nur ein leicht 
erhöhtes Risiko für inzidente Alzheimer Demenz auf, welches sich nicht signifikant von 
der Kontrollgruppe unterschied. Diese Studie unterstreicht die Bedeutsamkeit von 
subjektiver Gedächtnisverschlechterung, speziell wenn diese als sorgenvoll erlebt wird, 
als einen frühen prädiktiven Marker für eine spätere Alzheimer Demenz in älteren 
Allgemeinarztpatienten. Desweiteren weisen die Ergebnisse dieser Studie auch auf die 
Grenzen neuropsychologischer Schwellenwerte zur Definition von einzelnen 
Risikostadien der Alzheimer Demenz hin, da sich das Risiko von Personen mit 
Gedächtnissorgen aber noch „noch normaler Gedächtnisleistung“ nicht von dem 
derjenigen Personen mit Sorgen und mit minimalem objektivierbaren Defizit 
unterschied. 
Studie 2 untersuchte die prädiktive Vorhersagekraft von sorgenvollen 
subjektiven Gedächtnisbeschwerden für inzidente Alzheimer Demenz bei 
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Gedächtnisambulanzpatienten mit einer MCI Diagnose. Dabei wurde zunächst die 
Hypothese geprüft ob sorgenvolles SCD zusätzlich zur objektiven 
Gedächtnistestleistung, welche (im Gegensatz zum prä-MCI Stadium) in diesem 
Risikostadium bereits substantiellen prädiktiven Wert hat, einen Beitrag zur 
Vorhersagekraft von inzidenter Alzheimer Demenz leisten kann. Desweiteren wurde 
geprüft ob die Vorhersagekraft von SCD mit Sorgen von der Ausprägung des 
objektiven Gedächtnisdefizits zum Zeitpunkt der Messung beeinflusst („moderiert“) 
wird. Der Grund für diese Annahme wurde oben in der Beschreibung des 
Arbeitsmodells für den temporären Verlauf von SCD im Zuge der Alzheimer Krankheit 
dargelegt. Die Ergebnisse der Studie lieferten Evidenz für die Gültigkeit beider 
Hypothesen. Das Vorhandensein von sorgenvollen Gedächtnisbeschwerden bei MCI 
Patienten ging mit einem mehr als zweifach erhöhten Risiko für inzidente Alzheimer 
Demenz im Verlaufszeitraum von durchschnittlich ca. 2.5 Jahren einher. Die Größe 
dieses Haupteffekts war vergleichbar mit dem des APOE4 Genotyps, des wichtigsten 
genetischen Risikofaktors für die sporadische Alzheimer Demenz, und bestand auch 
unter statistischer Kontrolle für die objektive Gedächtnisleistung. Desweiteren zeigte 
sich entsprechend der zweiten Hypothese ein signifikanter Interaktionseffekt zwischen 
objektiver Gedächtnisleistung und sorgenvollen Gedächtnisbeschwerden im Hinblick 
auf das Alzheimer Demenz Risiko. Das mit Vorhandensein von sorgenvollem SCD 
assoziierte Risiko war besonders hoch bei nur leicht objektiv beeinträchtigten Patienten 
und sank mit abnehmender Gedächtnisleistung, d.h. es war niedriger bei zur 
Basismessung bereits stärker beeinträchtigten MCI Patienten. Die Ergebnisse dieser 
Studie validieren bzw. erweitern zum einen die Befunde von Studie 1 zur besonderen 
Bedeutung von Sorgen über die erlebte Gedächtnisverschlechterung durch eine 
Replikation des Effektes in einem anderen Setting (Memory Clinic) und anhand von 
Individuen, die sich in einem näher an der Demenz befindlichen Risikostadium (MCI) 
befinden. Zum anderen liefern sie empirische Evidenz für die im oben beschriebenen 
Arbeitsmodell postulierte Dynamik von SCD im Hinblick auf die Nutzbarkeit als 
prädiktiver Marker. Der Nutzen von SCD ist besonders hoch bei noch früher objektiver 
Beeinträchtigung während er im bereits fortgeschrittenen MCI Stadium limitiert zu sein 
scheint. 
Als Fortsetzung von Studie 2 untersuchte die dritte Studie dieser Arbeit die 
Prädiktionskraft von Gedächtnissorgen bei MCI Patienten im Hinblick auf das 
 111 
Vorhandensein eines Alzheimer Demenz typischen Biomarkerprofils. Es wurden die 
gleichen Hypothesen formuliert wie auch bei der Vorhersage inzidenter Alzheimer 
Demenz in Studie 2. Zusätzlich wurde hier auch ein quantitatives Maß für SCD 
eingesetzt und mit dem Prädiktor der sorgenvollen Gedächtnisbeschwerden verglichen. 
Es zeigte sich auch hier, dass beide SCD Maße signifikante Prädiktoren für das 
Vorhandensein eines Alzheimer Demenz typischen Biomarkerprofils waren, dies auch 
unter Kontrolle der objektiven Gedächtnisleistung. Ein Interaktionseffekt zwischen 
SCD und objektiver Gedächtnisleistung konnte hingegen nicht gefunden werden, was 
möglicherweise auch an der geringeren Stichprobengröße verglichen zur longitudinalen 
Studie 2 gelegen haben mag (nur ca. 33% der MCI Kohorte haben Biomarker 
Information). Das Hauptergebnis dieser Studie, die Assoziation von SCD mit 
Biomarkern der Alzheimer Demenz, erweitert bereits aus dem präklinischen Bereich 
vorliegende Befunde zu einer solchen Assoziation und legt nahe, dass eine bessere 
Operationalisierung von SCD, welche über den unspezifischen Bericht von kognitivem 
Abbau gemäß MCI Kriterien hinausgeht, auch noch im MCI Stadium von prädiktivem 
Nutzen sein könnte. 
Zusammenfassend haben die hier vorgestellten Studien eine Reihe von Beiträgen 
zur Erforschung von SCD im Bereich der Alzheimer Krankheit geleistet. Ergebnisse 
dieser Arbeit haben z.B. Eingang in die Definition eines Rahmenkonzeptes für die 
Erforschung von SCD im Bereich der präklinischen Alzheimer Krankheit  gefunden 
(Jessen et al. 2014a). Diese Kriterien erwähnen den qualitativen Aspekt der Sorgen um 
die erlebte Gedächtnisverschlechterung, zusammen mit weiteren Aspekten, als einen 
Faktor, der die Wahrscheinlichkeit von Alzheimer als Ursache der Beschwerden erhöht. 
Grenzen der vorliegenden Studien sind vor allem durch die Form der 
retrospektiven Analyse und die damit verbundene eingeschränkte Anzahl der SCD 
Aspekte bzw. Items, die untersucht werden konnten, gegeben. Weitere Forschung ist 
nötig um zu bestimmen, welche Aspekte von SCD, in welchem Stadium der 
prodromalen Alzheimer Krankheit besonders prädiktiv für eine spätere Alzheimer 
Demenz sind, und wie diese Aspekte optimal erfasst werden sollten. Desweiteren ist 
unklar, ob SCD selbst als ein longitudinales Outcomemaß in klinischen 
Frühinterventionsstudien verwendet werden könnte. Mit dieser Frage verbinden sich 
Fragen nach Zeitstabilität, Reliabilität und Änderungssensitivität von SCD 
Operationalisierungen bzw. Messverfahren, welche weitgehend noch nicht erforscht 
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sind. Da diese Fragen auch selbst für objektive Testverfahren nicht hinreichend geklärt 
sind, und daher intensiv beforscht werden, könnten Erkenntnisse diesbezüglich auch für 
die SCD Forschung nutzbar gemacht werden. Die forschende Neuropsychologie kann 
hier, aufgrund ihrer Schnittstellenfunktion zwischen psychometrischer Grundlagen- und 
klinisch angewandter Forschung, wichtige Beiträge leisten. 
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Important terms and abbreviations 
Abbreviation Definition and Explanation 
AD Alzheimer’s disease. AD is a neurodegenerative disease that leads to progressive 
cognitive and functional decline. AD is commonly divided into an asymptomatic 
stage (biomarkers abnormal, absence of cognitive impairment), and a 
symptomatic stage (biomarkers abnormal, presence of cognitive impairment). 
The symptomatic stage can be divided clinically into the stage of (pre- mild 
cognitive impairment) Subjective Cognitive Decline (SCD), Mild Cognitive 
Impairment (MCI) and dementia (Visser et al. 2012). If biomarker information 
is available, an in-vivo diagnosis of MCI or dementia due to AD is possible 
according to research criteria of either an International Working Group (IWG2 
criteria) or the National Institute on Aging and the Alzheimer's Association 
(NIA-AA criteria). 
APOE Apolipoprotein E gene, “APOE4” describes the dementia risk allele epsilon 4. 
“Positive ApoE4 status” comprises individuals with heterozygous and 
homozygous APOE4 genotype. 
CERAD Consortium to Establish a Registry for Alzheimer’s Disease. The CERAD is a 
research consortium that was founded in the USA in 1986 with the aim to 
standardize procedures for diagnosis and evaluation of AD. The 
neuropsychological test battery developed by CERAD has been employed in 
many US and international studies and is also often used in the routine memory 
clinic practice. The German version of the CERAD test battery is the core 
battery of the DCN cohort (see study 2 and study 3 of this thesis) and parts of 
the CERAD have also been used in the AgeCoDe study (see study 1). The 
battery consists of various subtests, including the Mini-Mental State 
Examination (MMSE), and is specifically designed to assess the cognitive 
domains most commonly affected in AD. The various subtests are described in 
the methods section of study 2 and 3. The Word List Delayed Recall subtest was 
used throughout the studies as a measure of objective memory impairment and 
to define the amnestic MCI groups in study 1. 
CSF Cerebrospinal Fluid (from which biomarkers of AD pathology can be 
measured). The commonly derived AD biomarkers from CSF are CSF-Aβ42, a 
marker of brain amyloid pathology, and CSF-Tau/CSF-pTau181, markers of 
Tau-mediated neuronal dysfunction and degeneration. 
 114 
FCSRT Free and Cued Selective Reminding Test. The FCSRT is an episodic memory 
measure that controls for successful encoding and probes response to cueing. 
Recall in the FCSRT consists of a free recall phase and a cued recall phase in 
which semantic cues are given for the non-recalled words of the free recall 
phase. The initial prodromal AD criteria put forward by an International 
Working Group of Dubois and colleagues (Dubois et al. 2007) specified a 
memory deficit not normalized by cueing as the core clinical phenotype of 
prodromal AD and favored tests like the FCSRT to measure this specific deficit. 
The FCSRT was used as an alternative memory measure to the CERAD delayed 
free recall in study 3 of this thesis. 
HR Hazard Ratio, a measure of effect size in Cox Proportional Hazard Regression 
analysis. The HR gives the relative risk factor associated with a categorical or 
continuous exposure variable in comparison to a reference category or value. A 
Hazard Ratio greater than one means a greater risk in the exposed group or with 
increasing values of the continuous measure (e.g. HR = 2 means “two times the 
risk”). A Hazard Ratio smaller than one means less risk. The range of a HR is 
from zero to infinity. 
MCI Mild Cognitive Impairment. MCI is defined as a condition of objective mild 
deficits in one or more cognitive domain together with evidence of a cognitive 
decline from worse performance. Importantly, the level of cognitive impairment 
must not significantly interfere with daily living (i.e. a diagnosis of dementia is 
not warranted). In the absence of longitudinal objective test information, 
evidence of a decline in performance is usually corroborated, subjectively, by 
the patient and/or by an informant or a clinician who knows the patient well. The 
criterion of SCD is therefore not mandatory for the diagnosis of MCI. 
Pre-MCI Pre-MCI is used as a prefix to Subjective Cognitive Decline (SCD) in this thesis. 
Used in conjunction with SCD it describes individuals with SCD but normal 
cognitive test performance, i.e. not warranting a diagnosis of MCI. The  term 
“pre-MCI SCD”, thus, describes a specific patient group, not the symptom of 
SCD per se. 
MMSE Mini-Mental State Examination. The MMSE is a common, short 
neuropsychological assessment tool to measure global cognitive functioning in 
MCI and dementia (Folstein et al. 1975). The MMSE is included as a subtest in 
the German version of the CERAD neuropsychological assessment battery. 
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MRI Magnetic resonance imaging. MRI is a medical imaging technique that uses 
magnetic fields and radio waves instead of radionuclides (see PET) to visualize 
anatomic structures and processes in the body. In Alzheimer’s disease, brain 
imaging via MRI is used to measure atrophy of brain structures (“structural 
MRI”) and is considered a marker of Tau-mediated neurodegeneration. In 
contrast to structural MRI, functional MRI is a technique that uses the natural 
association between cerebral blood flow and neuronal activation to measure the 
brain’s activity in specific areas, e.g. during performance of a cognitive task. 
OR Odds Ratio, a measure of effect size in logistic regression analysis. The metric 
of the odds ratio is similar to the Hazard Ratio (HR, see above). 
PET Positron emission tomography. PET is a functional imaging technique that uses 
nuclear positron-emitting radionuclides (tracers) to visualize functional 
processes in the body. In AD research PET brain imaging is used mostly in two 
forms: 1.) Brain PET Aβ imaging is used to visualize amyloid β (Aβ) plaque 
formation in the brain. The most common tracer compound in this regard is 
Pittsburgh compound B (“PiB-PET imaging”). 2.) As a measure of neuronal 
dysfunction, 
18
F-fluoro-deoxy-glucose PET (FDG-PET) is used to measure 
reduced brain metabolism (which indicates reduced synaptic activity). 
Besides these 2 established PET imaging forms, Tau-imaging has emerged as an 
in vivo imaging technique of tau pathology in the brain. 
SCD Subjective Cognitive Decline. SCD describes the subjective notion of cognitive 
worsening. This term describes the symptom per se, not a diagnostic patient 
group (see also pre-MCI SCD and section 2.4.1). 
SCD-I SCD-Initiative. The SCD-I is an international network of research experts on 
SCD in the field of preclinical (i.e. pre-MCI) AD. The aim of the SCD-I is to 
improve SCD operationalization and assessment and to develop common SCD 
criteria for better comparability across international studies (Jessen et al. 2014a). 
SMDS Subjective Memory Decline Scale (Jorm et al. 1997). The SMDS is a 
quantitative SCD scale. It is used as one of two SCD measures in study 3 of this 
thesis. It contains four questions on self-experienced increasing difficulties in 
everyday memory (e.g. “Do you have more trouble remembering things that 
have happened recently?”; “Are you worse at remembering where belongings 
are kept?”). Responses to each question are rated as follows: 0, “no, not more 
difficult than in the past”; 1, “Yes, a bit worse than in the past” 2, “yes, much 
more difficult than in the past”. A summary score of 0-8 points can be derived. 
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